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Abstract 
 Metabolic syndrome is a syndrome characterised by central obesity, 
dyslipidaemia, hypertension, fatty liver disease and insulin resistance that ultimately 
raises the risk of heart disease, diabetes, stroke, cancers and osteoarthritis. In 
combating metabolic syndrome, lifestyle changes are considered the most important 
initial steps which include a healthy, well-balanced diet and increased physical 
activity. Enrichment of beneficial fatty acids and incorporation of functional foods and 
bioactive nutrients are part of healthy dietary regimes in treating metabolic syndrome. 
These strategies provide options other than drug therapies that may cause adverse 
effects. Nevertheless, the effectiveness of these foods or bioactive nutrients in treating 
metabolic syndrome has yet to be fully explored. Therefore, in this thesis, I examined 
the physiological effects of individual saturated fatty acids (lauric, myristic, palmitic 
and stearic acid), linseed components (lignans, raw linseed and defatted linseed) and 
high amylose wheat (5% and 20%) using a validated diet-induced rat model of 
cardiovascular, liver and metabolic changes mimicking most of the changes in the 
human metabolic syndrome. 
Male Wistar rats fed with either diet containing 20% of lauric, myristic, 
palmitic, or stearic acid or corn-starch or high-carbohydrate, high-fat diet for 16 weeks 
showed that longer-chain saturated fatty acids (myristic, palmitic and stearic) and the 
mixture of stearic and trans fats in beef tallow produced obesity, in contrast to rats 
treated with lauric acid that exhibited low total fat mass, abdominal circumference and 
visceral adiposity index. Lauric acid supplemented rats also showed a normal 
cardiovascular and hepatic structure compared to other saturated fatty acids. This study 
suggests that replacing beef tallow with stearic and palmitic acids would show small 
improvements but replacement with lauric and possibly myristic acids in human diets 
would markedly attenuate the development of metabolic syndrome. 
 Linseed is a rich source of plant lignans such as secoisolariciresinol 
diglucoside, as well as dietary fibre. Supplementation of lignan (0.03%) and defatted 
linseed (3%) in a high-carbohydrate, high-fat diet for eight weeks lowered body weight 
gain, total fat mass, improved cardiovascular functions, reduced hepatic steatosis and 
altered metabolic profiles, which can be regarded as beneficial to health, whereas raw 
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linseed (5%) exacerbated adiposity with no changes in other metabolic biomarkers 
except for reduced systolic blood pressure. This study suggests that lignan and dietary 
fibre in defatted linseed could reduce the symptoms of metabolic syndrome. In 
contrast, positive physiological effects of raw linseed diminish possibly due to the 
properties of raw linseed that may pass through the intestine undigested, which means 
the nutritional benefits are unable to be realised.  
Another functional food described in this thesis is high amylose wheat flour. 
In this study, two dosages (5% and 20%) of high amylose wheat flour were 
supplemented in high-carbohydrate, high-fat diet for 8 weeks. Rats fed with 5% high 
amylose wheat flour showed no changes in the metabolic parameters. However, high-
carbohydrate, high-fat diet-fed rats fed 20% high amylose wheat flour showed reduced 
body fat mass and increased lean mass despite no change in the body weight. The 
addition of 20% high amylose wheat in the diet was also associated with better 
glycaemic control, decreased insulin and leptin concentrations with cardioprotective 
and hepatoprotective effects. These effects are probably due to the increased resistant 
starch content in high amylose wheat, thus ameliorating the risk of developing 
metabolic syndrome.  
The studies in this thesis provided evidence that not all saturated fatty acids are 
equal, with lauric acid producing fewer pathophysiological changes in most 
parameters than other saturated fatty acids in this model of diet-induced metabolic 
syndrome. Studies from linseed components and high amylose wheat clearly indicate 
that these foods or food components have the potential to reverse most of the risk 
factors associated with metabolic syndrome. The most likely mechanisms of these food 
or food components are through the cardioprotective and hepatoprotective effects 
produced by anti-inflammatory responses. 
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Chapter 1 Introduction 
1.1 Metabolic syndrome, saturated fatty acids and functional foods 
1.1.1 Background 
Obesity has become one of the major public health challenges, contributing to 
many comorbidities worldwide (Swinburn et al., 2011) and unfortunately no country 
to date has reversed its obesity epidemic (Roberto et al., 2015). Thus, all countries are 
still far from achieving the target in the Global Action Plan from the World Health 
Organisation (WHO) for the Prevention and Control of Non-Communicable Diseases 
(NCD) 2013–2020 and its accompanying Non-Communicable Disease Global 
Monitoring Framework for a zero increase in prevalence from 2010 to 2025 (Roberto 
et al., 2015). The target to be attained is a 25% relative reduction in premature 
mortality from NCDs by 2025 and a halt in the rise of global obesity (Roberto et al., 
2015).  
The cause of obesity has been clearly established as a positive imbalance 
between energy intake from ingested food and energy use for daily activities; this 
imbalance results in excess subcutaneous and visceral fat deposition (Eknoyan, 2006). 
This is closely linked to the escalating prevalence of metabolic syndrome. A group of 
organisations including WHO, European Group for the study of Insulin Resistance 
(EGIR), the National Cholesterol Education Program Adult Treatment Panel (ATPIII) 
and International Diabetes Federation (IDF) have defined certain diagnostic criteria 
for metabolic syndrome, also known as syndrome X (Table 1.1).  
The criteria are mainly a cluster of interconnected physiological, biochemical, 
clinical and metabolic factors that directly increase the risk of cardiovascular disease, 
type 2 diabetes mellitus, and all-cause mortality (Kaur, 2014). Central obesity, insulin 
resistance, atherogenic dyslipidaemia, endothelial dysfunction, genetic susceptibility, 
elevated blood pressure, hypercoagulable state and chronic stress are the factors which 
constitute the syndrome (Kaur, 2014). In 2012, the WHO International Classification 
of Disease (ICD-9) code (277.7) defined metabolic syndrome as a first order risk factor 
for atherothrombotic complications (Kaur, 2014). 
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Table 1.1: Diagnostic criteria and definition of metabolic syndrome (Iyer et al., 2009). 
 
 
 
 
 
 
 
Clinical Measure WHO 1998 EGIR 1999  ATPIII 2004 IDF 2005 
Insulin Resistance Impaired glucose tolerance 
(IGT), Impaired 
fasting glucose (IFG), 
Insulin resistance (IR) 
plus any two of the 
 
Plasma insulin >75th 
percentile 
plus any two of the 
following;- 
 
 
 
 
 
 
 
None 
Any three of the following 
five features;- 
None 
Any three of the following 
five features;- 
Dyslipidaemia Triglycerides (TG)> 
1.695mmol/L, 
High density lipoprotein 
cholesterol (HDL- C) 
< 0.9mmol/L (males) 
   
TGs ≥150 mg/dL 
and/or HDL-C 
<39 mg/dL in men or 
women 
 
TG > 1.695mmol/L, 
HDL-C 
< 40mg/dL (males) 
< 50mg/dL (females) 
 
TG > 1.7mmol/L or on 
TG Rx, 
HDL-C < 1.03mmol or 
on HDL-C Rx 
Blood pressure > 140/90mmHg ≥140/90 mm Hg or on 
hypertension treatment 
> 130/85mmHg > 130/85mmHg 
Plasma glucose  
> 7.0mmol/L (fasting) 
 
IGT or IFG (but not diabetes) 
 
>5.5mmol/L 
> 5.5mmol/L (includes 
diabetes) 
Central obesity Waist/Hip ratio (WHR) > 
0.90 (males); 
0.85 (females) 
   
  
  
 
Waist circumference  ≥94 cm 
in men or ≥80 cm in women 
Waist circumference > 
102cm (males); > 88cm 
(females) 
 
Waist circumference > 
94 cm 
Others Urinary albumin excretion 
ratio > 20mg/min 
    
 
   
World Health Organization, (1998), European Group for the study of Insulin Resistance (EGIR, 1999),  National Cholesterol Education Programme 
(Adult Treatment Panel III) (2001), International Diabetes Federation (2005). 
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Another complication resulting from metabolic syndrome is non-alcoholic 
fatty liver disease that is related to the release of adipokines from adipose tissue (Pala 
et al., 2012). Non-alcoholic fatty liver disease ranges from simple steatosis to chronic 
steatohepatitis and cirrhosis (Angulo, 2002). In addition, obesity also increases the risk 
of reproductive complications, pulmonary abnormalities, osteoarthritis and could 
possibly lead to cancer (Segula, 2014, Malnick and Knobler, 2006). Based on this, 
further studies need to be undertaken to reduce the prevalence and suggest options to 
ameliorate this epidemic. 
1.1.2 Obesity and metabolic syndrome prevalence    
Obesity has become a common issue at every stage of life. There are many 
different areas of research into obesity, for example the relationship between maternal 
obesity and the risks to the offspring (Catalano, 2015, Desai et al., 2014, Gaillard, 
2015). The global prevalence of obesity has doubled since 1980, with 1.9 billion adults 
being overweight and 600 million obese in 2014, accounting for 39% and 13% of total 
world population, respectively (World Health Organization, 2015). Results from the 
2013-2014 National Health and Nutrition Examination Survey (NHANES) in the USA 
showed that obesity prevalence remains unchanged since 2005 among men, but 
increased in women (Zylke and Bauchner, 2016). Based on 2013-2014 NHANES data, 
35% of men were obese (BMI ≥30) and 5.5% were morbidly obese (BMI≥40); among 
adult women, 40.4% were obese and 9.9% were morbidly obese (Zylke and Bauchner, 
2016). In Australia, the Australian Bureau of Statistics reported that in the year 2015, 
71% of Australian men and 56% of women were overweight (Australian Bereau of 
Statistics, 2015). The trend showed one in four adults were obese, and 27% of children 
were overweight or obese. Australia is not on track to meet either Council of Australian 
Governments (COAG) or National Preventative Health Taskforce (NPHT) targets for 
2019 and 2020 (Australian Bereau of Statistics, 2015), which are to increase the 
proportion of children and adults with healthy body weights by 3% within 10 years 
(Australian Bereau of Statistics, 2015).  
It is predicted that the prevalence of overweight and obesity will continue to 
rise and by the year 2030, 57.8% of the world’s adult population (3.3 billion people) 
will be affected if these observed trends persist (Kelly et al., 2008). Obesity is a part 
of the metabolic syndrome and associated with many other chronic diseases, such as 
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cancer and osteoarthritis, thus leading to increased mortality. Metabolic syndrome 
prevalence in the world among the elderly ranges from 45-65% depending on the 
criteria selected in defining metabolic syndrome (Pradeepa et al., 2016). With an 
ageing of population, conditions in combination of multiple chronic diseases will have 
an enormous impact on the health system, especially on the costs and quality of care 
received (Vogeli et al., 2007). 
The prevalence of metabolic syndrome varies considerably across the globe, 
with Table 1.2 showing multiple definitions of metabolic syndrome with different 
criteria and cut-off points. These variations of cut-off points used to identify 
individuals with the syndrome has led to confusion, especially among researchers and 
clinicians. Moreover, this also makes direct comparisons between studies more 
difficult. From Table 1.2, it can be summarised that metabolic syndrome occurs not 
only in developed countries but also in developing countries and the trend is more 
prevalent among women, except in Australia. This could be due to more women than 
men meeting the criteria for each definition of metabolic syndrome.        
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Table 1.2 Prevalence of metabolic syndrome per definition.  
 
NA: Not available. 
Country Age n NCEP/ATPIII IDF WHO Harmonized EGIR Reference 
Australia ≥25 11247 Overall: 22.1 
Men: 24.4 
Women: 19.9 
Overall: 30.7 
Men: 34.4 
Women: 27.2 
Overall: 21.7 
Men: 25.4 
Women: 18.2 
NA Overall: 13.4 
Men: 15.6 
Women: 11.3 
(Cameron et 
al., 2007) 
Brazil ≥18 
 
2130 NA NA NA Overall: 32.0 
Men: 30.9 
Women: 33 
NA (Dutra et al., 
2012) 
China ≥60 2334 Overall: 30.5 
Men: 17.6 
Women: 39.2 
Overall:  46.3  
Men: 34.8 
Women: 54.1 
NA NA NA (Keenan et 
al., 2006) 
India (East 
region) 
20-80  1178 NA Overall: 33.5 
Men: 24.9 
Women: 42.3 
NA NA NA (Prasad et 
al., 2012) 
India (South 
region) 
≥60 222 Overall: 45.9 Overall: 37.4 
Men: 31.0 
Women: 45.8 
Overall: 45.5 NA NA (Pradeepa et 
al., 2016) 
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Table 1.2 Continued. 
NA: Not available. 
 
 
Country Age n NCEP/ATPIII IDF WHO Harmonized EGIR Reference 
Iran 25-64 5417 NA Overall: 32.9 NA NA NA (Noshad et 
al., 2016) 
Malaysia ≥18 4341 Overall: 34.3 
Men: 31.1 
Women: 36.1 
Overall: 37.1 
Men: 32.1 
Women: 39.8 
Overall: 32.1 
Men: 31.8 
Women: 32.2 
Overall: 42.5 
Men: 40.2 
Women: 43.7 
NA (Mohamud 
et al., 2012) 
Romania 20-79 2681 NA NA NA Overall: 38.5 
Men: 43.2 
Women: 34.2 
NA (Popa et al., 
2016) 
United States ≥20 3601 Men: 33.7 
Women: 35.4 
Men: 39.9 
Women: 38.1 
NA NA NA (Ford, 2005) 
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1.1.3 Pathophysiology of metabolic syndrome 
Positive energy balance results in excessive visceral fat accumulation which 
contributes to an overabundance of circulating fatty acids and further leads to reduced 
insulin sensitivity (Despres and Lemieux, 2006). Progressive loss of β-cell functions 
such as glucose-stimulated insulin secretion ultimately leading to β-cell apoptosis 
induced by glucotoxicity and lipotoxicity (Weir et al., 2001, Cnop et al., 2005). The 
consequence is hyperinsulinaemia and defects of insulin action causing glucose 
intolerance. Insulin resistance will then increase secretion of triglycerides (TG) and 
very low-density lipoproteins (VLDL) that result from increased flux of free fatty acids 
to the liver. The TG surplus (hypertriglyceridaemia) is then deposited at undesirable 
sites such as liver, skeletal muscle, heart and pancreas and this is known as ectopic fat 
deposition (Despres and Lemieux, 2006). Insulin resistance is also accompanied by 
other alterations in the metabolic profile which include increased pro-inflammatory 
cytokines, prothrombotic factors and non-alcoholic fatty liver disease. 
Leptin, ghrelin and insulin are three “fat hormones” that affect the brain 
associated with changes in food intake (Korek et al., 2013). Leptin is secreted by 
adipocytes and other tissues and its plasma concentrations are positively associated 
with the amount of body fat. It promotes suppression of appetite and increased energy 
use and is associated with long-term energy balance (Wannamethee et al., 2007). 
Ghrelin on the other hand is secreted by the stomach directly before a meal, acts as a 
potent and fast-acting appetite stimulant and affects energy balance by decreasing 
glucose and fat oxidation and increasing energy storage (Cummings et al., 2001). Both 
leptin and ghrelin affect insulin sensitivity and glucose homeostasis (Soni et al., 2011). 
Impaired insulin sensitivity may both induce increased insulin concentrations and lead 
to raised leptin concentrations by down-regulation of the hypothalamic leptin receptors 
or the subsequent satiety response to leptin (Mohamed et al., 2014). Insulin is 
responsible for regulating body weight via down-regulation of circulating ghrelin 
concentrations (Erdmann et al., 2005).  
Hypertension is frequently associated with the several metabolic abnormalities, 
of which obesity, glucose intolerance, and dyslipidemia are the most common 
(Ferrannini and Natali, 1991). Remodelling of cardiovascular may also be the 
underlying mechanism of hypertension. Cardiac remodelling is a process of change in 
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the size, structure and function of the heart (Reddy et al., 2005). These physiological 
responses lead to hypertrophy, necrosis and apoptosis of the myocyte, fibroblast 
proliferation and fibrosis in the interstitium (Remme, 2003). These consequently leads 
to abnormalities in myocardial function including impaired contractility and 
relaxation, diminished cardiac pump function, dilatation and increased sphericity of 
the heart (Remme, 2003) and ultimately progresses to systolic and diastolic cardiac 
dysfunction, which increase the risk of thrombosis and heart failure. 
Non-alcoholic fatty liver disease (NAFLD) is regarded by researchers as the 
hepatic manifestation of metabolic syndrome (Yang et al., 2016). NAFLD includes a 
spectrum of disease that range from simple steatosis to steatohepatitis, advanced 
fibrosis and cirrhosis (Yang et al., 2016). Hepatic steatosis happens when there is 
excess deposition of free fatty acids and triglycerides in hepatocytes, in addition to 
protein kinase Cε activation that leads to impairment of hepatic insulin action (Yang 
et al., 2016). This underlying aetiology of NAFLD promotes the development and 
progression of cardiovascular disease and diabetes. 
The gut plays a vital role in food digestion, absorption and excretion. 
Hormones produced by the cells lining the gastrointestinal tract affect gut health and 
this includes glucagon-like peptide-1 that may be involved in the regulation of obesity 
and diabetes (Iepsen et al., 2014). Other important factors influencing gut health are 
gastrointestinal motility and gut microbiota. Gastrointestinal motility is the regulation 
of gastric emptying that represents the most important brake against delivery of 
nutrients to the intestine in excess of digestive and absorptive capacity (Wisén and 
Hellström, 1995). Gastric emptying of solid food is accelerated in obese subjects, 
which may precipitate hunger and frequent eating (Xing and Chen, 2004). However, 
there are contradictory reports regarding gastric emptying in obese people (Wisén and 
Hellström, 1995). Furthermore, obese people have larger gastric volume so that satiety 
signals are not triggered in response to gastric distension (Wisén and Hellström, 1995). 
Mechanisms that are responsible for regulating gut motility include the endocrine 
(cholecystokinin) and enteric nervous systems and gastrointestinal regulatory peptides, 
are also of importance for feeding behaviour and metabolism (Wisén and Hellström, 
1995). Obesity is associated with low-grade inflammation. The gut microbiome may 
contribute to the low-grade inflammation characterising these metabolic abnormalities 
9 
(Everard and Cani, 2013, Ding et al., 2010). Gut microflora exerts a crucial role in the 
development of fat mass and altered energy homeostasis (Turnbaugh et al., 2006, 
Bäckhed et al., 2004). In addition, the gut barrier alterations resulting from obesity and 
type-2 diabetes lead to disruption in the gut microbiota-host symbiotic relationship 
(Everard and Cani, 2013, Everard et al., 2013). This discovery provides new insight 
into the potential linkage between gut microbes, gut barrier function (metabolic 
endotoxaemia) and white adipose tissue inflammation, particularly with diet-induced 
obesity (Cani et al., 2007, Cani et al., 2008). However, it is not clear whether the simple 
sugars and saturated fats of the high energy diet change the growth patterns of the gut 
microbiota and hence cause the metabolic changes in the body or whether metabolic 
changes induced by the diet lead to the changes in the profile of gut microflora 
(Puupponen-Pimiä et al., 2002).  
Foods high in prebiotics selectively promote the growth and activity of 
beneficial bacteria in the gut. Prebiotics are defined as nondigestible food ingredients 
that promote the growth and/or activity of one or a limited number of bacteria in the 
colon, thus improving host health (Gibson and Roberfroid, 1995). Later, the definition 
was refined to include other benefits from selective targeting of particular 
microorganisms (Gibson et al., 2004). The ecology system of gut microbiota comprises 
of balanced representations of symbionts (bacteria with health-promoting functions) 
and pathobionts (bacteria that potentially induce pathology) (Figure 1.1) (Boulangé et 
al., 2016). This crosstalk of gut microbiota in mammalian host then modulates host 
physiology, metabolism and inflammatory status (pro- or anti-inflammatory). A 
healthy gut microbiota will reduce gut permeability, endotoxemia, pro-inflammatory 
cytokines and increase insulin sensitivity and beneficial active molecules such as short 
chain fatty acids (SCFA). Meanwhile, an altered (dysbiotic) gut microbiota contributes 
to insulin resistance, low grade inflammation, and fat deposition through a range of 
molecular interactions with the host and therefore can indirectly participate in the onset 
of obesity and metabolic diseases (Boulangé et al., 2016).
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Figure 1.1: Effects of healthy gut microbiota and dysbiotic gut microbiota and the association of high fat, high sugar and other environmental 
factors to gut health and its metabolic consequences.  
Adapted from (Boulangé et al., 2016).
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1.1.4  Why are obesity and metabolic syndrome on the rise? 
Obesity is most commonly caused by excessive energy intake relative to energy 
expenditure. However, other aetiology includes genetic, physiological, social, 
economic, environmental, psychological and even political factors that interact to 
varying degrees to promote the development of obesity (Aronne et al., 2009). Today, 
food and marketing industries play an important role in the obesity epidemic. 
Advertisement for fast, junk and processed foods can be widely seen, with advances 
in technology making it more convenient for everyone to overeat (Cairns et al., 2013, 
McClure et al., 2013). Sophisticated digital marketing techniques are used by food 
marketers to target youth across a host of platforms, including cell phones, video 
games and social media. In addition, drastic increases in sugar intake, which includes 
corn syrup and other sweeteners, were highlighted in a study in the United States (Bray 
et al., 2004). These high-caloric foods are usually available in large portions and are 
relatively inexpensive, which directly contributes to increased and excessive daily 
caloric intake (Drewnowski and Darmon, 2005). Moreover, today’s fast-paced 
lifestyles have shifted the trend towards eating out more and cooking at home less 
(Smith et al., 2013). Additionally, less access to physical activity (fewer sidewalks), 
less physical education in schools (Gabbard, 2001), and more time spent on sedentary 
behaviours such as television watching, surfing the internet and playing video games 
worsen this scenario (Andersen et al., 1998). 
 
1.1.5 Financial burden of obesity 
Obesity-health related disorders impose substantial financial burdens on 
individuals, families, communities and the country as a whole.  In Australia, the 
Australian Diabetes, Obesity, and Lifestyle (Ausdiab) study in 2005 indicated that total 
direct costs for overweight and obesity in 2005 were $21 billion ($6.5 billion for 
overweight and $14.5 billion for obesity) (Scholze et al., 2010). The number of 
overweight and obese adults had increased from 4.6 million in 1989–90 to 7.4 million 
in 2004–2005 resulting in an annual direct cost to the health system of approximately 
$2837 for each overweight or obese individual (Scholze et al., 2010). The main 
contributions to direct health care costs in those with a body mass index and waist 
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circumference defined as overweight were prescription medication, hospitalisation and 
ambulatory services, each accounting for about 32% (Colagiuri et al., 2010). 
Meanwhile, indirect costs for obesity including hospitalisation, prescription 
medication, and ambulatory services accounted for 36%, 33% and 25%, respectively. 
The same study estimated indirect costs of $35.6 billion per year, resulting in an overall 
total annual cost of $56.6 billion (Colagiuri et al., 2010). Direct medical costs refer to 
preventive, diagnostic and treatment services related to obesity, meanwhile indirect 
costs relate to morbidity and mortality costs including productivity at work (Hammond 
and Levine, 2010).  
 In the United States, the medical care costs were estimated to be $147 billion 
in 2008 (Finkelstein et al., 2009), and it was reported that the annual nationwide loss 
of production costs of obesity-related absenteeism ranged between $3.38 billion ($79 
per obese individual) and $6.38 billion ($132 per obese individual) (Trogdon et al., 
2008). The National Cholesterol Education Program Adult Treatment Panel III (NCEP 
ATPIII) reported total costs to Medicare were 20% higher among participants with 
metabolic syndrome ($40,873 vs. $33,010; P < 0.001). This study also found, after 
controlling for age, sex, race/ethnicity and other covariates, the abdominal obesity, low 
HDL cholesterol and elevated blood pressure were associated with 15% (95% CI 4.3–
26.7), 16% (1.7–31.8), and 20% (10.1–31.7) higher costs, respectively (Curtis et al., 
2007). 
In Europe, the total annual costs attributed by metabolic syndrome in 
hypertension patients for 2008 was €24,427 (Germany), €1,900 (Spain) and €4,877 
(Italy) million in Germany, and it was predicted to increase by 57% (€38,955), 180% 
(€5,329) and 157% (€12,523) in 2020 (Scholze et al., 2010). The increased incidence 
of metabolic syndrome is directly associated with higher cost of care (Scholze et al., 
2010). 
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1.1.6 Strategies and prevention 
The prevention and management of metabolic syndrome are complex as they 
involve social and cultural issues, local environment, food industry, public policies, 
personal attitudes and behaviour and human biology. These factors are interconnected, 
but we are still far from achieving sustained reduction in the prevalence of overweight 
and obesity. Standard behavioural treatment for obesity typically includes lifestyle 
modification (dietary and physical activity regimens) and it has been established that 
subjects who fully and continuously adhere to these regimens experience large weight 
losses and minimal weight regain (Klem et al., 1997). These ongoing lifestyle 
modifications require a set of skills involving significant planning in making healthy 
choices, estimating portion sizes, and diligence in monitoring caloric intake and 
activity. Clinical trials focusing on both food intake and exercise in obese patients 
showed small but significant decreases in body weight of 1.56 kg compared to control 
subjects at 12 months (Dombrowski et al., 2014). However, these behavioural changes 
may include non-adherence as maintaining the intervention needs high self-control and 
motivation (Foster et al., 2005). Limitations found in most research on behavioural 
treatment include being conducted in university-based clinic programs; such studies 
tell us little about the effectiveness of these approaches in settings outside of 
specialised clinics (Foster et al., 2005). 
Diets low in carbohydrates and fats, low in glycaemic index, high in protein 
and high in fibre can reduce the risk of developing metabolic syndrome (Steckhan et 
al., 2016). This includes Mediterranean and Nordic diets (Calton et al., 2014, Kesse-
Guyot et al., 2013). Complex lifestyle modification interventions can reduce metabolic 
syndrome-related abnormalities (Yamaoka and Tango, 2012) and a combination of a 
healthy dietary pattern with exercise protects patients from metabolic problems and 
cardiovascular events (Oh et al., 2011). In addition, lifestyle changes and physical 
exercise associated with a proper diet can reduce the prevalence of metabolic 
syndrome by 24% (Mecca et al., 2012). Figure 1.2 summaries the strategies that can 
be involved in reducing metabolic syndrome. 
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Figure 1.2: Strategies to reduce metabolic syndrome. 
 
Omega-3 fatty acids supplementation decreased metabolic syndrome 
prevalence after lifestyle modification program, where metabolic syndrome patients 
were given long-chain polyunsaturated fatty acids (LC-PUFA) supplementation and 
protein meal replacement under calorie-restricted dietary conditions (de Camargo 
Talon et al., 2015). Omega-3 fatty acids exert beneficial effects on metabolic 
parameters, including reductions in blood glucose and triglyceride concentrations, 
HOMA-IR, circulating fatty acid profiles and the concentrations of the inflammatory 
cytokine IL-6 (de Camargo Talon et al., 2015). A high intake of omega-3 fatty acids 
including α–linolenic (ALA), eicosapentaenoic acid (EPA) and docosahexaenoic acid 
(DHA) attenuated the signs of metabolic syndrome in a rat model (Poudyal et al., 
2011).  
 Pharmacological interventions are effective in treating severe metabolic 
diseases including chronic obesity. Weight-loss drugs that have been used include 
fenfluramine, sibutramine and rimonabant as these drugs suppress food intake (Brown 
et al., 2015). Other treatments include thyroid hormones and inhibitors of gut enzymes 
such as α-glucosidase, α-amylase and sucrase (Douglas and Munro, 1982). These 
hormones and inhibitors promote the loss of fat through increased metabolic rate or 
through decreased absorption of nutrients from the gut (Douglas and Munro, 1982). 
However, these drugs are not devoid of adverse effects and evidence showed a rising 
trend in the occurrence of undesirable complications among patients (Brown et al., 
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2015). Both rimonabant and sibutramine were withdrawn from the market because of 
their adverse effects in 2009 and 2010, respectively (Kang and Park, 2012). Orlistat, a 
lipase inhibitor, is also used for weight reduction but also caused adverse effects. This 
includes reduction in the bioavailability of fat-soluble vitamins because of the 
inhibition of fat digestion (Halford, 2006). Due to these side effects, not a single 
prescription drug currently available will produce significant achievement in weight-
loss with complete safety. In addition, there are only a few studies examining the long-
term safety and efficacy of many of the drug combinations for obesity currently being 
prescribed (Brown et al., 2015, Yanovski and Yanovski, 2014).  
This could be one reason why functional foods are in high demand by the 
market. The growing interest in functional foods with scientifically sustained claims 
include dietary phytochemicals, dietary fibre, resistant starch, prebiotics, probiotics 
and other bioactive compounds in foods that have high potential for health promotion 
and chronic disease prevention (Brown et al., 2015). Diets rich in fruits and vegetables 
are associated with a lower risk of all-cause mortality, particularly cardiovascular 
mortality (Wang et al., 2014). In addition, the intake of whole grains and cereal fibre 
was inversely associated with reduced total and cause-specific mortality (Huang et al., 
2015b). Despite the long lists of functional foods, this thesis will focus on saturated 
fatty acids, linseeds and linseeds products and high amylose wheat as potential 
treatments for metabolic syndrome. 
1.1.7 Saturated fatty acids and metabolic syndrome 
Non-communicable diseases definitely impair the overall quality of life. One 
of the major reversible causes of non-communicable diseases is increased dietary 
intake. Human diets primarily consist of carbohydrates, proteins and fats as 
macronutrients. Nutrient-dense dietary fats and carbohydrates have been considered 
as causes of cardiometabolic conditions (Mozaffarian et al., 2011). Over the years, 
saturated fatty acids (SFA) have been generalised as raising blood low-density 
lipoproteins and thereby increasing the cardiovascular disease risk (Ruiz-Núñez et al., 
2016). In addition, SFA increased endoplasmic reticulum stress, inflammation and 
liver injury to a greater extent than unsaturated fatty acids (Wang et al., 2006, Gentile 
et al., 2011). Recently, there were controversial findings around SFA where there was 
no clear evidence to support SFA links to increased risk of coronary heart disease 
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(Chowdhury et al., 2014, de Oliveira Otto et al., 2012). The research to date has tended 
to be based on generalisations on chemical structure rather than the biological actions 
of individual SFA (Poudyal and Brown, 2015). Moreover, a much-debated question is 
whether the health risk is based upon the quantity rather than the quality of the SFA. 
The inconsistency of findings and uncertainty on the biological effects of individual 
SFA, therefore, need to be explored to fill the gaps and to offer new insights into the 
body of knowledge. 
Dietary fat also provides the essential fatty acids, linoleic and α–linolenic 
acids, to all tissues as these are fundamental to basic physiological functions as energy 
sources, elements of membrane phospholipids and main fuel molecules (Ruiz-Núñez 
et al., 2016). There is a broad spectrum of fatty acids of varying chain length and 
degree of desaturation (Mu and Hoy, 2004). Saturated fatty acids can be classified 
chemically into four subclasses according to their chain length (Figure 1.3): short (3 
to 7 carbon atoms), medium (8 to 13 carbon atoms), long (14 to 20 carbon atom) and 
very long (≥ 21 carbon atoms) (FAO, 2010). The most commonly found SFA in our 
diets are lauric acid (C 12:0), myristic acid (C 14:0), palmitic acid (C 16:0) and stearic 
acid (C 18:0) (Figure 1.3). In healthy people, more than 95% of fatty acids consumed 
in their diet are available to the bloodstream through efficient processes of digestion 
and absorption (Calder, 2015a). De novo synthesis of fatty acids also occurs in the 
human body either from glucose and fructose or from other fatty acids; exceptions to 
this are the essential fatty acids, linoleic and α–linolenic acids, which must come from 
the diet (Calder, 2015b). 
Stearic acid is mostly found in beef tallow and cocoa, palm oil is rich in 
palmitic acid, coconut oil is rich in lauric acid and myristic acid can be found in nutmeg 
oil and butter fat (Poudyal and Brown, 2015, Zock et al., 1994). SFA effects on lipids 
and lipoproteins are modulated by the food sources (Astrup et al., 2011). The majority 
of plant oils contain a significant amount of saturated fatty acids, particularly palmitic 
acid. As a result of its widespread availability in the diet, palmitic acid is the most 
common dietary fatty acid, with stearic acid (18:0) and myristic acid also making 
important contributions to the diet. Depending on the foods eaten, lauric acid (12:0) 
and short- and medium-chain fatty acids may also be consumed in significant 
quantities (Calder, 2015b).  
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The negative impact of saturated fatty acids was first suggested by Keys in the 
Seven Countries Study (Keys et al., 1984). Data from several sources highlighted the 
effects of SFA on total cholesterol (TC), low-density lipoprotein (LDL-C), triglyceride 
(TG) and high-density lipoprotein (HDL-C) (Maki et al., 2012b, Fattore et al., 2014, 
Cox et al., 1995). Different diets rich in palm oil, stearic acid, monounsaturated fatty 
acids (MUFA) or polyunsaturated fatty acids (PUFA) were compared and results 
showed that palm oil raised TC, LDL-C, and HDL-C as well as apoB and apoAI 
(Fattore et al., 2014). When compared to diets with a high content of myristic and/or 
lauric acid, palm oil was associated with lower TC, HDL-C and apoAI and no 
differences in TG, TC:HDL-C or VLDL-C (Fattore et al., 2014). Using lauric acid at 
the energy equivalent of butter resulted in lower TC and LDL-C, but both the butter 
and coconut oil diets raised TC and LDL-C compared to safflower oil (Cox et al., 
1995). A follow-up study by the same investigators in a community-based intervention 
showed that coconut oil reduced LDL-C and apoB compared to butter-based diets (Cox 
et al., 1998). Apart from the findings that linked SFA with dyslipidaemia, others also 
emphasised the effects of SFA on insulin resistance, impaired glucose tolerance, 
systemic inflammation and abdominal obesity (Cascio et al., 2012).  
Since then, emphasis on the restriction of SFA was applied in dietary 
guidelines aiming to improve cardiometabolic health. It is important that current 
advice has a solid scientific basis noting the weaknesses of previous studies given the 
large social impact of dietary advice (Calder, 2015a). This has led to the re-evaluation 
of dietary guidelines for intake and a re-appraisal of the effects of SFA on health (de 
Souza et al., 2015). The role of total fat intake vs. dietary fat quality with respect to 
obesity and weight gain remains controversial and this will be highlighted by this 
thesis as one of the study’s most significant findings. 
 
 
18 
 
 
Figure 1.3: Structures of common dietary saturated fatty acids (SFA). 
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Several meta-analyses have found that intake of SFA was not associated with 
coronary heart disease mortality or other cardiovascular events (Skeaff and Miller, 
2009, Siri-Tarino et al., 2010, de Souza et al., 2015). The concern is now that the health 
effects of reducing SFA consumption vary depending on whether the replacement 
nutrient is carbohydrate, MUFA or PUFA. A systematic review suggested decreased 
SFA consumption, but with increases in carbohydrates, rather than MUFA or PUFA, 
as the replacement nutrient (Micha and Mozaffarian, 2010).  In essence, replacing SFA 
with PUFA modestly lowers coronary heart disease risk, with ~10% risk reduction for 
a 5% energy substitution; whereas replacing SFA with carbohydrate has no benefit and 
replacing SFA with MUFA has uncertain effects (Micha and Mozaffarian, 2010). 
Intervention with progressively increased carbohydrate from 47 to 346 g/day 
with concomitant decreases in total and saturated fat, found that high intakes of 
saturated fat including regular consumption of whole eggs, full-fat dairy, high-fat beef 
and other meats do not contribute to accumulation of plasma SFA in the context of a 
low carbohydrate intake (Volk et al., 2014). Further, a gradual decrease in saturated 
fat to 32 g/day at the highest carbohydrate phase also showed that there were no 
significant changes in the proportion of total SFA in any plasma lipid fractions (Volk 
et al., 2014).  
These findings contradict the popular idea that dietary SFA per se are harmful 
because the role of total fat intake vs. dietary fat quality with respect to obesity and 
other cardiometabolic events is still controversial.  
1.1.8 Functional foods 
It is important to find novel ways to treat metabolic syndrome and these novel 
interventions may include functional foods and nutraceuticals. Functional foods are 
defined as foods either natural or modified that contain biologically active components 
which in adequate amounts can improve health and well-being and reduce the risk of 
disease (Ozen et al., 2012). These foods generally contain health-promoting 
components beyond traditional nutrients; however, it should remain as food and not in 
the form of pills or capsules (Ozen et al., 2012). In the USA, functional foods are 
regulated by Food and Drug Administration (FDA) under the Federal, Food, Drug, and 
Cosmetic Act of 1938 (Sikand et al., 2015). Under this Act, food manufacturers are 
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limited to four categories of claims on food labels as follows: nutrient content claims; 
structure-function claims; health claims and qualified health claims (Sikand et al., 
2015). These functional foods are seen as an alternative way of reducing the rising 
costs of healthcare and ultimately improving the quality of life. Moreover, due to 
increasing interest in health and well-being and readily available information, 
consumer demand for functional foods is increasing and has resulted in the need for 
exploration of food products with beneficial health properties. Based on previous 
studies, the range of readily-available functional foods includes coffee; black tea; low-
fat milk; fruits and vegetables; fermented products; cereals and grains (Shiby and 
Mishra, 2013, Sikand et al., 2015, Brown et al., 2015). This thesis, however, will only 
focus on the health effects of two grains, linseed and high amylose wheat, for the 
management of metabolic syndrome. 
 
1.1.8.1 Linseed as functional food 
Linseed, also known as flax (Linum privatissimum), belonging to the Lineaceae 
family, is a blue flowering annual herb that produces small, flat, golden yellow or 
reddish brown seeds with a crispy texture and nutty taste (Figure 1.4) (Kajla et al., 
2015).  Linseed has been previously described as an excellent source of α–linolenic 
acid (ALA, 18:3n-3) (Poudyal et al., 2013a) and the lignan, secoisolariciresinol 
diglucoside (SDG) (Adolphe et al., 2010) that possess health-beneficial effects. More 
details on linseed as a functional food will be covered in Section 1.2 (Linseed as a 
functional food for the management of obesity). 
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Figure 1.4: Raw linseed, defatted linseed and lignans isolated from linseed.
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1.1.8.2 High-amylose wheat as a functional food 
Wheat (Triticum spp.) is one of the staple foods and a major grain cash crop 
besides rice and maize (Cooper, 2015). This crop originated in both the Levant region 
of the Near East and the Ethiopian Highlands probably around 9,000 years ago and is 
now cultivated worldwide (Cooper, 2015). Millions of tonnes of wheat are produced 
globally each year to meet the demands of consumers. The grain is an important source 
of nutrients, protein, carbohydrates, vitamins, minerals and dietary fibre in human 
food. The vital role of grains in the everyday diet of humans is the basis for modifying 
the major components in cereal grains such as fibre or resistant starch (RS). 
Modification of the grain crops with higher RS will increase nutritional benefits to 
give a profound impact on global population health and the world economy. Resistant 
starch plays a role similar to dietary fibre with beneficial effects on human health and 
provides protection from chronic diseases such as colon cancer, diabetes, obesity, 
osteoporosis and cardiovascular disease (Sestili et al., 2010). 
The manipulation of the amylose/amylopectin ratio in wheat has been made 
commercially viable by the emerging evidence on health benefits of resistant starch 
and the elucidation of the role of enzymes involved in the starch biosynthetic pathway 
along with the isolation of genetic variants for these enzymes (Lafiandra et al., 2010). 
Wheat starch is composed of two main components: amylose and amylopectin (Figure 
1.5) with amylose contributing 20%–30% of the total starch and amylopectin the 
remaining 70%–80% (Cauvain, 2012). Amylopectin is highly branched, easily 
digested to produce a larger rise in blood glucose and subsequently, a larger rise in 
insulin, whereas amylose is a straight chain that limits the amount of surface area 
exposed for digestion and decreases the rate of digestion to glucose. Characteristics of 
four different types of resistant starch are presented in Table 1.3.
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Figure 1.5: Structures of amylose and amylopectin.
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Table 1.3: Characteristics of four different types of resistant starch (RS). 
Type of RS Characteristics  
RS1 The starch is physically inaccessible to digestion due to 
intact cell walls, e.g. grains. 
RS2 Native starch granules protected from digestion by the 
structure of the starch granule. 
RS3 Retrograded starch – e.g. cooked then cooled potato, rice 
or pasta (forms as it cools). 
RS4 Chemically modified starches – do not occur naturally 
but are created to be resistant to digestion. 
Source: (Topping and Clifton, 2001). 
Amylose predominates in resistant starch (RS) and it is defined as the fraction 
of starch that is not hydrolysed in the small intestine (Sharma et al., 2008). RS in the 
presence of heat and water will lead to gelatinisation that makes it easily digested. 
However, at lower temperatures, resistant starch tends to recrystallise and form 
retrograded amylose (Sharma et al., 2008). The retrogradation process increases 
enzyme resistance, hence reducing the digestion rate (Chung et al., 2006). RS is largely 
fermented in the large intestine by the gut bacteria, which leads to the production of 
short-chain fatty acids (SCFA). SCFA are reported to improve the colonic epithelial 
health (Cummings et al., 1996). 
 An elevated amylose content lowers postprandial glycaemia (Hallstrom et al., 
2011, Åkerberg et al., 1998, Granfeldt et al., 1995). This is closely related to the 
formation of enzyme-resistant starch that influences the glycaemic response by 
limiting available glucose (Hallstrom et al., 2011). Another factor contributing to this 
is the formation of complexes between amylose and surrounding lipids and proteins 
that resist enzymatic degradation that may be additional factors contributing to a lower 
rate of starch digestion in products with elevated amylose contents (Hallstrom et al., 
2011).  
 Dietary resistant starch is also positively associated with increased gut 
hormones such as serum glucagon-like peptide 1 (GLP-1) and peptide tyrosine 
tyrosine (PYY) (Charrier et al., 2013). These hormones are associated with increased 
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fermentation and increased caecal butyrate production (Keenan et al., 2006). These 
anorectic gut hormones also play a role in regulating the appetite which can be a 
potential mechanism to combat obesity (De Silva and Bloom, 2012). Accumulating 
evidence supports replacing rapidly digestible starch with resistant starch, thereby 
reducing body weight and adiposity (Birt et al., 2013). However, there is a paucity of 
evidence for increased amylose consumption, for example as high amylose wheat flour 
(Figure 6) improves the signs of metabolic syndrome in a high-carbohydrate, high-fat 
diet. Thus, it warrants further study to quantify the effects on health. 
Figure 1.6: High amylose wheat flour. 
1.1.9 Animal models of obesity and metabolic syndrome 
Animal models have played a critical role in the exploration and characterization 
of disease pathophysiology, target identification, and in the in vivo evaluation of novel 
therapeutic agents and treatments for years. The ideal animal model should replicate, 
to a major extent, both a human disease phenotype and its underlying causality, the 
latter in terms of a mechanism of action that mimics the human disease (McGonigle 
and Ruggeri, 2014). In animal models, the underlying physiological, biochemical and 
molecular biological mechanisms can be examined in a more invasive manner that 
would be unethical in humans, under controlled conditions and without the 
confounding genetic/social factors. Various species such as rat, mouse, guinea pig, 
sheep, dog and pig have been used as models to study human medicine and nutritional 
sciences. 
Pigs are an appropriate biomedical model for humans due to many genetic 
(Lunney, 2007), anatomical (Pracy et al., 1998) and physiological similarities to 
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humans (Puiman and Stoll, 2008). As an example, pigs have been used for studies on 
arterial restenosis because they are devoid of brown fat postnatally and because of their 
similar metabolic features, cardiovascular system and proportional organ sizes 
(Spurlock and Gabler, 2008). However, this type of model is an expensive and time-
consuming option (Litten-Brown et al., 2010). Further, there are relatively few studies 
on cardiovascular disease models in pigs.  
Rodent models have been established in biomedical research for over 100 years 
and have offered many advantages for studies on cardiovascular and metabolic 
diseases. This includes genetic models of obesity and diabetes, including db/db mice, 
ob/ob mice, Zucker diabetics fatty rats and Otsuka-Long Evans Tokushima fatty rats. 
The characteristics of these models include mutations in the leptin gene or receptor 
and decreased cholecystokinin-1 receptor density (Panchal and Brown, 2010). Leptin 
controls energy intake and expenditure, meanwhile cholecystokinin is a peptide 
hormone secreted from L-cells in the intestine that regulates digestion and food intake. 
Genetically engineered diabetic mice models, either transgenic or knockout, were also 
used in metabolic syndrome studies. In these models, proteins involved in 
development of obesity and diabetes were removed which included insulin receptor, 
GLUT4, IRS-1 and IRS-2 (Panchal and Brown, 2010). Other widely-used models 
include type 1 diabetes induced by single injections of alloxan or streptozotocin to 
induce selective necrosis of pancreatic β-cells in rats, mice and rabbits (Damasceno et 
al., 2014). These models provide useful information about particular targeted proteins, 
its receptor and the intracellular pathways involved in the regulation of metabolism 
(Panchal and Brown, 2010).  
The use of hypercaloric diets as models is also a common strategy used to induce 
metabolic syndrome. The diets include fructose, sucrose, cholesterol, saturated fats 
and salt. Researchers have used different combinations of these foods to mimic 
metabolic syndrome. These diet-induced models differ in the contribution of 
carbohydrate and fat to available calories and the sources of fat. In this thesis, the high-
carbohydrate, high-fat diet-induced model of the metabolic syndrome in rats was used. 
This diet has been used because it mimics the human diet associated with the 
development of metabolic syndrome (Panchal et al., 2011). More details are explained 
in Chapter 2. 
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Obesity and Functional Foods
In the short term, energy from food is stored predominantly
as glycogen for rapid release as glucose; in the longer term,
fats are favoured for energy storage. This storage allows the
energy from times of excess to be used in times of famine.
Continued excess energy intake means that stores keep
increasing, resulting in obesity, especially in the abdomen.
Obesity is an enormous cost to the community as it greatly
increases the risk of chronic diseases including diabetes,
disability, depression, cardiovascular disease and some
cancers, as well as mortality [1]. Food is essential for
nutrition, but non-nutritive components of food can promote
health and reduce the risk of disease. This combination of
nutrition and health benefits defines functional foods and
includes bioactive fatty acids, phenolic compounds, plant
sterols, dietary calcium and dietary fibre [2].
History of Linseed
Wild flax fibres were possibly used for making cords by
early hunter-gatherers 32,000-26,000 years ago in Dzud-
zuana cave, Georgia [3], but the evidence for identification
as flax is argued [4]. Flax or linseed (Linum usitatissimum
L.) is now known only as a cultivated plant with domesti-
cation in the Near East as one of the original crops in agri-
culture more than 8000 years ago, with pale flax as the
progenitor [5–7]. Linseed is the emblem of Northern Ireland,
and common linseed is the national flower of Belarus. Lin-
seed has been widely used to make linen for cloth since
ancient times. Linseed oil has been used for medicinal pur-
poses in both ancient and modern societies and has been
discussed as a modern functional food [8].
Linseed is found in two varieties with shiny yellow or
dark brown seed. The seed is oblong in shape, flattened with
a pointed tip, smooth glossy surface, comprising an embryo
with two cotyledons surrounded by a thin endosperm [9].
Linseed is mainly grown for its oil as a major source of
α-linolenic acid (ALA, Fig. 13.1), the essential n-3 fatty
acid, but there are also industrial, medicinal and nutritional
uses. Linseed yields vary depending on the season, weather
and location, with best yields in moderate-to-cool climates
[10]. Canada is the world’s largest producer of linseed with
2013 production of 712,000 tons or around 32 % of the
world production of 2.2 million tons; other countries pro-
ducing more than 100,000 tons in 2013 were China, Russia,
Kazakhstan, India and Ethiopia [11, 12]. Australia is one of
many minor producers with about 7000 tons in 2013. The
average yield in Canada in 2013 was 1728 kg/ha with lower
average yields in Australia of 1133 kg/ha and India of
435 kg/ha [12].
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1.2 Linseed as functional food for the management of obesity
Linseed Composition
Canadian linseed contained an average of 41 % oil, 20 %
protein, 29 % total carbohydrate mainly as fibre (28 %) with
some sugars and starches (1 %), 7.7 % moisture and 3.4 %
ash [13]. Comparisons of protein, fat and carbohydrate
content of linseed, linseed meal, de-oiled linseed meal and
processed fractions of linseed oil are available [14]. The
2012 survey of Canadian linseeds showed that the oil con-
tained 56.7 % ALA, 19.2 % oleic acid, 14.7 % linoleic acid,
5.0 % palmitic acid, 3.4 % stearic acid and 0.2 %
non-esterified fatty acids [14]. Linseeds contain plant lig-
nans, especially secoisolariciresinol diglucoside (SDG),
which act as precursors of mammalian lignans also known as
enterolignans (Fig. 13.2), as well as vitamins and minerals
(Table 13.1) [8].
Isolation of Linseed Oil
High-quality linseed oil is produced commercially by pro-
cesses that include seed cleaning, flaking, cooking, pressing,
solvent extraction using n-hexane and solvent removal [15].
These methods will influence the quality of oil because of
the heat involved during the procedures. In addition, the use
of n-hexane in defatting linseed meal enriches cyanogenic
glycosides such as linustatin (Fig. 13.3), neolinustatin and
linamarin which can result in goitrogenic problems in
humans [16]. Cold press isolation is preferred to obtain
high-quality oil but this process consumes more energy with
lower yield [17]. The lack of refining processes of cold press
oil is a marketing advantage by producing “first press” oil
[18]. Alternative extraction methods that improve yield and
maintain quality and stability of the oil include supercritical
fluid extraction, accelerated solvent extraction, aqueous
enzymatic extraction, ultrasound-assisted extraction and
microencapsulation of oil by spray-drying techniques [17,
19]. The oil yields obtained by supercritical fluid and
accelerated solvent extraction of 36.49 g and 41.90 g/100 g
seeds, respectively, compared well to conventional solvent
extraction of 42.40 g/100 g [15].
Pharmacology and Therapeutic
Benefits of ALA
Linseed is high in the essential n-3 fatty acid, ALA.
The Australian Heart Foundation recommends the con-
sumption of at least 2 g/day of ALA to reduce the risk of
heart disease [20].
ALA is highly bioavailable with oral absorption in adults
of 96 % [21] while a small proportion may also be converted
to conjugated linolenic acid primarily in the caecum and
colon by the gut microbiota [22]. In preterm infants,
absorption of [U-(13)C] labelled ALA from preterm for-
mulae ranged from 74 to 98 % with higher absorption with
increasing birth gestation [23]. Higher plasma ALA con-
centrations were observed after whole linseed supplemen-
tation compared to milled seed or linseed oil
supplementation [24, 25]. Further, in vivo experiments in
rats suggest that emulsification of linseed oil increases the
rate and extent of ALA recovery in the thoracic lymph duct
when compared to non-emulsified oil (Cmax = 14 mg/ml at
3 h and 9 mg/ml at 5 h, respectively) with higher area under
the curve in the emulsion group (48 mg × h/ml and
26 mg × h/ml, respectively) [26].
Once absorbed, ALA has at least three metabolic fates. It
may undergo β-oxidation and carbon recycling, be deposited
as ALA predominantly in adipose tissue, skin and muscle, or
undergo a series of elongation and desaturation steps to
produce eicosapentaenoic acid (EPA; 20:5n-3), docosapen-
taenoic acid (DPA; 22:5n-3) and docosahexaenoic acid
(DHA; 22:6n-3) [27–29]. In vivo tracer studies have shown
that the oxidation of ALA in rats is efficient and comparable
to lauric, oleic and linoleic acids, the most highly oxidisable
fatty acids [30]. Of the total ingested ALA, 58.9 % was
assumed to be removed by oxidation, 0.4 % was excreted in
faeces, 10.6 % accumulated as ALA in adipose tissue, 9.7 %
accumulated in the carcass-skin compartment, 4 % accu-
mulated as ALA in organ compartment and 17.2 % accu-
mulated as long-chain derivatives (14 % as DHA and 3.2 %
as EPA + DPA) [31]. Similar results were obtained
for disappearance, excretion and total accumulation with
DHA [31].
Fig. 13.1 Chemical structure of ALA
174 S.R. Shafie et al.
Fig. 13.2 Structures of SDG and its metabolites
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The extent of conversion of ALA to EPA and DHA in
humans has been a matter of great debate [29, 32, 33].
Healthy young men consuming a diet providing 6.3 %
calories from ALA (linseed oil diet containing 28.8 %
energy from fat) increased ALA concentrations in the serum
and peripheral blood mononuclear cells lipids along with
increase in the EPA and DHA contents of mononuclear cell
lipids [34]. A physiological compartmental model of ALA
metabolism derived from plasma concentration-time curves
for radiolabelled ALA, EPA, DPA and DHA after con-
sumption of 1 g oral dose of an isotope tracer ALA suggests
that only about 0.2 % of the plasma ALA was destined for
the synthesis of EPA, but approximately 63 % of the plasma
EPA was accessible for the production of DPA and 37 % of
DPA was available for the synthesis of DHA [35]. However,
in plasma phospholipids, which may more closely resemble
hepatic n-3 fatty acid metabolism, 7 % of dietary ALA was
incorporated into plasma phospholipids, 99.8 % of which
was converted into EPA and 1 % of the EPA was converted
into DPA and subsequently into DHA [36]. This study
suggests that the limited incorporation of dietary ALA into
the hepatic phospholipid pool contributes to the low hepatic
conversion of ALA into EPA [36]. A low conversion of
ALA-derived EPA into DPA might be an additional obstacle
for DHA synthesis [36]. However, in women, estimated net
fractional conversion of ALA to EPA was 21 %, to DPA
was 6 % and to DHA was 9 % with approximately 22 %
undergoing β-oxidation [37]. These results suggest that
women may possess greater capacity for ALA conversion
than men.
Table 13.1 Vitamins and minerals in linseed
Linseed components Quantity/100 g of seed Proportion of recommended dietary
intake (%)
Men Women
Vitamins
Ascorbic acid 0.50 mg 1.1 1.1
Thiamine 0.53 mg 44.2 48.2
Riboflavin 0.23 mg 17.7 20.9
Niacin 3.21 mg 20.1 22.9
Pyridoxine 0.61 mg 46.9 46.9
Pantothenic acid 0.57 mg 9.5 14.25
Folic acid 112 µg 28 28
Biotin 6 µg 20 24
γ-Tocopherol 8.5–39.5 mg – –
Minerals
Calcium 236 mg 23.6 23.6
Copper 1 mg 58.8 83.3
Magnesium 431 mg 107.8 139
Manganese 3 mg 54.5 60
Phosphorus 622 mg 62.2 62.2
Potassium 831 mg 21.9 21.9
Sodium 27 mg 2.9–5.9 2.9–5.9
Zinc 4 mg 28.6 50
Sources Flax Council of Canada (2007) [13] and Nutrient reference values for Australia and New Zealand from National Health and Medical
Research Council [135]
Fig. 13.3 Chemical structure of linustatin
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Obese Patients
Whether ALA-rich linseed promotes weight loss in obese
humans is controversial. Short-term (2–8 weeks) dietary
intervention studies with linseed oil or flour supplementation
in obese patients did not provide any evidence of weight loss
[38, 39]. However, 12 weeks of linseed supplementation
(30 g/day) in patients with metabolic syndrome decreased the
prevalence of metabolic syndrome along with reduced central
obesity, body weight, serum glucose, total- and LDL-
cholesterol, apolipoprotein (Apo) B, ApoE and blood pres-
sure [40]. However, it should be noted that the patients in the
12-week study were also undergoing lifestyle counselling
using the American Heart Association guidelines [40].
Nevertheless, clinical studies consistently report benefi-
cial effects of linseed in obese patients. In overweight or
obese men and postmenopausal women with pre-diabetes,
13 g of ground linseed for 12 weeks decreased glucose and
insulin concentrations and insulin sensitivity (HOMA-IR)
[41]. Similar improvement in HOMA-IR was observed in
obese glucose-intolerant patients [42]. Further, in
middle-aged men and postmenopausal women, 40 g/day of
ground linseed-containing baked products for 10 weeks
improved insulin sensitivity suggesting that these effects are
also observed in non-obese patients [43].
However, both short-term (3 weeks) and long-term
(3 months) intervention studies with ALA from different
sources including linseed oil did not improve glycaemic
control in healthy or diabetic patients [44, 45]. ALA
(6 g/day) from fortified rapeseed oil for 3 weeks in healthy,
non-obese subjects did not affect fasting serum concentra-
tions of glucose, insulin, fructosamine or hemoglobin A1c
(HbA1c) [44]. ALA (5.5 g/day from 10 g/day linseed oil) in
type 2 diabetic patients for 3 months also did not affect
fasting serum glucose, insulin or HbA1c concentrations [45].
Together, these studies suggest that non-ALA components
from linseed may be responsible for the improved insulin
sensitivity in response to linseed supplementation.
Obesity-related inflammation is a key determinant of
insulin sensitivity [46] with increased pro-inflammatory
cytokines such as tumor necrosis factor-α (TNF-α),
interleukin-6 (IL-6) and monocyte chemoattractant protein-1
(MCP-1) and decreased anti-inflammatory adipokines such
as adiponectin linked to the development of insulin resis-
tance and type 2 diabetes [47]. It is possible that the
improved insulin sensitivity in response to linseed noted
above may be mediated by suppressing the pro-
inflammatory state. However, this effect may be dependent
on the form of linseed supplementation. A total of 13 g/day
ground linseed (2.9 g/day ALA) for 12 weeks did not affect
plasma C-reactive protein (CRP), adiponectin or IL-6 con-
centrations [41]. Markers of systemic inflammation did not
change at the higher dose of 40 g/day (8.4 g/day ALA)
ground linseed for 10–12 weeks [42, 43]. In contrast, linseed
flour may have anti-inflammatory effects in obese patients
since 30 g/day linseed flour supplementation (5 g/day ALA)
for 2 weeks decreased CRP, serum amyloid A and fibro-
nectin concentrations [39]. In morbidly obese patients, a
higher dose of 60 g/day linseed flour (10 g/day ALA) for
12 weeks decreased neutrophil count and prevented further
increases in fibrinogen and complement C4 concentrations
and prothrombin time [48].
Improved insulin sensitivity and decreases in the
pro-inflammatory state may be further assisted by reduced
apparent digestibility of fat in response to dietary linseed
supplementation [49]. Linseed supplementation in rye bread
for 8 weeks increased faecal dry weight and excreted fat
suggesting decreased fat digestibility without affecting
average transit time [49]; further, linseed does not affect
satiety [50]. In women in the late postoperative period fol-
lowing Roux-en-Y gastric bypass, whole or defatted linseed
did not affect hunger, satisfaction, fullness or desire to eat for
up to 180 min after ingestion of test meals [50]. However,
defatted linseed increased serum leptin concentrations [50].
Obesity is also a key risk factor for breast cancer, particularly
in postmenopausal women [51]. Elevated oestradiol, oestrone
and testosterone concentrations are important predictors of
breast cancer in postmenopausal women [52–54]. In post-
menopausal women, consuming 7.5 g/day of ground linseed
for the first 6 weeks and 15 g/day for an additional 6 weeks
decreased oestradiol, oestrone and testosterone concentrations
with pronounced effects in overweight/obese women [55]. The
decreases in these hormone concentrations in response to lin-
seed do not seem to worsen osteoporosis. A systematic review
of 30 human and animal studies suggested that ALA from
linseed oil, but not the lignan fraction, benefited osteoporotic
bone, especially together with oestrogen therapy [56].
Further, in obese insulin-resistant patients, ALA supple-
mentation (20 g/day for 4 weeks) from margarine products
based on linseed oil increased systemic arterial compliance
without changing mean arterial pressures [57]. Many animal
and human studies have confirmed the blood pressure lower-
ing effects of linseed but only after 12 weeks of treatment [58].
Other sources of ALA, such as rapeseed oil, perilla oil
and chia seed, reduced blood pressure with greater reduc-
tions in diastolic blood pressure [59–62], serum inflamma-
tory biomarkers such as CRP, plasminogen activator
inhibitor-1 (PAI-1) and TNF-α, as well as YKL-40
(chitinase-3-like protein 1), an inflammatory biomarker for
coronary artery disease [60, 62, 63], and reduced triglyc-
erides [59, 63] in obese or overweight patients with meta-
bolic syndrome but with no effect on body weight.
In summary, whole linseed improves insulin sensitivity,
linseed flour but not oil attenuates the pro-inflammatory state
and linseed oil but not the lignan fraction benefits osteo-
porotic bone in obese or overweight patients.
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Obese Rodents
Studies in obese rats and mice suggest that linseed may
protect from obesity-associated heart, kidney and liver
damage, supporting the beneficial effects of linseed in obese
patients. We have previously demonstrated that linseed and
chia seed oil supplementation for 8 weeks, both containing
about 59 % ALA, did not reduce total body fat in a
high-carbohydrate, high-fat diet-induced model of metabolic
syndrome in rats but induced lipid redistribution away from
the abdominal area and improved glucose tolerance, insulin
sensitivity, dyslipidaemia, hypertension and left ventricular
dimensions, contractility, volumes and stiffness [64, 65].
Additionally, both linseed and chia seed oil supplementa-
tions reversed inflammation in the heart and the liver, cardiac
fibrosis and hepatic steatosis [64, 65].
The obese spontaneously hypertensive/NIH-corpulent
(SHR/N-cp) rat is a genetic model of obesity and type 2
diabetes that consistently develops nephropathy resembling
human diabetic nephropathy [66]. Addition of 20 % linseed
meal to the diets of obese SHR/N-cp rats for 6 months did
not affect body weight or plasma glucose but decreased
plasma insulin concentrations [66]. Measures of renal
function such as plasma creatinine, creatinine clearance and
urinary urea excretion also did not change but urinary pro-
tein excretion was lower in rats fed linseed meal diet [66].
Further, the percentage of abnormal glomeruli with mesan-
gial expansion and the tubulointerstitial score as an index of
severity of tubulointerstitial damage were reduced in rats fed
linseed meal [66]. Linseed oil supplementation reduced
concentrations of fasting serum insulin, urinary thiobarbi-
turic acid reactive substances, hepatic triglycerides and
cholesterol with higher hepatic mRNA expression of PPAR-
γ as early as 4 weeks in SHR/N-cp rats fed a high-fat
diet [67]. Further, linseed meal (20 % of energy) lowered
plasma total, LDL- and HDL-cholesterol, and plasma
triglyceride concentrations and lowered hepatic fat deposi-
tion [68]. Consistent with these findings in the liver, dietary
linseed oil supplementation for 12 weeks in high-fat diet-fed
rats prevented hepatic steatosis with increased EPA
and DHA and lowered arachidonic acid incorporation
into hepatic phospholipids [69]. These effects may be
mediated, at least in part, by SDG as discussed in subse-
quent sections.
In Zucker fatty rats, linseed supplementation for 9 weeks
did not affect obesity, oral glucose tolerance, pancreatic
function or molecular markers related to insulin, glucose and
lipid metabolism [70]. However, ALA-rich linseed oil sup-
plemented diet for 8 weeks decreased adipocyte size and
adipose tissue concentrations of MCP-1, IL-10 and TNF-α
[71]. Linseed oil supplementation reduced T-cell infiltration
into the adipose tissue but did not alter macrophage infil-
tration [71].
Some of the effects of linseed oil may also be neurally
regulated. In a mouse model of diet-induced obesity, partial
substitution of the fatty acid component of the diet by lin-
seed oil attenuated hypothalamic inflammation, hypothala-
mic and whole body insulin resistance and whole body
adiposity [72]. In addition, after intracerebroventricular
injection in obese rats, pure ALA reduced spontaneous food
intake and body mass gain [72]. These effects were
accompanied by the reversal of functional and molecular
hypothalamic resistance to leptin/insulin and increased
pro-opiomelanocortin and cocaine- and amphetamine-
mediated upregulation of transcript expressions [72]. Addi-
tionally, ALA inhibited the AMP-activated protein
kinase/acetyl-CoA carboxylase (AMPK/ACC) pathway and
increased carnitine palmitoyltransferase 1 (CPT1) and
stearoyl-CoA desaturase-1 (SCD-1) expression in the
hypothalamus [72]. Finally, acute hypothalamic injection of
ALA activated signal transduction through the recently
identified G protein-coupled receptor (GPR) 120 unsaturated
fatty acid receptor [72].
Possible Mechanisms of Action of ALA
The mechanisms of action of ALA can be broadly classified
into three categories depending on its metabolism. Firstly,
ALA may act directly, as shown in studies on insulin
secretion and sensitivity. ALA is considered to be the
endogenous ligand of GPR40 and GPR120, and these
receptors are the predominant mediators of ALA-induced
insulin secretion [73]. The insulinotropic effects of ALA
may be augmented by ALA-induced expression and secre-
tion of insulin-like growth factor-I from hepatocytes [74].
Further, the effects of ALA could be mediated by reduced
production of pro-inflammatory cytokines from adipose tis-
sue [71] leading to improved insulin sensitivity in both
animal and human studies as discussed in preceding sec-
tions. Further, ALA supplementation may suppress the
expression and activity of SCD-1 [64, 65, 75–77]. Sup-
pressed SCD-1 activity reduces body adiposity, increases
insulin sensitivity, provides resistance to diet-induced obe-
sity and may produce anti-inflammatory effects such as
reduced macrophage inflammatory response, reduced
expression of MCP-1, TNF-α, PAI-1 and vascular cell
adhesion molecule 1 (VCAM-1), as well as chemokine
receptor 2, colony stimulating factor 1 (CSF-1) receptor and
decreased DNA-binding activity of NF-κB p65/50 [78–82].
Secondly, assuming adequate conversion, some of the
effects of ALA could be mediated by EPA and DHA. EPA
and DHA limit both hypertrophy and hyperplasia of adipo-
cytes, increased lipolysis and increased fat oxidation, assis-
ted by increased expression and activity of CPT1 and
peroxisomal acyl-CoA oxidase gene that regulate the
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alternate pathway of fatty acid oxidation [29]. Further, EPA
and DHA can also directly act on GPR120 in the
enteroendocrine L cells to secrete glucagon like peptide-1, a
potent insulin secretagogue [83].
Thirdly, metabolites of EPA and DHA could also mediate
the effects of ALA. 5-hydroxy-eicosapentaenoic acid
(5-HEPE), a direct metabolite of EPA, is a potent agonist for
GPR119, expressed in the pancreas and the intestine, and
enhances glucose-dependent insulin secretion [84]. Further
metabolism of EPA by the action of lipoxygenase and
cyclooxygenase produces eicosanoids that induce vasodilata-
tion and are potent anti-inflammatory and anti-thrombotic
molecules [29, 85]. EPA-derived 15-hydroxy-eicosapentaenoic
acid (15-HEPE) may have anti-inflammatory effects through
the inhibition of 5-lipoxygenase, a major enzyme that generates
pro-inflammatory lipid mediators [86]. Additionally,
ω-hydroxyl fatty acids such as 7,18-epoxyeicosatetraenoic
acid and 19,29-epoxy docosapentaenoic acid derived by the
action of cytochrome epoxygenases on EPA and DHA,
respectively, have potent anti-inflammatory effects and reduce
blood pressure [86]. Effects on renal function may be mediated
by ALA-derived oxylipins associated with reduced glomeru-
lomegaly in diet-induced obese rats fed a linseed oil supple-
mented diet [87].
DHA metabolites including resolvins, protectins, mar-
esins, docosatrienes and neuroprotectins are important res-
olution phase mediators of inflammation [88–90] that could
mediate important anti-inflammatory responses to ALA.
The production of DHA-derived 17-hydroxy-DHA, the
precursor of resolvin D1 and protectin D1, is decreased in
adipose tissue of obese mice [91]. Further, in these obese
mice, 17-hydroxy-DHA decreased the expression of pro-
inflammatory cytokines (TNF-α, F4/80 and IL-6), increased
adiponectin expression and improved glucose tolerance and
insulin sensitivity [91]. In db/db mice, treatment with
resolvin D1 (2 µg/kg) improved glucose tolerance,
decreased fasting blood glucose concentrations, increased
insulin-stimulated Akt phosphorylation in adipose tissue,
increased adiponectin, decreased IL-6 and reduced
F4/80+CD11c+ macrophages in adipose tissue indicating the
important role of resolvin D1 in resolution of inflammation
[92]. These studies provide evidence for the role of
DHA-derived resolvin D1 in attenuation of inflammation,
and hence, ALA-derived DHA could produce the same
responses in obesity.
Isolation and Pharmacology of SDG
from Linseed
Linseed is one of the richest sources of plant lignans with
SDG as the major component at 1–26 mg/g of seeds or about
75–800 times greater concentrations than in other fibre-rich
plants [13, 93]. SDG content depends on the linseed cultivars,
growing region and method of analysis [94]. SDG is stored in
plants as a complex macromolecular structure with an ester
linkage to 3-hydroxy-3-methyl glutaric acid to give a
molecular weight of*4000 Da [95]. Other lignans in linseed
include isolariciresinol and pinoresinol, also found in similar
concentrations in sesame seeds [96], and matairesinol [97].
The most common extraction method for SDG uses aliphatic
alcohol extraction followed by alkaline hydrolysis and chro-
matographic separation [16]. This was less efficient than
direct alkaline hydrolysis in aqueous or alcoholic solutions as
an initial alcoholic extraction did not completely recover the
lignan from the plant matrix [98].
The biological responses to SDG from linseed are related
to the gut bacteria-mediated conversion to the enterolignans,
enterodiol and enterolactone (Fig. 13.2) [99, 100]. Interac-
tions between dominant and subdominant intestinal anaer-
obes were involved in lignan breakdown by deglycosylation,
demethylation, dehydroxylation and dehydrogenation of
SDG [101, 102]. The oral bioavailability of lignans was
influenced by the microflora present in the intestine, antibi-
otic use, food matrix, type and form (aglycone or conju-
gated) of plant lignan, chronic exposure and other
host-related factors such as age and gender [103]. Entero-
diol and enterolactone are absorbed by the colonic epithe-
lium either as glucuronides or sulphate conjugates or as free
forms into the blood stream or directly excreted via faeces
[104]. Conjugated enterolignans are absorbed from intestinal
tract and transported to the liver, while free forms are con-
jugated before being released into the bloodstream [105].
Both forms undergo enterohepatic circulation with further
metabolism in the colon and excretion in the urine in con-
jugated form [106]. The enterolignans are excreted via urine
with conjugated enterolignans excreted mainly as
monoglucuronides with only small amounts excreted as
monosulphates or free aglycones [107, 108].
Pharmacokinetic studies on oral SDG have been reported
in both animals and humans. SDG was administered to male
and female Sprague–Dawley rats by gavaging 3H-SDG
(3.7 kBq/g body weight) and unlabelled SDG (5.3 µg/g
body weight) daily [109]. Total lignan content was excreted
primarily in faeces (40–83 %) and urine (1.2–5.2 %) in both
genders. After 1–7 days dosage with SDG, most of the tissue
lignans were accumulated in the liver (48–56 %) in both
males and females. Prolonged 3H-SDG dosage demonstrated
an increased accumulation in skin and kidneys. Serum
concentrations were stable after exposure for 7 days. Gender
differences in lignan tissue distribution were observed, with
higher concentrations in females in heart and thymus at all
time points. This finding suggests the possibility for distinct
treatment responses in males and females [109].
In a human study, 6 male and 6 female healthy volunteers
ingested a single dose of SDG (1.31 µmol/kg body weight)
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[99]. Enterodiol and enterolactone reached their maximum
plasma concentrations at 14.8 ± 5.1 h and 19.7 ± 6.2 h,
respectively, after ingestion. Enterodiol showed a shorter
mean elimination half-life of 4.4 ± 1.3 h than enterolactone
(12.6 ± 5.6 h). Enterolactone demonstrated a higher mean
area under the curve (1762 ± 1117 nmol/L h) than entero-
diol (966 ± 639 nmol/L h). Similarly, enterolactone
(35.8 ± 10.6 h) has a longer residence time than enterodiol
(20.6 ± 5.9 h). These results indicate that enterolignans
accumulate in plasma when SDG is consumed 2–3 times a
day before reaching a plateau state. This study also showed
that, within 3 days, up to 40 % of the ingested SDG was
excreted via urine as enterolignans, with 58 % as entero-
lactone [99].
The bioavailability and pharmacokinetics of SDG have been
measured using a range of dosages and purities of the SDG
[110]. Healthy postmenopausal women were given 25, 50, 75,
86 or 172 mg of SDG and purity of 28.8, 43 or 74 % SDG for
one week. The sugar moiety of SDGwas efficiently hydrolysed
by gastrointestinal bacteria to produce secoisolariciresinol.
Enterolignans appeared in the plasma after 5–7 h with a plasma
elimination half-life of 4.8 h. Serum enterodiol and enterolac-
tone concentrations peaked after 12–24 h and 24–36 h,
respectively, and the half-lives were 9.4 h and 13.2 h. This
study observed linear dose responses over a relatively wide
range of dietary SDG intakes. In addition, the bioavailability of
secoisolariciresinol was correlated (r2 = 0.835) with cumulative
5-day lignan excretion. Changes in the SDG purity did not
change the pharmacokinetics, and serum enterolignan concen-
trations reached steady state after oneweek of daily dosing. This
study suggests that SDG is first hydrolysed and then metabo-
lised in a time-dependent sequence in the gastrointestinal tract
to secoisolariciresinol, enterodiol and ultimately enterolactone,
and these metabolites are efficiently absorbed and predomi-
nantly excreted via urine [110].
Therapeutic Benefits in Humans
The effects on cardiovascular function have been investi-
gated using different SDG doses, different purity of the
compound, with interspecies differences that influence the
pharmacokinetic reactions and length of study period.
A better understanding of SDG metabolism is needed to
verify the best model and method to determine the potential
for improvements in cardiovascular health.
A study on moderately hypercholesterolaemic non-obese
men given a low dose of SDG (100 mg, equivalent to 7.5 g
of linseed) did not change the body weight and BMI of the
subjects at 12 weeks [111]. However, the treatment
decreased the ratio of LDL-/HDL-cholesterol and serum
cholesterol concentrations. These effects may be mediated
by a decrease in the mRNA expression levels of sterol
regulatory element-binding protein-1c (SREBP-1c) in the
liver. Further, this treatment regimen decreased the activities
of the plasma hepatic diseases risk markers, alanine
transaminase (ALT) and γ-glutamyl transferase (GGT), but
not aspartate transaminase (AST) [111].
Recently, a short-term trial using 40 g dose of golden lin-
seed for 28 days in obese subjects showed no significance
difference in body weight, BMI, waist circumference or blood
pressure [112]. However, the results obtained demonstrated
reduced fasting blood glucose concentrations and the study
suggested increased glucose elimination via increased
translocation of GLUT4 on the cell membrane and increased
basal glucose uptake by redistribution of GLUT1 as plausible
mechanisms. Reduction in three indicators of cardiac damage,
lactate dehydrogenase (LDH), total creatine kinase (CK) and
CK-MB isoform, strongly suggests cardioprotective effects
with SDG from golden linseed [112]. Furthermore, the lignans
such as SDG were most likely to be responsible for the
improved function of the liver (measured as serum activities of
ALT and AST) and kidneys (measured as serum creatinine,
uric acid and blood urea nitrogen). Furthermore, SDG
decreased serum malondialdehyde (MDA) and protein car-
bonyls and increased glutathione, indicating reversal of the
oxidative stress. In addition, increases in antioxidant enzyme
activities (superoxide dismutase, catalase and glutathione
peroxidase) were observed after 28 days of treatment [112].
Actions in Rodents and Rabbits
SDG and secoisolariciresinol demonstrated strong free rad-
ical scavenging activity and antioxidant activity in vitro
[113]. The pharmacological responses to SDG and its
metabolites have been measured in different animal models
including rabbits, rats and mice. Different mechanisms of
action leading to anti-atherogenic and cardioprotective
effects have been proposed.
SDG treatment in hypercholesterolaemic rabbits showed
consistent cholesterol-lowering and anti-atherosclerotic
responses [114–116]. Reduction of serum cholesterol,
LDL-cholesterol and lipid peroxidation products and an
increase in HDL-cholesterol were seen after 8 weeks of
treatment with 15 mg/kg body weight of SDG in 1 %
cholesterol diet and 40 mg/kg body weight of lignan com-
plex in 0.5 % cholesterol diet in rabbits [114, 115]. These
studies suggest the decreases in serum total cholesterol and
LDL-cholesterol with lignan complex could be due to the
3-hydroxy-3-methyl glutaric acid and SDG content of the
lignan complex [115]. Lower serum and aortic MDA con-
centrations were associated with reduced development of
atherosclerosis in rabbits fed the lignan complex. These
effects may be mediated by antioxidant activity of SDG to
prevent oxygen radical-induced endothelial cell injury [115].
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A different intervention which included 2 months of regular
diet following 2 months of a high cholesterol diet with
supplementation of 20 mg SDG/kg body weight/day resul-
ted in no reduction in serum lipids. However, prevention of
progression of atherosclerosis was seen that may be asso-
ciated with a reduction of aortic oxidative stress [116].
Lipid homoeostasis was evaluated in diet-induced
hypercholesterolaemic female Wistar rats treated with
either SDG or secoisolariciresinol at different dosages of 0, 3
or 6 mg SDG/kg body weight/day or 0, 1.6 or 3.2 mg
secoisolariciresinol/kg body weight/day, respectively, for
4 weeks [117]. Both SDG and secoisolariciresinol showed
dose-dependent reduction in the serum and hepatic choles-
terol concentrations. These changes were accompanied by
increased hepatic expression of acetyl-CoA acetyltransferase
2 by SDG (3 and 6 mg/kg body weight/day) and decreased
hepatic expression of cytochrome P450 7a1 by secoisolari-
ciresinol (3.2 mg/kg body weight/day). No other changes
were observed in hepatic expression of lipid controlling
targets in rats treated with SDG or secoisolariciresinol [117].
High-carbohydrate (10 % fructose in drinking water)
diet-fed male Sprague–Dawley rats as a model of hyper-
triglyceridaemia were used to measure dose-dependent effects
of 0, 3 and 6 mg SDG/kg body weight/day for 2 weeks [117].
In contrast to the hypercholesterolaemic rats, no changes in
body and organ weights, serum triglycerides, phospholipids
and non-esterified fatty acid concentrations, and hepatic
steatosis relative to vehicle control fructose-fed rats were
measured at any dose [117]. SDG administration did not
change the hepatic expression of PPAR-α or SREBP-1c fol-
lowing 10 % fructose in water supplementation [117].
Acute hyperlipidaemia can be produced in rats with
poloxamer-407 (1 ml of 30 %, w/v; intraperitoneally) as it
inhibits lipoprotein lipase and elevates the production of
triglycerides. Oral treatment with a methanol fraction of lin-
seed lignan concentrate (MF-FLC) in poloxamer-407
hyperlipidaemic rats was evaluated at 0, 15 h and 24 h
after injection [118]. The administration of MF-FLC
(100 mg/kg) and n-3 fatty acid (1 ml/kg; mainly contain-
ing DHA) reduced serum cholesterol, triglycerides and
VLDL-cholesterol, whereas HDL-cholesterol was increased
[118]. The combination of MF-FLC and n-3 fatty acid acts
mainly by blocking cholesterol synthesis.
In rats given 2 % cholesterol for 8 weeks, SDG 20 mg/kg
body weight improved lipid profiles after 2 weeks treatment.
Dietary supplementation of SDG reduced infarct size,
improved myocardial function and enhanced neovasculari-
sation in the infarcted myocardium. These effects were
mediated through improved thickness of ventricular wall
during diastole and systole as well as improved left ven-
tricular systolic function in the rats treated with SDG. Fur-
thermore, SDG enhanced cardiac function by increasing
protein expression of endothelial NOS (eNOS), vascular
endothelial growth factor (VEGF) and hemeoxygenase-1
(HO-1) in SDG-treated rats [119].
In high-fat diet-fed mice, SDG supplementation (0.5 and
1.0 % (w/w) for 4 weeks) reduced high-fat diet-induced
increases in visceral and liver fat accumulation, and in
plasma lipids, insulin and leptin concentrations [120]. These
effects of SDG were accompanied by suppressed SREBP-1c
mRNA expression in the liver, increased adiponectin mRNA
expression in the white adipose tissue and increased CPT1
mRNA expression in the skeletal muscle [120]. Further, the
SDG metabolite, enterodiol, induced adipogenesis-related
mRNA expression including adiponectin, leptin, GLUT4
and PPAR-γ, and induced PPAR-γ DNA-binding activity in
3T3-L1 adipocytes [120].
Linseed lignans may be able to prevent obesity in rodents.
Treatment with 0.02 % SDG (35 %) lignan-enriched linseed
powder (LEFP) lowered body weight as compared to high-fat
diet control group due to lower visceral fat weight. In addition,
lower plasma concentrations of leptin and higher plasma
concentrations of adiponectin reflected a low visceral fat
weight in treated rats. Supplementation with LEFP for
12 weeks improved systolic blood pressure and serum
triglycerides, LDL-cholesterol and HDL-cholesterol concen-
trations. However, a limitation of this study should be noted as
LEFP also contains other bioactive compounds including
coumaric acid glucoside and ferulic acid glucoside [121].
Male Wistar rats were pretreated with 500 mg/kg flax
lignan concentrate (FLC) for 8 days before isoprenaline
(ISO) at a dose of 5.25 mg/kg on day 9 and 8.5 mg/kg on
day 10 to induce moderate lesions in the myocardium [122].
The results showed that ISO + FLC rats had lower CK-MB,
LDH and AST levels indicating protection against necrotic
damage of the myocardial membrane. Inflammation, necro-
sis and congestion were observed in a smaller area of the
heart in FLC + ISO compared to the ISO rats indicating that
the rat hearts were partially protected by pretreatment with
FLC (500 mg/kg) against isoprenaline-induced cardiotoxic-
ity [122].
Isolation and Therapeutic Effects of Dietary
Fibre from Linseed Mucilage
Linseeds contain approximately 8 % of the exopolysaccha-
ride, mucilage [123], that can be easily extracted from the
seed coat using water as this allows swelling of cell walls
and then extrusion of the content on the surface of the seeds
[124]. Basic or acid treatments will also extract the mucilage
but these methods lead to higher concentrations of proteins
in the mucilage and their subsequent denaturing [125].
Improved techniques have been introduced using
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non-classical heating modes such as microwave and ultra-
sound [126, 127]. However, these procedures with longer
treatment times and higher temperatures can lead to degra-
dation of the polysaccharides [127, 128]. The extraction
yield of mucilage is also dependent on both the procedure
and the variety of the raw material [129]. Linseeds contain
approximately 28 % fibre, of which 70–80 % is
water-soluble with most of these compounds present in the
outermost layer of the seed hull [124]. The kernel of linseeds
contains about 20 % fibre [130]. The major constituents of
linseed mucilage are neutral and acidic polysaccharides, with
the neutral fraction of the linseed mucilage composed mainly
of arabinoxylans (Fig. 13.4) [131]. Linseed mucilage is used
in the food industry to be incorporated into the daily diet in
beverages, dairy products, bakery products and processed
foods including thickeners, emulsifiers, stabilisers and fat
replacers [130].
Human Studies
Linseed also consists of insoluble (viscous) dietary fibre that
was found to play a role in cholesterol regulation. A study
comparing three different diets, a low-fibre control diet, a
diet with linseed fibre drink and a diet with linseed fibre
bread for seven days, showed that a diet with 5 g dietary
linseed fibre lowered fasting total cholesterol and
LDL-cholesterol by 12 and 15 %, respectively, as compared
to control group [132]. Linseed drink increased faecal
excretion of energy and fat excretion by 23 and 55 %,
respectively. Linseed bread ingestion was less effective than
linseed drink due to the effect of differences in food matrix
as baked products had less ability to induce viscosity due to
processing and storage [132]. These results were consistent
with a study showing that consumption of six wheat flour
chapattis containing linseed gum (5 g) for three months by
type 2 diabetic patients lowered fasting blood glucose, total
cholesterol and LDL-cholesterol [133].
An intervention of rye bread enriched with whole linseed
(10 %) was tested for 7 days in 11 healthy young men to
measure the apparent digestibility of fat and the gastric
transit time [49]. Linseed rye bread results in an increase in
the faecal fat excretion. The possible mechanisms proposed
from the results were inhibition of the pancreatic lipase
activity, or binding of fat in the gastrointestinal tract by
linseed. Linseed mucilage is proposed to be responsible for
these effects as arabinoxylans present in linseed showed
faecal bulking effects [49].
In a double-blind randomised crossover 7-h test meal
study, 18- to 40-year-old males were given diets containing
low dietary fibre, whole linseed, low dose mucilage and high
dose mucilage [124]. This study identified the role of these
interventions on the changes in plasma metabolic profile
including glucose, triglycerides, non-esterified fatty acids and
Fig. 13.4 Structure of arabinoxylans
182 S.R. Shafie et al.
insulin concentrations during 7 h. High dose mucilage meal
reduced the area under the curve for triglycerides and
non-esterified fatty acid concentrations during 7 h. High dose
mucilage meal also provided greater feeling of satiety with
less hunger and food intake compared to low-fibre meal
[124]. High dose mucilage-containing meal exhibited a
slower increase in ghrelin towards the end of the day indi-
cating a delayed gastric emptying affected by a higher dietary
fibre content of the meal. In addition, these effects may be due
to the impaired dietary triglyceride absorption from the small
intestine and increasing clearance of chylomicron particles
and chylomicron remnant uptake, as well as impaired emul-
sification of lipids [124]. Other mechanisms may involve
direct fat-binding and increased viscosity resulting in
increased emulsified lipid droplet size and decreased lipolysis
due to decreased insulin concentrations. Fermentation of
linseed fibre in distal ileum may result in short chain fatty
acids which may play a role in reducing the non-esterified
fatty acids along with the reduction in the rate of glucose
uptake leading to a decreased demand for insulin to match the
rate of glucose uptake in peripheral tissues [124]. Another
study suggests the plausible mechanism of the involvement of
linseed fibre in interference with bile acid metabolism which
hinders micelle formation and inhibits re-uptake of bile acids
that leads to increased hepatic synthesis of bile acids, thus
reducing cholesterol concentrations [132].
Rodent Studies
In male Wistar rats, dietary fibres including extracted linseed
fibre and whole linseed fibre were tested for 21 days.
Increased faecal fat excretion and reduced body fat and energy
digestibility were seen in rats given extracted linseed fibre that
in consequence suppressed body weight gain. There results
were not seen in the rats that were given dietary fibre from
cellulose, whole linseed or ground linseed [134]. The
decreased energy availability from linseed fibre could be the
reason for the decrease in the body weight. Increased content
in caecum and colonwas also observed in these rats, indicating
increased fermentation with extracted linseed fibre [134].
Conclusion
Linseeds have been used for millennia as food and medicine,
but the evidence supporting their use as a functional food for
the treatment of obesity is relatively recent. Obesity is a
complex disorder, so it is unlikely that a single compound
will reverse the multi-organ effects. Linseeds provide ALA
as an essential n-3 fatty acid, SDG as a lignan as well as fibre
mainly as mucilage. These constituents have multiple bio-
logical effects to decrease the changes in obesity, probably
by different mechanisms. The combination as linseeds can
therefore be accurately described as a functional food. The
full potential of linseeds in human obesity needs to be
defined, and further studies on molecular mechanisms are
also necessary.
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1.3 Objectives 
The main objective of this research is to investigate the effects of saturated fatty 
acids and cereal-based products as functional foods on a validated rat model of 
metabolic syndrome. Towards achieving this primary objective, the related aims 
associated with it are identified as follows: 
1. To determine the effects of different saturated fats together with a high intake 
of simple sugars such as fructose on cardio-metabolic health and on gut structure and 
function; and  
2. To determine the effects of bioactive metabolites (lignans), raw linseed, 
defatted linseed, 5% high amylose wheat, and 20% high amylose wheat on cardio-
metabolic health and on gut structure and function.  
 
The hypotheses of the study are that: 
1. Increased dietary saturated fats together with a high intake of fructose will 
induce metabolic changes and alter gut structure and function in the host but these 
changes will depend on the saturated fatty acid that is administered; and  
2. Lignans, raw linseed, defatted linseed and high amylose wheat will produce 
similar improvements in attenuating the metabolic changes and on gut structure and 
function in rats fed a high-carbohydrate, high-fat diet. 
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Chapter 2 Rat model, materials and methods 
2.1 Rat model 
Metabolic syndrome is usually linked to poor dietary habits that are associated 
with western/cafeteria diet that is rich in fructose, sucrose and animal fat. To mimic 
metabolic syndrome in humans, an appropriate animal model fed with a similar diet 
producing metabolic syndrome complications is warranted. An established rat model 
using complex diet composition including fructose, condensed milk and beef tallow 
exhibits complications including hyperinsulinaemia, impaired glucose tolerance, 
central obesity, non-alcoholic fatty liver disease, cardiac remodelling, hypertension 
and endothelial dysfunction along with mild renal damage and increased pancreatic 
islet mass (Panchal et al., 2011). The advantage of using rat model is it shortened the 
period to develop the syndrome rather than years or decades as in humans. Animal 
study also provides the basic understanding of the intervention strategy before 
translating into human trials. This high-carbohydrate, high-fat diet-induced metabolic 
syndrome rat model has been used earlier to testing natural products for the attenuation 
of metabolic syndrome (Panchal et al., 2012, Poudyal et al., 2013b, Bhaswant et al., 
2015). Different responses resulting from these interventions clearly suggest that this 
model is capable in responding to the pharmacological or nutritional interventions. 
Thus, utilisation of this model is the most relevant as it is close in mimicking human 
metabolic syndrome. 
2.2 Rats and diet 
Male Wistar rats (6 – 8 weeks old, weighing 250 - 300 g, n = 72) were purchased 
from the Animal Resource Centre in Perth, Australia. Rats were housed individually 
in temperature-controlled, 12-h-light/-dark conditions in the animal house facility of 
the University of Southern Queensland.  The rats were acclimatised and were given 
free access to water and standard rat chow prior to diet intervention. All experimental 
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protocols were approved by University of Southern Queensland Animal Ethics 
Committee under the guidelines of the National Health and Medical Research Council 
of Australia. After the acclimatisation period, rats weighing 330 – 340 g were 
randomly allocated into different experimental groups according to studies. 
2.3 Oral glucose tolerance test (OGTT) 
OGTT (Figure 2.1) was performed at 0 week, 8 weeks and 16 weeks (Poudyal 
et al., 2012a, Panchal et al., 2011). Prior to OGTT, the rats underwent food deprivation 
and water ad libitum for 12 hours (overnight). Rats supplemented with fructose water 
were given normal drinking water during this period. The rats were given a dosage of 
2 g/kg body weight of glucose as a 40% solution via oral gavage using a syringe. Tail 
vein blood samples were taken at 30, 60, 90 and 120 minutes following glucose 
administration. The tail vein was pricked and blood was taken to measure the basal 
blood glucose concentrations using Medisense Precision Q.I.D glucose meter (Abbott 
Laboratories, Bedford, MA, USA).   
Figure 2.1: Oral gavage for oral glucose tolerance test 
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2.4 Systolic blood pressure (SBP) and abdominal circumference 
 
SBP measurements were performed on all groups of rats at week 0, week 8 and 
week 16  (Poudyal et al., 2012a, Panchal et al., 2011). The systolic blood pressure of 
the rats was measured under light sedation following intraperitoneal (IP) injection of 
Zoletil (tiletamine 10 mg/kg, zolazepam 10 mg/kg; Virbac, Peakhurst, NSW, 
Australia). Blood pressure measurements were measured using an MLT1010 Piezo-
Electric Pulse Transducer (ADInstruments, Sydney, Australia) and inflatable tail-cuff 
connected to an MLT844 Physiological Pressure Transducer (ADInstruments) and 
PowerLab data acquisition unit (ADInstruments). The abdominal circumference of 
rats was measured using a standard measuring tape during the period of anaesthesia 
for SBP measurements. 
 
2.5 Body composition by dual energy X-ray absorptiometry (DXA) 
 
DXA (Figure 2.2) was performed to measure body composition (bone mass/fat 
mass/lean mass) of the rats at 16 weeks, 2 days prior to euthanasia for 
pathophysiological assessment. Rats were lightly anaesthetised with Zoletil (tiletamine 
15mg/kg with zolazepam 15mg/kg) and Ilium Xylazil (xylaxine 6mg/kg), 
interperitonially. Rats were placed on the Norland XR36 DXA (Norland Corp., Fort 
Atkinson, WI, USA) scanner bed on a sheet of paper in the prone position (Ward LC, 
2009). The scanner was operated according to manufacturer’s instructions for animal 
scanning using manufacturer's recommended software for use with laboratory animals 
(Small Subject Analysis Software, version 2.5.3/1.3.1; Norland Corp) (Panchal et al., 
2011). The precision error of lean mass for replicate measurements, with repositioning, 
was 3.2%. Visceral adiposity index (%) was calculated as: ([retroperitoneal fat 
(g)+omental fat (g)+epididymal fat (g)]/[body weight (g)]×100) and expressed as 
adiposity percent (Panchal et al., 2011). 
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Figure 2.2: Dual energy X-ray absorptiometry (DXA) machine for scanning for body 
composition 
 
2.6 Metabolic rate 
 
Indirect calorimetry was used to measure oxygen consumption and carbon 
dioxide production using a 4-chamber Oxymax system (Columbus Instruments, 
Columbus, OH), with one rat per chamber at 16 weeks. The rat was provided with ad 
libitum food and water during the measurement. Oxygen consumption (VO2) and 
carbon dioxide production (VCO2) were measured individually from each chamber. 
The respiratory exchange ratio (RER=VCO2/VO2) was calculated by Oxymax 
software (v. 4.86). The interpretation of RER values is that oxidation of carbohydrate 
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produces a RER of 1.00, whereas fatty acid oxidation results in a RER of 0.70 
(McLean, 1987). The energy expenditure was derived by assessment of the exchange 
of oxygen for carbon dioxide that occurs during the metabolic processing of food. 
2.7 Isolated Langendorff heart preparation 
Rats were euthanised via intra-peritoneal (IP) injection of Lethabarb 
(pentobarbitone sodium, 100 mg/kg, i.p.; Virbac). Then, heparin (200 IU; Sigma-
Aldrich Australia) was injected through the right femoral vein and blood (~5mL) was 
withdrawn from the abdominal aorta. Hearts were removed and used in isolated 
Langendorff heart preparations (Figure 2.3) to assess left ventricular function of the 
rats (Panchal et al., 2011). Hearts isolated from the rats were immediately perfused 
with modified Krebs-Henseleit bicarbonate buffer containing (in mmol/L): NaCl, 
119.1; KCl, 4.75; MgSO4, 1.19; KH2PO4, 1.19; NaHCO3, 25.0; glucose, 11.0; and 
CaCl2, 2.16 to maintain heart viability. The buffer was aerated with 95% O2–5% CO2 
and maintained at 35°C. The isovolumetric ventricular function was measured by 
inserting a latex balloon catheter into the left ventricle connected to a Capto SP844 
MLT844 physiological pressure transducer and Chart software on a Maclab system 
(ADInstruments). All left-ventricular end-diastolic pressure values were measured 
during pacing of the heart at 250 beats/ min using an electrical stimulator. End-
diastolic pressures were obtained from 0 to 30 mm Hg for calculation of diastolic 
stiffness constant (k, dimensionless). 
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Figure 2.3: Isolated Langendorff heart apparatus 
 
2.8 Aortic contractility 
 
Thoracic aortic rings (~4 mm in length) were suspended in an organ bath 
chamber (Figure 2.4) with a resting tension of approximately 10 mN. Cumulative 
concentration–response (contraction) curves with concentrations ranging from 10-9 to 
10-4 mol/L were measured for noradrenaline (Sigma-Aldrich Australia); 
concentration–response (relaxation) curves with concentrations ranging from 10-9 to 
10-4 mol/L were measured for acetylcholine (Sigma-Aldrich Australia) and sodium 
nitroprusside (Sigma-Aldrich Australia) in the presence of a submaximal (70%) 
contraction to noradrenaline (Poudyal et al., 2010). 
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Figure 2.4: Organ bath setup 
 
2.9 Ileum and colon contractility 
 
Sections of distal ileum and colon of 1 cm length were isolated and immersed in 
a Petri dish containing Tyrode’s solution to ensure tissue viability. The tissues were 
tied with thread and placed in the organ baths with a continuous supply of gas (95% 
O2 – 5% CO2) and were maintained at 37°C to keep the tissue alive. The tissues were 
stabilised at a resting tension of 10 mN. The ileum and colon reactivity as responses 
to acetylcholine (contraction) with a concentration ranging from 10-9 to 10-4 mol/L was 
measured based on dose-response on a MacLab system using Chart software 
(ADInstruments).  
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2.10 Tissue collection and histology 
After performing Langendorff heart perfusion, hearts were separated into right 
and left ventricle (with septum) for weighing. Livers and abdominal fat pads 
(retroperitoneal, epididymal and omental) were isolated and weighed. Organ weights 
were normalised to the tibial length at the time of removal and expressed as mg of 
tissue/mm of tibial length. The heart, liver, small and large intestines of rats (n = 2 
from each group) were exclusively used for histopathological analysis (Poudyal et al., 
2012a). Thin sections (7 µm) of tissues were cut and fixed on slides. Heart sections 
were stained with picrosirius red to study collagen deposition and were analysed using 
fluorescent microscopy (EVOS® FL Cell Imaging System). Haematoxylin and eosin 
stain (Figure 2.5) was used to visualise infiltration of inflammatory cells in both heart 
and liver and then analysed using the same microscope. Periodic acid and Schiff 
reagent stain was used to visualise goblet cells in small and large intestines. From each 
tissue sample, three slides were prepared and two random, non-overlapping fields were 
selected from each slide. A representative picture was randomly selected from each 
group. 
Figure 2.5: Histology staining apparatus 
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2.11 Biochemical analyses 
 
To obtain plasma, blood was centrifuged at 5000×g for 15 minutes within 30 
minutes of the collection into heparinised tubes (Poudyal et al., 2012a). Plasma was 
separated and transferred to Eppendorf tubes for storage at −20°C before analysis. 
Plasma activities of alanine transferase (ALT), aspartate aminotransferase (AST) and 
alkaline phosphatase (ALP) and plasma concentrations of total cholesterol, 
triacylglyceride (TG) and non-esterified fatty acids (NEFA) were determined. All 
these variables were measured using kits and controls supplied by Olympus using an 
Olympus analyser (AU 400, Tokyo, Japan) at The University of Queensland, Gatton 
campus.  
Plasma concentrations of insulin and leptin (Laboratory Diagnostics) were 
measured using ELISA (ALPCO Immunoassays and ENZO) commercial kits 
according to manufacturer-provided standards and protocols using a Titertek 
Multiskan MCC/340 spectrophotometer (Flow Laboratories) and FLUOstar Omega 
Microplate Reader - BMG LABTECH.  
 
2.12 Statistical analysis 
 
All data were presented as mean ± SEM. Each group consists of 12 rats. All 
group data was tested for variance using Bartlett’s test. Variables that were not 
normally distributed were transformed (using log 10 functions) prior to statistical 
analysis. The effects of diet, treatment and their interactions were tested by two-way 
analysis of variance. When interaction and/or the main effects were significant, means 
were compared using Newman-Keuls multiple-comparison post hoc test. Where 
transformations did not result in normality or constant variance, a Kruskal-Wallis non-
parametric test was performed. All statistical analyses were performed using GraphPad 
Prism version 6 for Windows (San Diego, CA). A p value of < 0.05 was considered as 
statistically significant. 
 
 
52 
Chapter 3 Saturated fatty acids in metabolic 
syndrome in rats. 
3.1 Introduction 
Dietary fat is one of the lifestyle factors most often claimed to be responsible 
for the high prevalence of obesity. Many studies have proposed that the type of dietary 
fat plays a more significant role in the aetiology of obesity and metabolic syndrome 
than the absolute amount (Cordain et al., 2005, Agatston, 2005, Bray et al., 2002). 
However, it remains controversial which fatty acids promote obesity. Moreover, 
different dietary fatty acids, even within the same class, elicit different physiological 
responses (Poudyal and Brown, 2015). Saturated fat has long been generalised as the 
main cause of obesity, diabetes and heart diseases. The major saturated fatty acids 
(SFA) usually consumed in human diets are lauric acid (C12:0), myristic acid (C14:0), 
palmitic acid (C16:0) and stearic acid (C18:0) (Jonnalagadda et al., 1995) with the 
richest dietary sources being coconut oil, nutmeg oil, palm oil and beef tallow, 
respectively (Laureles et al., 2002, Piras et al., 2012, Scholtz et al., 2004, Monsma and 
Ney, 1993).  
Epidemiological and clinical studies suggest that saturated fatty acids can have 
different effects on body weight regulation and accumulation of fat in the adipose 
tissues (Hariri et al., 2010b, Storlien et al., 2001, Ferreira et al., 2014). One large study 
with 810 participants demonstrated that a higher saturated fat intake for 6 months in 
adults was associated with a greater weight gain at 18 months (P = 0.002) (Lin et al., 
2012). In contrast, a randomised crossover study of eight overweight or obese subjects, 
replacing SFA with monounsaturated fatty acids (MUFA) for 4 weeks, promoted 
weight loss, but SFA by itself did not promote weight gain (Piers et al., 2003). 
However, different nature of study, sample sizes and time frames could contribute to 
differences in study findings. In the USA, a substantial decline in the percentage of 
energy from total dietary fat and saturated fat during the last two decades has 
corresponded with a massive increase in obesity, and similar trends are occurring in 
other affluent countries (Willett, 2002). This suggests that dietary SFA itself is not a 
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determinant of adiposity. A review on possible roles of dietary fats in obesity using 
animal models show that high saturated fat diets induce obesity (Panchal et al., 2014). 
However, wide variations in fatty acid content and source as well as widely different 
micronutrient compositions (Hariri and Thibault, 2010) make it impossible to 
determine the effects of fat quantity or quality on obesity in animal models. Thus, it is 
important to have well-designed animal models in examining the effects of individual 
saturated fatty acids.  
 An established model of rats fed a high-carbohydrate, high-fat diet for 16 
weeks has previously shown that this diet mimics many signs of human metabolic 
syndrome (Panchal et al., 2011, Poudyal et al., 2012b). Rats fed this diet developed 
hypertension, cardiac fibrosis, higher cardiac stiffness, endothelial dysfunction, 
impaired glucose tolerance, greater abdominal fat deposition, altered plasma lipid 
profile, hepatic steatosis with higher plasma activities of liver enzymes, higher plasma 
concentrations of markers of oxidative stress and inflammation as well as increased 
inflammatory cell infiltration in the heart and the liver (Panchal et al., 2011).  
Since this model mimics most of the signs of diet-induced human metabolic 
syndrome, we conducted the present study to determine the cardiovascular, liver and 
metabolic effects of rats fed corn starch diet or the high-carbohydrate high-fat diet 
containing 20% beef tallow or one of four different saturated fatty acids (lauric, 
myristic, palmitic or stearic acids).  
 
3.2 Methods 
3.1.1 Rats and diet 
All animal experiments were approved by the Animal Ethics Committees of 
the University of Southern Queensland and Queensland University of Technology 
under the guidelines of the National Health and Medical Research Council of 
Australia. The experimental groups consisted of 72 male Wistar rats (9–10 weeks old) 
weighing 332±1g purchased from Animal Resource Centre (www.arc.wa.gov.au). 
Rats were individually housed in a temperature-controlled, 12-h light/dark cycle 
environment with free access to water and food at the University of Southern 
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Queensland Animal House. The rats were grouped into 6 groups of 12 animals. Control 
(CS) diet contained 57% corn starch, 15.5% powdered rat food (Specialty Feeds, Glen 
Forest, Western Australia, Australia), 2.5% Hubble, Mendel and Wakeman salt 
mixture, and 25% water. High fat-high carbohydrate (HCHF) - based diets consisted 
of 17.5% fructose, 39.5% sweetened condensed milk, 20% beef tallow or SFA (20% 
lauric acid (HLA), 20% myristic acid (HMA), 20% palmitic acid (HPA) or 20% stearic 
acid (HSA)), 15.5% powdered rat food, 2.5% Hubble, Mendel and Wakeman salt 
mixture, and 5% water. The preparation and macronutrient and micronutrient 
compositions of CS and HCHF were previously described (Panchal et al., 2011, 
Poudyal et al., 2012a).  All CS-based diets included drinking water without any 
additives while drinking water for H-based diets was supplemented with 25% fructose. 
The carbohydrate intake in both CS and H groups was approximately 68 %. 
Measurements of body weight, and food and water intakes were taken daily to monitor 
the day-to-day health of the rats. Feed conversion efficiency (%) was calculated as:  
feed conversion efficiency (%)= increase in body weight(%)daily energy intake(kJ)  x 100
The increase in body weight (%) was defined as body weight difference between day 
56 (end of week 8) and day 112 (end of week 16); daily energy intake was defined as 
average daily energy intake from the end of week 8 to the end of week 16. 
3.1.2 Echocardiography 
Echocardiographic examinations (Phillips iE33, 12 MHz transducer) were 
performed to assess the cardiovascular structure and function in all rats at the end of 
protocol (Panchal et al., 2011, Poudyal et al., 2012a). Serial, in vivo left parasternal 
and left apical echocardiographic images of rats were obtained using the Hewlett 
Packard Sonos 5500 (12MHz frequency fetal transducer) at an image depth of 3 cm 
using two focal zones. Rats were anaesthetised with Zoletil (tiletamine 15mg/kg with 
zolazepam 15mg/kg; i.p.) together with Ilium Xylazil (xylazine 6mg/kg; i.p.) to 
produce general anaesthesia in rats for 2-3 hours without evidence of cardiac 
depression and positioned in dorsal recumbency. Electrodes attached to the skin 
overlying the elbows and right stifle facilitated the simultaneous recording of a lead II 
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electrocardiogram. Left ventricular M-mode measurements at the level of the papillary 
muscles included measurement of interventricular septum in diastole, diastolic 
posterior wall thickness (LVPWd), internal systolic dimensions, and end-diastolic 
dimension (LVIDd), posterior wall thicknesses and fractional shortening. Cardiac 
output, ejection fraction and left ventricular mass were derived from these values. 
Pulsed-wave Doppler analyses of mitral valve inflows were used as estimates of 
diastolic function. Following the scan, all rats were administered 5 mL (2.5mL each in 
2 sites) of saline subcutaneously and were allowed to recover at a higher room 
temperature (24-25°C) to prevent dehydration and hypothermia respectively.  
 
3.1.3 Other methods 
All other methods were performed as described in Chapter 2 which included 
oral glucose tolerance test, systolic blood pressure, body composition, metabolic rate, 
isolated Langendorff heart preparation, ileum and colon contractility, tissue 
collections, histology and biochemical analysis. 
 
3.1.4 Statistical analysis 
All data were presented as mean ± SEM. Differences between the groups were 
determined by one-way analysis of variance. Statistically significant variables were 
treated with Tukey’s post hoc test to compare each group of animals. All statistical 
analyses were performed using GraphPad Prism version 6 for Windows (San Diego, 
CA). P value of < 0.05 was considered as statistically significant. 
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3.2 Results 
3.2.1 Dietary intake and body composition 
The dietary intake and body composition for each group of rats is presented in 
Table 3.1. The food intake in the CS group was higher than in the other groups. This 
is because the texture of the food for CS is light and powdery. HCHF and HLA diet- 
fed rats had similar food intakes, with higher intakes than HMA, HPA and HSA diet- 
fed rats. HCHF and HMA groups showed similar water intakes which were lower than 
HLA, HPA and HSA groups. Stearic acid (HSA) and palmitic acid (HPA) showed 
highest energy intakes when compared to CS, HCHF, HLA and HMA but no 
difference with HPA (Table 3.1). However, HCHF diet-fed rats had increased body 
weight gain together with an increased feed conversion efficiency. Overall, final body 
weight depended on the fatty acid in the diet with HCHF > HPA = HMA = HSA > 
HLA groups. It was clearly shown in Figure 3.1 that HLA did not gain weight 
throughout the study. This can be compared with the changes in total fat mass, lean 
mass, abdominal circumference and visceral adiposity index (Table 3.1). The 
reduction in visceral adiposity index in HLA group was due to decreased total 
abdominal fat pads as shown in Table 3.1. For HMA, HPA and HSA rats, lean mass, 
fat mass, abdominal circumference and visceral adiposity index were similar. HLA 
rats had no difference in respiratory exchange ratio from other groups, however HLA 
rats had a lower heat production than other groups. 
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Figure 3.1: Body weight of CS, HCHF, HLA, HMA, HPA and HSA throughout 16 
weeks.  
Data are shown as mean ± SEM. End-point means without a common letter in each 
data set significantly differ at p<0.05 and n=12/group. 
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Table 3.1: Dietary intake, body composition and fat tissues proportions in CS, HCHF, HLA, HMA, HPA and HSA. 
Variable CS HCHF HLA HMA HPA HSA 
Food intake, g/d 40.2±0.7a 25.0±0.6cd 24.2±1.0d 27.7±0.4bc 29.7±0.8b 30.1±0.7b 
Water intake, mL/d 26.1±1.2b 25.2±1.0b 36.5±1.3a 29.1±0.7b 34.4±0.7a 35.1±0.8a 
Body weight gained, % 26.6±1.9c 55.2±5.1a -11.1±2.8d 34.7±1.9bc 42.1±4.6ab 34.1±3.4bc 
Energy intake, kJ/d 451.8±7.0d 543.2±12.8c 545.0±20.1c 601.2±7.6b 660.5±11.1a 671.0±14.9a 
Feed conversion efficiency, % 19.5±1.4b 33.7±2.7a -7.4±2.0c 19.3±1.0b 20.9±1.9b 16.9±1.6b 
Bone mineral content, g 11.6±0.3c 15.4±0.6a 10.0±0.2c 13.5±0.4b 13.6±0.6ab 13.1±0.4bc 
Total fat mass, g 79.5±11.0bc 207.7±27.2a 54.4±3.2c 132.4±9.9b 122.7±12.9b 122.9±9.5b 
Total lean mass, g 305.0±7.5a 311.2±16.6a 229.3±6.5b 300.3±7.3a 305.9±8.2a 307.1±7.5a 
Abdominal circumference, cm 20.2±0.2b 22.8±0.5a 17.4±0.3c 21.5±0.3ab 21.5±0.2ab 21.4±0.3b 
Visceral adiposity index, % 4.0±0.3b 11.3±2.0a 3.6±0.3b 5.9±0.3b 5.4±0.5b 4.9±0.4b 
Respiratory exchange ratio 1.01±0.03a 1.01±0.03a 0.9±0.03a 0.94±0.02a 1.01±0.02a 1.01±0.03a
Heat production, Kcal 3.16±0.15b 3.87±0.09a 2.46±0.09c 3.33±0.16ab 3.47±0.13ab 3.44±0.11ab 
Retroperitoneal fat, mg/mm 155.1±15.6b 572.2±73.0a 98.0±12.1c 256.3±15.4b 248.4±30.7b 205.6±16.8bc 
Epididymal fat, mg/mm 98.0±7.0bc 273.9±23.2a 49.0±4.7c 128.6±7.2b 128.7±21.0b 120.3±13.2b 
Omental fat, mg/mm 88.6±8.9c 257.9±24.6a 66.6±6.0cd 153.1±7.0b 138.2±17.2bc 126.9±9.8bc 
Total abdominal fat, mg/mm 341.8±28.4bc 1104.0±118.1a 213.6±21.9c 538.1±26.6b 515.3±67.1b 452.8±36.6bc 
All data are presented as mean ± SEM and n = 10 for each group. Mean values within a row with different superscript letters are significantly 
different (P < 0.05).  
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3.2.2 Hepatic structure and function 
The wet weights of livers from CS rats were lower than HCHF-fed rats (Table 
3.2). HCHF-fed rats had higher liver wet-weights than HLA and HSA-fed rats and no 
difference was found between HMA and HPA-fed rats. The livers from HLA group 
were the smallest compared to other H-fed rats but similar in size to the CS group. 
Plasma liver function in CS-fed rats showed lower ALT, AST and ALP activities 
compared to HCHF rats. HLA-fed rats had elevated plasma markers of liver function 
in comparison with CS, HCHF, HMA and HPA (Table 3.2). However, the values were 
no different to rats fed with HMA diet for plasma markers of ALT and ALP and not 
different in AST with HCHF diet. Figure 3.2 showed increased hepatic lipid deposition 
and inflammatory cell infiltration in all groups. Compared to CS, HCHF and HLA 
(Figure 3.2A, 3.2B and 3.2C) groups, HMA, HPA and HSA groups showed increased 
fat vacuoles (Figure 3.2D, 3.2E and 3.2F). HLA liver tissue appeared to be normal. 
 
3.2.3 Metabolic changes 
Plasma concentrations of total cholesterol (TC) for CS-fed rats showed no 
difference with HCHF-fed rats (Table 3.2). Similarly, there were also no differences 
in TC for CS-fed rats with either HPA or HSA rats. Results showed that plasma TC 
was higher in HLA diet–fed group compared to others, but it was no different to the 
HMA, HPA and HSA diet-fed groups (Table 3.2). Plasma non-esterified fatty acids 
(NEFA) concentrations were lower in CS rats compared to HCHF rats. The HLA group 
showed lower NEFA concentrations compared to HCHF and HSA rats and there was 
no difference with CS-fed rats. For plasma triglycerides, HCHF rats had higher 
concentrations than CS rats but not different from HMA, HPA and HSA rats. The HLA 
group had lower plasma triglyceride concentrations compared to the HCHF, HMA, 
HPA and HSA groups.  
Plasma insulin and leptin concentrations were also measured in this study 
(Table 3.2). CS-fed rats had lower plasma insulin concentrations than HCHF-fed rats. 
The HMA, HPA, HSA and HCHF groups displayed similar plasma insulin 
concentrations. In contrast to other H-fed rats, the plasma insulin concentration of 
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HLA rats was similar to CS rats. This change in plasma insulin concentration is 
consistent with the findings in plasma leptin concentration, with CS rats showed lower 
plasma leptin concentration compared to HCHF rats and HCHF rats had the highest 
plasma leptin concentration compared to other H-fed rats. The lowest plasma leptin 
concentration was found in HLA rats and it was different from HCHF, HMA and HSA 
rats, but not different from CS and HPA rats.
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Table 3.2: Hepatic structure and function, plasma lipid profiles and metabolic parameters in CS, HCHF, HLA, HMA, HPA and HSA groups at 16 
weeks. 
Variable CS HCHF HLA HMA HPA HSA 
Liver, mg/mm 203.2±9.3c 345.9±11.2a 201.0±9.2c 303.8±7.8ab 322.2±16.5ab 295.8±10.7b 
ALT, U/L 19.4±1.5c 40.9±3.3b 54.2±3.8a 47.3±2.8ab 37.7±2.5b 39.0±2.6b 
AST, U/L 57.4±3.9b 66.4±2.3ab 75.3±4.0a 60.4±3.4b 56.2±1.7b 55.5±2.5b 
ALP, U/L 121.7±7.1c 248.7±17.9b 326.1±19.9a 339.8±23.2a 234.9±21.2b 213.3±10.8b 
Total cholesterol, mmol/L 1.4±0.1c 1.6±0.0ab 1.9±0.1a 1.8±0.1a 1.6±0.1ab 1.7±0.1ab 
NEFA, mmol/L 1.1±0.1d 4.8±0.3a 2.3±0.3cd 3.2±0.3bc 3.6±0.6abc 4.1±0.4ab 
TAG, mmol/L 0.4±0.0c 1.9±0.2a 0.7±0.1c 0.8±0.1c 1.0±0.1bc 1.4±0.2ab 
Week 16 OGTTAUC, mmol/l. min 687.3±35.7a 725.5±21.1a 482.0±18.7b 629.0±19.4a 670.8±27.8a 719.6±23.6a 
Insulin, µg/L 2.4±0.5ab 4.1±0.3a 1.4±0.4b 3.8±0.6a 3.6±0.4a 3.6±0.6a 
Leptin, µg/L 3.2±0.4c 11.3±1.7a 1.9±0.3c 7.9±0.7ab 5.5±1.2bc 9.7±1.5ab 
All data are presented as mean ± SEM and n = 10 for each group. Mean values within a row with unlike superscript letters are significantly different 
(P < 0.05). ALT: Alanine aminotransferase, AST: Aspartate transaminase, ALP: Alkaline phosphatase, NEFA: Non-esterified fatty acids, TAG: 
Triglycerides, OGTT: Oral glucose tolerance test.  
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Figure 3.2: Haematoxylin and eosin staining of hepatocytes (original magnification x 20) in rats fed CS, HCHF, HLA, HMA, HPA and HSA. 
Figures showing inflammatory cells (marked as “in”) around the portal region in A (CS), B (HCHF), C (HLA), D (HMA), E (HPA) and F (HSA) 
in rats. No inflammatory cells were observed in CS and HLA livers.  
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3.2.4 Oral glucose tolerance test 
OGTT for this study showed differences between control groups (CS and 
HCHF) (Figure 3.3). For CS group, blood glucose rose at 30 minutes and slowly 
returned to a normal concentration at 120 minutes. In contrast, the HCHF group 
reached the highest concentration of blood glucose at 60 minutes and then decreased 
but not to basal values at 120 minutes. HLA had a smaller rise in fasting blood glucose 
concentrations than other fatty acids and maintained the blood glucose concentrations 
for 2 hours. Responses in HMA, HPA and HSA did not differ with CS. 
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Figure 3.3: Oral glucose tolerance test in CS, HCHF, HLA, HMA, HPA and HSA diet-
fed rats at week 16.  
Data are shown as means±S.E.M. Means of values at 120 min without a common 
alphabet significantly differ. n=12/group. 
 
3.2.5 Cardiovascular changes 
Physiological changes in cardiovascular function following different diets have 
been presented in Table 3.3. The heart rate of all rats showed no difference between 
groups. The CS heart wet weight was lower than HCHF heart wet weight. However, 
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there was a difference in heart wet weight between CS, HLA and HPA rats, with HLA 
diet-fed rats showing the lowest heart wet weight (Table 3.3). Echocardiographic 
assessments (Table 3.3) of HLA diet–fed rats observed smaller LV internal diameter 
(LVIDd) and stroke volume. However, indices of relative wall thickness, fractional 
shortening, ejection fraction and heart rate showed no difference when compared to 
other groups. In addition, lauric acid reduced LV wet weight and reduced estimated 
LV mass. HCHF rats had higher diastolic stiffness constant than CS rats in the isolated 
Langendorff heart. There was no difference in diastolic stiffness between HLA diet–
fed rats and CS diet–fed rats, but different from HCHF, HMA, HPA and HSA hearts. 
Systolic blood pressure was increased in HCHF rats compared to CS rats. The systolic 
blood pressure in HCHF rats was higher than in HLA and HMA rats. HLA diet–fed 
rats had lower systolic blood pressure compared to HCHF, HMA, HPA and HSA 
groups. 
CS rats showed normal left ventricular tissue morphology in histological 
sections (Figure 3.4). HCHF showed increased infiltration of inflammatory cells 
(Figure 3.4B). In HLA rats, improved tissue architecture of the left ventricle was found 
compared to HCHF rats (Figure 3.4). Greater interstitial collagen deposition was 
shown in HCHF (marked “cd”; Figure 3.5B) as compared to other rats (Figure 3.5). In 
addition, HCHF, HPA and HSA rats showed interstitial fibrosis in Figure 3.5B, Figure 
3.5E and Figure 3.5F. No major changes were observed in CS, HLA and HMA rats 
(Figure 3.5A, Figure 3.5C and Figure 3.5D) and the tissue morphology of the heart 
appeared normal.  
 
 
 
65 
 
Table 3.3: Changes in cardiovascular structure and function. 
 
Variable CS HCHF HLA HMA HPA HSA 
Heart rate, bpm 342.7±30.1 322.5±17.0 296.3±24.5 359.8±15.2 328.8±25.5 309.5±23.4 
Heart weight, mg/mm 21.8±0.8b 25.3±1.0ab 16.2±0.5c 23.7±0.7ab 25.9±1.4a 22.3±0.7ab 
Estimated LV mass, g 0.83±0.03c 1.06±0.04a 0.67±0.03d 0.89±0.05bc 1.03±0.03ab 0.96±0.03abc 
LV+septum wet weight, mg/mm 18.2±0.8a 20.0±0.9a 13.0±0.4b 19.3±0.5a 20.1±1.0a 18.2±0.7a 
Right ventricle wet weight, mg/mm 3.6±0.3c 4.7±0.2b 3.1±0.1c 4.4±0.2b 5.8±0.5a 4.1±0.1bc 
LVIDd, mm 7.36±0.19b 8.33±0.15a 6.52±0.16c 7.55±0.23b 7.93±0.16ab 7.86±0.18ab 
LVPWd, mm 1.65±0.08ab 1.79±0.05a 1.55±0.04b 1.71±0.03ab 1.83±0.04a 1.72±0.06ab 
Relative wall thickness 0.46±0.03 0.43±0.01 0.49±0.02 0.46±0.01 0.47±0.01 0.45±0.02 
Fractional shortening, % 53.2±3.3 43.0±1.6 50.5±4.9 50.4±3.0 42.6±2.4 41.9±2.0 
LV developed pressure, mmHg 69.7±7.1 66.6±9.6 74.0±9.9 53.1±5.3 84.4±9.8 78.1±8.5 
(+)dP/dt, mmHg.S-1 1339.6±127.9 1265.1±171.3 1396.0±185.8 877.3±210.2 1510.4±237.5 1334.8±202.0 
(-)dP/dt, mmHg.S-1 -702.0±183.9 -849.4±151.1 -935.7±160.2 -589.0±81.1 -774.7±254.0 -942.6±126.9 
Diastolic stiffness (k) 22.0±0.5c 28.2±0.5a 21.8±1.0c 25.3±0.7b 26.6±0.7ab 27.0±0.4ab 
Ejection fraction, % 88.3±2.4 81.1±1.7 84.6±3.3 86.3±2.2 80.3±2.2 79.8±2.0 
Ejection time, ms 78.2±2.6b 87.0±2.3ab 94.9±2.8a 80.4±2.9b 84.0±2.4ab 85.6±3.8ab 
All data are presented as mean ± SEM and n = 10 for each group. Mean values within a row with unlike superscript letters are significantly 
different (P < 0.05). LV: left ventricle, LVIDd: left ventricular internal dimension in diastole, LVPWd: left ventricular posterior wall 
dimensions. 
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Table 3.3: Continued. 
Variable CS HCHF HLA HMA HPA HSA 
Stroke volume, µL 374.5±30.3b 492.7±24.3a 245.9±14.9c 391.4±29.2ab 420.0±22.8ab 412.2±31.2ab 
Cardiac output, mL/min 133.5±19.3a 159.9±12.7a 71.3±5.7b 139.1±10.4a 137.2±12.1a 125.1±11.0a 
Systolic wall stress, mmHg.cm-1 75.8±9.1b 131.6±9.0a 101.7±18.4ab 95.0±11.3ab 127.9±11.2a 137.8±8.4a 
Systolic blood pressure, mmHg 127.7±1.1d 157.8±2.8a 136.2±5.3cd 141.7±1.2bc 150.4±2.5ab 152.9±3.5a 
Ascending aorta, cm/sec 98.6±6.0 97.4±4.6 83.4±6.8 96.3±3.9 97.8±3.5 98.9±2.7 
Descending aorta, cm/sec 87.3±5.4 96.2±5.8 81.4±4.0 95.1±2.9 97.0±5.9 95.0±6.0 
All data are presented as mean ± SEM and n = 10 for each group. Mean values within a row with unlike superscript letters are significantly 
different (P < 0.05). 
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Figure 3.4 Haematoxylin and eosin staining of left ventricle (original magnification x 20) in rats fed CS, HCHF, HLA, HMA, HPA and 
HSA. 
Figures showing inflammatory cells (marked as “in”) in A (CS), B (HCHF), C (HLA), D (HMA), E (HPA) and F (HSA) in rats. No 
inflammatory cells were observed in CS and HLA hearts. 
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Figure 3.5: Picrosirius red staining of left ventricle (original magnification x 20) in rats fed CS, HCHF, HLA, HMA, HPA and HSA. 
Figures showing collagen deposition (marked as “cd”) and hypertrophied cells (marked as “hy”) in A (CS), B (HCHF), C (HLA), D 
(HMA), E (HPA) and F (HSA) in rats. 
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3.2.6 Ileum and colon contractility and histology  
Organ bath studies on the ileum and colon (Figure 3.6) showed that CS, HCHF, 
HLA, HMA and HSA showed similar responses to acetylcholine in the ileum. 
Similarly, no differences were found between groups in responses of acetylcholine in 
the colon.  Figure 3.7 shows the histological of colon tissue stained using periodic acid 
and Schiff (PAS) reagent. Results showed that the density of goblet cells (gc) were 
increased in the crypt of the colon of HCHF and HSA rats compared to other groups. 
 
Figure 3.6: Force of contraction (mN) on ileum and colon in CS, HCHF, HLA, HMA 
and HSA groups.  
All data are presented as mean ± SEM and n = 10 for each group. 
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Figure 3.7: Periodic acid and Schiff reagent staining (original magnification x 20) in rats fed CS, HCHF, HLA, HMA, HPA and HSA. . 
Figures showing goblet cells (gc) in the crypt of the colon in A (CS), B (HCHF), C (HLA), D (HMA), E (HPA) and F (HSA) in rats. 
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3.3 Discussion 
Numerous studies have reported that saturated fat is one of the major nutrients 
that causes detrimental effects to human health if consumed in excessive amounts 
(Doyle, 2004, Hariri et al., 2010b). Human diets contain dietary fats which incorporate 
a broad spectrum of fatty acids of varying chain length (Mu and Hoy, 2004). Studies 
suggest that saturated fat can have dramatically different effects on human lipid 
metabolism, adipocytes accumulation, hepatic steatosis and alteration of gut 
microbiota composition (de Wit et al., 2012, Mensink et al., 2003). However, these 
saturated fatty acids have not been previously compared individually in the same study 
to differentiate the physiological responses elicited by each fatty acid in models of 
metabolic syndrome. In this study, we have found that SFA from C12 to C18 gave 
different responses with, in general, worsening of cardiovascular, liver and metabolic 
parameters as chain length increased, with minimal changes with lauric acid (C12) and 
the most obvious changes with stearic acid (C18). 
Rats consuming HCHF-diet develop hypertension, cardiac deterioration, 
inflammation and abdominal obesity (Panchal et al., 2011). Further, an increase in total 
abdominal fat pad weight from HCHF-diet fed rats were also shown in this study. An 
excess of energy consumption from simple sugars and saturated fats lead to fat 
deposition in the adipocyte and this accumulation caused hypertrophy and hyperplasia 
of adipocytes (Panchal et al., 2011). However, rats fed with HLA showed a marked 
loss of body weight and body fat although the rats still had an abundant supply of 
fructose and fat from the diet to meet energy requirements. In addition, the energy 
intake by HLA rats was no difference to HCHF-fed rats. Fatty acid absorption and 
oxidation are related to the chain length (DeLany et al., 2000, Ramirez et al., 2001) , 
with absorption of medium-chain fatty acids (MCFA) being greater than long-chain 
fatty acids (LCFA) and decreased oxidation with increasing carbon numbers (DeLany 
et al., 2000, Ramirez et al., 2001). An in vivo investigation of four volunteers 
consuming heated meals containing labelled saturated fatty acids [C12 (lauric), C16 
(palmitic), or C18 (stearic)] or a C18 unsaturated fatty acid reported that lauric acid 
was the most highly oxidized, followed by the unsaturated fatty acids with stearic acid 
as the least oxidized (DeLany et al., 2000). In addition to fatty acid oxidation, there is 
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also a pathway that explains this which is the rate of de novo lipogenesis (Turner et 
al., 2009). MCFA such as lauric acid are more readily absorbed into the bloodstream 
and therefore these fatty acids are absorbed efficiently by the liver through the portal 
vein (Papamandjaris et al., 1998). This underlying pathway also shows that MCFA can 
enter the mitochondria via CPT-1–independent mechanisms for oxidation (Turner et 
al., 2009). These mechanisms explain the increase in energy expenditure and decreased 
adiposity observed with lauric acid diet-fed rats.  
One of the manifestations of metabolic syndrome is non-alcoholic fatty liver 
disease (Vanni et al., 2010). Increased activities of ALT, AST and ALP in plasma are 
indications of hepatic injury and this was shown in all rats fed with HCHF, HLA, 
HMA, HPA and HSA. Rats fed with HCHF diet also developed dyslipidaemia where 
the results showed that total cholesterol concentrations in HCHF groups were higher 
when compared to CS group. A study on 14 men showed that lauric acid raised total 
and LDL cholesterol concentrations compared with oleic acid, but was not as potent 
for increasing cholesterol concentrations as palmitic acid (Denke and Grundy, 1992). 
However, a meta-analysis showed that lauric acid greatly increased total cholesterol 
concentrations, but much of its effect was on HDL cholesterol (Mensink et al., 2003). 
Furthermore, the consumption of lauric acid decreased the ratio of total to HDL 
cholesterol. Myristic and palmitic acids had little effect on the ratio, and stearic acid 
reduced the ratio slightly (Mensink et al., 2003). 
Lauric acid fed-rats (HLA) had improved glucose tolerance after the glucose 
load of OGTT. This is in accordance with the literature which shows that a very small 
load of lauric acid (∼80 kJ) lowered blood glucose after both breakfast and lunch when 
given to patients with type 2 diabetes, when compared to a placebo with similar 
formulation but with the omission of lauric acid (Korek et al., 2013). The authors 
proposed the effect was related to GLP-1 in the portal circulation where vagal afferents 
with nerve endings bearing receptors for GLP-1 are present in the portal venous system 
and activation of these results in glucose lowering through enhanced hepatic and 
peripheral glucose uptake, in the absence of any stimulation of insulin secretion (Korek 
et al., 2013). Our study findings are consistent with this human study, with HCHF diet-
fed rats showing impairment of glucose clearance due to reduced insulin sensitivity.  
This effect may be due to increased islet mass and an increased number of α and β 
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cells within the islets of Langerhans in the pancreas, suggesting hyperplasia of these 
cell types (Panchal et al., 2011). 
Physiological parameters of cardiac function in all groups showed minimal 
chenges in heart rate, ejection fraction and fractional shortening. However, HLA diet-
fed rats showed a lower systolic blood pressure and no difference in the stiffness of 
heart as compared to CS group. There are only limited number of studies that have 
shown the effect of lauric acid on systolic blood pressure and the stiffness of the heart. 
However, one study determined that with a combination of fatty acids, the total 
proportion of lauric acid and myristic acid had a negative impact on the endothelial 
function index of healthy young men but interestingly did not have a similar effect in 
healthy young women, indicating that there may be a sex difference in cardiovascular 
effects of these fatty acids. This study also determined that serum fatty acid 
composition predicted endothelial vasodilatory dysfunction independently of serum 
NEFA (28). On the other hand, the inhibitory effects of saturated NEFA on 
endothelium-dependent relaxation have been reported (Edirisinghe et al., 2006). This 
study used aortic rings that were incubated for an hour with NEFA–albumin complexes 
derived from lauric (C12:0), myristic (C14:0), palmitic (C16:0), stearic (C18:0) and 
alpha-linolenic (C18:3) acids. It was observed that lauric acid had the smallest 
inhibitory effect (Edirisinghe et al., 2006). Increased NEFA is recognised as one of 
predisposing features of endothelial dysfunction. In our study, there is a consistent 
increase in plasma NEFA as chain length increases (lauric<myristic<palmitic<stearic 
acids). One of the potential mechanisms involved in this loss of endothelial function 
is a direct effect of NEFA in plasma on endothelium-dependent relaxation (Steinberg 
et al., 2000). Further, an association was reported between two individual SFA 
(palmitic and stearic acid) and the prevalence of peripheral artery disease (Naqvi et al., 
2012).  
Leptin is most commonly known as  an anti-obesity hormone that regulates 
food intake and energy expenditure (Hariri et al., 2010a). This study shows that 
different dietary fatty acid compositions affect the total fat mass and plasma leptin 
concentrations in different ways. The plasma leptin concentrations increased with 
increases of chain length, however, these increases did not correlate with increases in 
total fat mass. Our data suggests that it may be that the leptin concentration may be 
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reflective of individual fat deposition and not total fat mass. In contrast to this finding, 
other studies found that plasma leptin was proportional to the degree of fat-mass 
accumulation (Enos et al., 2013, Tilg and Moschen, 2006). Clearly, additional work is 
needed to elucidate the mechanism in relation to leptin concentrations with individual 
saturated fatty acids. 
The role of gut microbiota in contributing to human health is the focus of much 
current research with several studies of composition of gut microbiota showing 
association with the metabolic syndrome phenotype (de Wit et al., 2012), with lean 
and obese animals having different microbiota profiles, independent of genetic or diet 
induced obesity (Cani et al., 2007, Ley et al., 2005). Additionally, there is a positive 
relationship between gut dysfunction and metabolic endotoxaemia with obesity or 
insulin resistance (Shen et al., 2014). This suggests that diets rich in long chain fatty 
acids accelerate metabolic dysfunction and it also suggest that limiting total dietary fat 
intake, particularly from palm oil, would help promote healthy microflora, thereby 
improving intestinal health and reducing the risk of gut-related diseases (Shen et al., 
2014). The inclusion of fats in the diet can also affect the composition of epithelial 
cells in the gastrointestinal tract. A 12 week HCHF diet resulted in an increased 
number of goblet cells in the small intestine, with a reduction in this number following 
4 week on a basal diet containing nitrogen free extract (51.65%), crude protein 
(21.36%), crude fat (10.63%), total ash (7.41%), moisture (6.32%), crude fibre 
(2.63%), calcium (1.75%), phosphorus (1.1%), and water (0.23% per 100 g of the diet) 
(Hazarika et al., 2016). Further, consumption of palm oil with 3-fold higher 
concentration of palmitic acid resulted in increased mucus granule surfaces of goblet 
cells (>2-fold) in the rats’ colon (Benoit et al., 2015a). This study proposed that 
subsequent effects of increased goblet cells in the colon will increase transmucosal 
resistance, thereby changing the colonic barrier. These findings support the present 
study where there is increased density of goblet cells in the colon of rats fed palmitic, 
stearic acid and HCHF. However, the subsequent effects of these saturated fatty acids 
on goblet cells were not examined in the present study. Further study is warranted to 
rule out the possible mechanism involved especially the changes in gut structure and 
function. 
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Overall, the metabolic changes worsened with increased chain length and this 
was most obvious in stearic acid with impaired cardiovascular functions and increased 
collagen deposition in heart tissues. However, the responses from HCHF rats were 
more severe than stearic acid rats. These effects could be due to the presence of trans 
fatty acids (TFA) in beef tallow as previous studies have shown that TFA triggered 
systemic inflammation and endothelial dysfunction (Mozaffarian, 2006). Further, TFA 
induced dyslipidaemia, insulin resistance and obesity (Micha and Mozaffarian, 2009, 
Mozaffarian, 2006). Evidence from controlled dietary studies showed that TFA 
markedly worsened serum lipids by increased LDL-cholesterol (Katan et al., 1995). In 
addition, high TFA intake is also associated with higher concentrations of 
inflammatory cytokines (TNF-α, IL-6), C-reactive protein (CRP) and monocyte 
chemoattractant protein-1 (Mozaffarian et al., 2006).  Although evidence showed that 
TFA worsened metabolic syndrome, further studies need to be done to compare HCHF 
with pure trans fatty acids. 
3.4 Conclusion 
In conclusion, different types of saturated fatty acids showed different responses 
to the signs of metabolic syndrome. With the same amount of saturated fat given to 
each group, the HLA (lauric acid) group did not gain body weight throughout the study 
and had the lowest total fat mass, total lean mass, abdominal circumference and 
visceral adiposity index compared to others. The HLA group showed better responses 
in OGTT and blood pressure compared to the other groups. In contrast, HMA, HPA 
and HSA groups exhibited a worsening of disease states with increasing SFA chain 
length and the most obvious changes were found in rats fed with stearic acid. Palmitic 
and stearic acids produced lower physiological responses than beef tallow but still 
exhibited marked abnormalities in metabolic, cardiovascular and liver structure and 
function. This suggests that replacing beef tallow with stearic and palmitic acids would 
show small improvements, but replacement with lauric and possibly myristic acids in 
human diets would markedly decrease the development of metabolic syndrome. 
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Saturated fatty acids induce 
development of both metabolic 
syndrome and osteoarthritis in rats
Sunderajhan Sekar1, Siti Raihanah Shafie2, Indira Prasadam1, Ross Crawford3, 
Sunil K. Panchal2, Lindsay Brown2 & Yin Xiao1
The predominant saturated fatty acids (SFA) in human diets are lauric acid (LA, C12:0), myristic 
acid (MA, C14:0), palmitic acid (PA, C16:0) and stearic acid (SA, C18:0). The aim of this study was to 
investigate whether diets containing individual SFA together with excess simple carbohydrates induce 
osteoarthritis (OA)-like changes in knee joints and signs of metabolic syndrome in rats. Rats were given 
either a corn starch diet or a diet composed of simple carbohydrates together with 20% LA, MA, PA, 
SA or beef tallow for 16 weeks. Rats fed beef tallow, SA, MA or PA diets developed signs of metabolic 
syndrome, and also exhibited cartilage degradation and subchondral bone changes similar to OA. In 
contrast, replacement of beef tallow with LA decreased signs of metabolic syndrome together with 
decreased cartilage degradation. Furthermore, PA and SA but not LA increased release of matrix 
sulphated proteoglycans in cultures of bovine cartilage explants or human chondrocytes. In conclusion, 
we have shown that longer-chain dietary SFA in rats induce both metabolic syndrome and OA-like knee 
changes. Thus, diets containing SFA are strongly relevant to the development or prevention of both OA 
and metabolic syndrome.
Obesity is a major risk factor for osteoarthritis (OA) and this has led to the description of metabolic 
syndrome-associated OA as a new OA phenotype1. In adipose tissue, adipocytes store lipids but they also pro-
duce and release many adipokines that are then responsible for the chronic low-grade inflammation in obesity2. 
Leptin, one of these adipokines, has been extensively studied in the pathophysiology of obesity3. Leptin may serve 
as the mechanism linking obesity and OA, because it is involved in cartilage and chondrocyte pathophysiology4. 
Increased intake of either mono- or poly-unsaturated fatty acids in a healthy population of middle aged adults 
was linked with increased possibility of developing bone marrow lesions5. Also, free fatty acids may be involved 
in inflammatory metabolic diseases such as obesity and inflammatory joint diseases6. Thus, dietary saturated fatty 
acids (SFA) could initiate the link between OA and obesity7–9. This is supported by the alterations in subchondral 
bone structure in patients with increased SFA intake5 that may lead to OA. Further, treatment of human chondro-
cytes with palmitate induced apoptosis and caused articular cartilage degradation10. However, there are no studies 
that have examined the association between these diseases using individual dietary SFA, despite the importance 
of dietary SFA as a potential initiator of chronic human diseases including obesity and OA.
Obesity is excessive fat storage in the body which is a major component of metabolic syndrome, a constellation 
of hypertension, diabetes, dyslipidaemia and fatty liver disease that increases the risk of cardiovascular disease11. 
Although, it has been widely accepted that SFA as a group promotes abdominal obesity, dyslipidaemia, insulin 
resistance, impaired glucose tolerance and systemic inflammation12, this role of SFA in obesity, diabetes and car-
diovascular disease is now being challenged. Recent studies suggest that SFA-induced responses are dependent 
on chain length, with clear differences in biological responses between lauric acid and palmitic acid13. However, 
the roles of individual dietary SFA in OA have not been clearly defined.
Our previous studies reported that high-carbohydrate, high-fat diet (H; mainly containing fructose and beef 
tallow) for 16 weeks in young male Wistar rats mimics the symptoms of human metabolic syndrome including 
abdominal obesity, increased total body fat mass, elevated plasma lipids and blood pressure, impaired glucose 
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tolerance and insulin sensitivity, fatty liver and cardiovascular remodelling14. The present study has investigated 
the role of C12 to C18 SFA (lauric acid (LA; C12:0), myristic acid (MA; C14:0), palmitic acid (PA; C16:0) and 
stearic acid (SA; C18:0) as well as beef tallow (mainly SA and trans fatty acids) on both the signs of metabolic 
syndrome and OA development.
Results
SFA on metabolic syndrome. Rats given a high-carbohydrate diet together with beef tallow containing 
both saturated and trans fats (H diet) developed changes associated with human metabolic syndrome including 
abdominal obesity, hyperleptinaemia, hyperlipidaemia and liver dysfunction compared to a corn starch diet (C 
diet) (Table 1), however, H rats did not show hyperglycaemia and hyperinsulinaemia compared to C rats. C diet 
has low energy density and possibly for this reason, the food intake was higher in C rats than all other groups. 
Although the food intake was higher in C rats, energy intakes were higher in all high-fat diet groups than in C rats 
in the order of C < (HLA = H) < HMA < (HPA = HSA) (Table 1). With lower body weight gain, the feed conver-
sion efficiency was lower in HLA rats than in all other groups whereas H had higher feed conversion efficiency 
than other groups (Table 1). No difference in feed conversion efficiency was found in C, HMA, HPA and HSA 
although HMA, HPA and HSA had higher energy intakes. Body fat was highest in H rats and lowest in HLA rats 
while C, HMA, HPA and HSA had intermediate body fat. Lean mass was lower in HLA rats with no difference 
in other groups. Abdominal circumference was lower in HLA rats than in C rats while other groups were higher 
than C rats (Table 1). Abdominal fat pads were lowest in HLA rats while highest in H rats with other groups hav-
ing intermediate abdominal fat. Basal blood glucose concentrations were lowest in HLA rats with HMA slightly 
higher than HLA. HSA and H had higher blood glucose concentrations than other groups while C and HPA had 
intermediate blood glucose concentrations. HLA showed higher plasma activities of alanine transaminase, aspar-
tate transaminase and alkaline phosphatase than C rats. Alanine transaminase and alkaline phosphatase activities 
were higher in other groups than C rats whereas aspartate transaminase activity was equivalent to C rats. Plasma 
total cholesterol was higher in HLA rats than in C rats with other groups having intermediate concentrations of 
Variables C HLA HMA HPA HSA H
Food intake (g/d) 40.2 ± 2.2a 24.2 ± 3.3d 27.7 ± 1.3c 29.7 ± 2.6bc 30.1 ± 2.4b 25.0 ± 2.3d
Water intake (mL/d) 26.1 ± 4.1c 36.5 ± 4.5a 29.1 ± 2.4b 34.4 ± 2.2a 35.1 ± 2.7a 25.2 ± 3.5c
Body weight gained (%) 26.6 ± 6.3c −11.1 ± 9.8d 34.7 ± 6.8bc 42.1 ± 15.3b 34.1 ± 11.9bc 58.6 ± 14.1a
Energy intake (kJ/d) 452 ± 24d 545 ± 70c 601 ± 26b 652 ± 46a 671 ± 52a 543 ± 44c
Feed conversion efficiency (%) 19.3 ± 4.1b − 7.4 ± 6.5c 19.3 ± 3.5b 21.1 ± 6.2b 17.9 ± 4.4b 36.2 ± 6.8a
Total body fat mass (g) 79.5 ± 34.7cd 54.4 ± 9.7d 132.4 ± 31.2b 122.7 ± 40.9bc 122.9 ± 30.0bc 207.7 ± 81.6a
Total body lean mass (g) 305.0 ± 23.6a 229.3 ± 19.5b 300.3 ± 23.0a 305.9 ± 25.9a 307.1 ± 23.6a 310.6 ± 46.9a
Abdominal circumference (cm) 20.2 ± 0.7b 17.4 ± 1.1c 21.5 ± 0.9a 21.5 ± 0.8a 21.4 ± 1.0a 22.4 ± 1.1a
Visceral adiposity index (%) 4.01 ± 0.88c 3.56 ± 0.96c 5.93 ± 0.80b 5.35 ± 1.45bc 4.94 ± 1.26bc 10.07 ± 2.59a
RER 1.01 ± 0.06a 0.90 ± 0.08a 0.94 ± 0.06a 1.01 ± 0.05a 1.01 ± 0.09a 1.01 ± 0.07a
Heat (Kcal) 3.16 ± 0.38b 2.46 ± 0.24c 3.33 ± 0.41b 3.47 ± 0.35ab 3.44 ± 0.29ab 3.87 ± 0.23a
Retroperitoneal fat (mg/mm) 155.2 ± 46.7bc 98.0 ± 36.5c 256.3 ± 48.6b 248.4 ± 92.1b 205.6 ± 53.2bc 572.2 ± 219.1a
Epididymal fat (mg/mm) 98.0 ± 21.0b 49.0 ± 14.0c 128.6 ± 22.7b 128.7 ± 63.0b 120.3 ± 41.7b 273.9 ± 69.5a
Omental fat (mg/mm) 88.7 ± 26.8cd 66.6 ± 18.1d 153.1 ± 22.3b 138.2 ± 51.5b 126.9 ± 30.9bc 257.9 ± 73.9a
Total abdominal fat (mg/mm) 342 ± 85cd 214 ± 66d 538 ± 84b 515 ± 201b 453 ± 116bc 1017 ± 255a
Basal blood glucose concentrations (mmol/L) 3.59 ± 0.30ab 2.64 ± 0.46c 3.16 ± 0.37b 3.46 ± 0.56ab 3.98 ± 0.81a 3.86 ± 0.51a
Systolic blood pressure (mmHg) 126.9 ± 5.5d 136.2 ± 16.9c 141.8 ± 3.7bc 150.4 ± 7.9ab 152.9 ± 11.0a 157.7 ± 10.7a
Hepatic Function
Liver (mg/mm) 203.2 ± 28.0c 201.0 ± 27.6c 303.8 ± 24.8b 322.2 ± 49.5ab 295.8 ± 33.9b 345.9 ± 33.6a
Alanine transaminase (U/L) 19.4 ± 5.4c 54.2 ± 12.5a 47.3 ± 9.6ab 37.7 ± 7.6b 39.0 ± 8.9b 40.9 ± 11.1b
Aspartate transaminase (U/L) 57.4 ± 13.4b 75.3 ± 13.3a 60.4 ± 11.6b 56.2 ± 5.1b 55.5 ± 8.7b 66.4 ± 7.8ab
Alkaline phosphatase (U/L) 121.7 ± 24.8c 326.1 ± 66.0a 339.8 ± 80.2a 234.9 ± 63.7b 213.3 ± 37.6b 248.7 ± 59.5b
Total cholesterol (mmol/L) 1.42 ± 0.36c 1.98 ± 0.26a 1.78 ± 0.29ab 1.60 ± 0.18bc 1.69 ± 0.41abc 1.59 ± 0.11bc
NEFA (mmol/L) 1.09 ± 0.37d 2.32 ± 1.16c 3.15 ± 1.05bc 3.63 ± 1.69ab 4.10 ± 1.55ab 4.84 ± 1.13a
Triglycerides (mmol/L) 0.36 ± 0.17d 0.67 ± 0.42cd 0.88 ± 0.33c 1.04 ± 0.46bc 1.42 ± 0.68b 1.92 ± 0.67a
Plasma hormone concentrations
Insulin (μg/L) 2.35 ± 1.80ab 1.42 ± 1.22b 3.81 ± 2.25a 3.60 ± 1.23a 3.59 ± 2.15a 4.12 ± 1.09a
Leptin (μg/L) 3.21 ± 1.12 cd 1.93 ± 1.05d 7.94 ± 2.35bc 5.54 ± 3.71c 9.67 ± 3.87ab 11.37 ± 3.80a
Table 1.  Dietary intake and body composition in C, H, HLA, HMA, HPA and HSA rats. Measurement of 
dietary intake and body composition in rats fed the different diets (n = 10–12). All values are represented as 
mean ± SD. Mean values within a row with unlike superscript letters are significantly different (P < 0.05) with 
a > b > c > d. Abbreviations: C – corn starch diet-fed rats; H – high-carbohydrate, high-fat diet-fed rats; HLA 
– high-carbohydrate, high-lauric acid-fed rats; HMA – high-carbohydrate, high-myristic acid-fed rats; HPA 
– high-carbohydrate, high-palmitic acid-fed rats; HSA – high-carbohydrate, high-stearic acid-fed rats; RER – 
respiratory exchange ratio; NEFA – non-esterified fatty acids.
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total cholesterol. Plasma NEFA was lowest in C rats with HLA NEFA higher than C rats and H group with high-
est plasma NEFA concentrations. Further, other groups had intermediate plasma NEFA concentrations. Plasma 
triglycerides were higher in HMA rats than C rats while HSA and H were further increased with H having the 
highest plasma triglycerides. Plasma insulin concentrations were lower in HLA rats than H, HMA, HPA and HSA 
with C rats having intermediate concentrations. Plasma leptin concentrations were highest in H rats while lowest 
in HLA rats (Table 1).
Rats given a high-carbohydrate diet together with beef tallow (H diet) showed increased systolic blood pres-
sure and worsening cardiac function, both by echocardiography and also as an increased ventricular stiffness 
in isolated heart studies, without the development of heart failure, when compared to C rats. In contrast, HLA 
rats showed minor changes when compared with C rats. Replacement of beef tallow with HMA, HPA or HSA 
led to worsening cardiac function and increased systolic blood pressure compared with C or HLA rats (Table 1). 
Parameters such as relative wall thickness, fractional shortening, heart rate, LV developed pressure, ascending 
aorta flow and descending aorta flow did not show differences among the groups with different dietary fat sources 
(Supplementary Table 1).
SFA on histological features of the articular cartilage. The joints from C rats showed smooth articular 
cartilage surface, normal cellularity and exhibited strong intensity of Safranin O staining. The chondrocytes were 
flattened in the tangential layer and were distributed in short irregular columns in the radial layer of the articular 
cartilage (Fig. 1A). Mankin scores were in the range of 0–1 in the C rats indicating normal cartilage structure 
(Fig. 1B). In contrast, H, HPA and HSA rats showed degeneration of the articular cartilage especially at the sur-
face zone, indicated by surface irregularity, disorganisation of the articular cartilage with apparent chondrocyte 
clustering in the transitional and radial zones, and loss of proteoglycans shown by the weak intensity of Safranin 
O staining (Fig. 1A), with markedly increased Mankin scores (Fig. 1B). HMA and HLA rats showed cartilage 
structures that were similar to those of the C rats, with strong intensity of Safranin O staining and similar Mankin 
scores (Fig. 1A,B).
OA is characterised by reduced expression of the chondrogenic marker, aggrecan (ACAN), and increased 
expression of the hypertrophy and degradative markers, COL10 and MMP13. C rats showed strong expression 
of ACAN and limited expression of COL10 and MMP13. However, H, HPA and HSA rats exhibited degradative 
changes in cartilage structure that were greater than in HLA or HMA rats. ACAN expression decreased and 
expression of MMP13 and COL10 increased in H, HPA and HSA rats. HLA and HMA rats showed the least 
expression for MMP13 and COL10, but showed increased expression of ACAN in the cartilage compared to other 
SFA groups (Fig. 1C).
The number of apoptotic cells varied markedly between groups with only 8% of cells undergoing apoptosis 
in the C group compared to 24% in H rats. Replacement of beef tallow with HPA (26%) or HSA (40%) led to 
increased apoptosis that was greater than with HLA (10%) or HMA (14%) or in H rats (Fig. 1C).
SFA on bone morphology. Abnormal subchondral bone remodelling is recognised as a characteristic fea-
ture of OA. A 3-D representation of whole rat knee joint using micro-CT showed changes to the bone architecture 
of H, HPA and HSA rats compared to C, HLA or HMA rats (Fig. 2A). The region of interest was set as the medial 
and lateral tibial subchondral bone compartment. Tibial subchondral BV/TV decreased in H rats compared to 
that of the C rats. Replacement of beef tallow with LA or MA in diet increased tibial BV/TV while replacement 
of beef tallow with PA or SA decreased tibial BV/TV compared to H rats (Fig. 2B). Similarly to BV/TV, subchon-
dral bone mineral density (BMD) decreased in rats fed with the beef tallow diet (H) compared to the C diet. 
Replacement of beef tallow with LA or MA increased BMD. In contrast, replacement of beef tallow with PA or SA 
in diet decreased BMD compared to the H rats (Fig. 2C).
Diverse distribution of osteocytes in the subchondral bone region. In this study, the average 
osteocyte lacunae per mm2 (Avg.OS.L) was increased in H, HPA and HSA rats compared to C rats, suggesting 
increased bone remodelling and dysregulated mineral metabolism caused by the diets. Avg.OS.L density of HLA 
and HMA rats was very similar to that of the C rats. The decreased presence of average osteocyte nucleus (Avg. 
OS.N) in H, HMA, HPA and HSA rats compared to the C rats suggests the diets induced apoptotic death of the 
osteocytes (Supplementary Table 2).
SFA on human chondrocytes and bovine cartilage explants. Human chondrocytes isolated from 
cartilage specimens (grade 0–1) were stimulated with different SFA. To induce OA-like biological changes, the 
human chondrocytes were stimulated with IL-1β . There was an increased sGAG release from LA, MA and PA pel-
lets compared to the control pellet at day 3. The greatest sGAG release was seen from the pellets treated with SA 
in comparison to the control pellets (Fig. 3B). On day 7, the control 3D cultured chondrocyte pellets treated with 
BSA (carrier) showed increased presence of proteoglycans indicated by strong Safranin O staining and decreased 
sGAG release into the media (Fig. 3A). LA and MA-treated pellets showed staining intensity similar to control 
pellets. In contrast, PA and SA-treated chondrocyte pellets showed marked loss of proteoglycans and subsequent 
increase in sGAG release into the medium compared with the other groups (Fig. 3A,B). Treatment with IL-1β 
alone decreased the proteoglycan content in the chondrocyte pellet compared to the non-IL1β treated control 
pellet, showing that IL1β treatment promotes proteoglycan degradation. Addition of PA and SA increased the 
cartilage matrix degradation shown by decreased proteoglycan content in the chondrocyte pellet and increased 
release of sGAG into the medium compared to the control pellet, indicating the effect of IL-1β and SFA on carti-
lage degradation (Fig. 3A,B).
Since we observed increased sGAG release from both the PA and SA treated pellets, we performed a time 
course and a concentration-response experiment using these treatments. Increased concentrations of PA and 
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SA increased release of sGAG into the medium. Once again, the IL-1β treated chondrocytes exhibited increased 
sGAG release compared to PA and SA pellets that were not treated with it (Fig. 3C,D). To assess if the concen-
tration of IL-1β used in this study caused significant release of sGAG, we treated the chondrocyte pellets with 
different concentrations of IL-1β . The day 3 and day 7 sGAG release data showed that IL-1β at 10 ng/ml did not 
increase the rate of sGAG release in comparison with IL-1β at 1 ng/ml.
Loss of aggrecan (ACAN) is the first sign of degeneration with increased expression of degradative (MMP13, 
ADAMTS4, ADAMTS5) and hypertrophic markers (COL10 and RUNX2)15. Therefore, these markers were 
assessed in normal human chondrocytes treated with SFA with or without the addition of IL-1β using quantitative 
RT-PCR. In comparison with control samples, SFA-treated samples had decreased expression of ACAN (Fig. 4A) 
both in the presence and absence of IL-1β . The expression of ACAN was markedly down-regulated in LA and 
MA-treated groups, and the highest down-regulation was seen in PA and SA-treated groups both in the absence 
and presence of IL-1β . LA and MA-treated pellets had lower expression of COL10A (Fig. 4B), MMP13 (Fig. 4C), 
ADAMTS-4 (Fig. 4D), ADAMTS5 (Fig. 4E) and RUNX2 (Fig. 4F), in comparison with PA and SA-treated pellets 
(Fig. 5) in both the absence and presence of IL-1β .
The bovine explants in the control group treated only with BSA carrier exhibited a smooth articular cartilage 
surface and normal cellularity. Explants treated with LA or MA showed staining intensity similar to control 
explants. In contrast, explants treated with PA or SA showed decreased intensity of Safranin O staining compared 
to control explants (Fig. 5A). Consistent with the Safranin O staining results, marked increases in the release 
of sGAG were observed in the explants treated with PA or SA compared to control, LA or MA-treated explants 
(Fig. 5B). In bovine explants treated with IL-1β , the intensity of Safranin O staining was decreased upon stim-
ulation of different SFA. Addition of LA and MA decreased the proteoglycan content of the cartilage explants 
compared to the control explant and also increased the release of sGAG into the medium. Furthermore, addition 
Figure 1. (A) Histological evaluation of the knee joints. All pictures were obtained under 20X magnification 
(n = 8 per group), representing the medial tibial plateau. Safranin O/Fast Green staining shows the extent of 
proteoglycan loss among the different diet groups. Representative immunohistochemical staining shows the 
number of positive cells for ACAN, MMP13, COL10 among the different diet groups. Analysis of apoptotic 
chondrocytes among different diets were quantified using TUNEL assay (DAPI and TUNEL images shown). 
The numbers of TUNEL-positive cells per section of the articular cartilage were determined under fluorescence 
microscopy. For each immunostaining, negative control either without primary antibody or with isotype-
matched IgG instead of primary antibody was included. (B) Severity of articular cartilage degradation was 
graded using Mankin scoring system. (C) Quantitative histomorphometric analyses. Total positive cells per 100 
cells in the cartilage were counted using ImageJ (NIH, Bethesda, MD). All values are represented as mean ± SD. 
Scale bar is 100 μ m. (P < 0.05)
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of PA and SA decreased the proteoglycan content of the cartilage explant compared to the control explant and also 
increased sGAG release into the medium (Fig. 5A,B). In addition, treatment of PA and SA increased the sGAG 
depletion compared to the control explants both in the absence and the presence of IL-1β . In contrast, treatment 
of LA and MA showed sGAG depletion which was comparable to that of the control treated explants. However, 
when IL-1β was added to the explants, LA and MA treatment increased the sGAG depletion of the explants com-
pared to control explants, but were not lower compared to PA and SA treatment (Fig. 5C).
Discussion
The worldwide incidence of obesity has doubled since 1980, now affecting 475–600 million people, depending 
on the BMI cut-off used in the estimates16. The incidence of OA has also markedly increased over a similar time 
period17, leading to well-documented support for the concept that obesity is a modifiable risk factor for the inci-
dence and progression of OA18. The prevalence of both obesity and OA are greatest in patients over 65 years of 
age, and this is an increasing segment of the world’s population. Since both obesity and OA reduce mobility and 
increase cardiovascular risk, weight loss and exercise are recognised as key components for treatment of obese 
patients with OA18. Thus, understanding the common mediators for obesity and OA is clearly relevant to provide 
realistic and sustainable treatment options for obesity-associated OA.
Increased intake of dietary fat is one of the most important factors linking obesity and OA. Dietary fat is 
a key contributor to obesity and may help uncover the complex relationships between obesity and OA19. In 
obesity-related OA, SFA are relevant as they are the major dietary fatty acids. Our study strongly indicates that 
SFA produce parallel changes over the same time-frame in metabolic syndrome and typical OA-like lesions in the 
knee joint combined with increased chondrocyte death and breakdown of matrix in isolated bovine and human 
chondrocytes. Overall, the changes increase with SFA chain length with minimal changes following LA treatment 
to marked changes with SA treatment. These changes may be further increased by the presence of trans fatty acids 
as in beef tallow, but this proposal needs to be further tested by treatment with pure trans fatty acids. A plausible 
Figure 2. Micro-CT analyses of knee joints of rats fed the different diets (n = 8). (A) A 3-D Image of the 
whole knee joints of rats and the reconstructed axial micro CT cross-section images (insert) of region of interest 
i.e. the medial and lateral tibial plateau showing altered subchondral bone architecture (yellow arrows show 
abnormal bone morphological changes). For morphometric analyses, (B) the bone volume fraction (BV/TV) 
was calculated as the ratio of segmented bone volume (BV) to the total volume (TV) of the region of interest. 
In addition, (C) the bone mineral density (BMD) of the region of interest was also calculated. All values are 
represented as mean ± SD (P < 0.05).
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mechanism is suggested by the correlation between obesity and OA-like changes and plasma leptin concentra-
tions but other hormones and cytokines released from macrophages may also be involved, as discussed below. 
This is consistent with the reported increase in palmitate- or stearic acid-induced apoptosis in chondrocytes10,20. 
In addition, previous studies have reported that SFA-rich high-fat diet increased the severity of OA8,21,22.
The changes in cartilage observed in this study are characteristic of OA-induced cartilage damage with 
increased PA and SA inducing marked depletion of proteoglycan content and increased expression of MMP13 
and COL10 proteins shifting the balance of matrix homeostasis towards catabolism. MMPs are capable of degrad-
ing all components of the extracellular matrix, and their enhanced activity has been strongly implicated in carti-
lage degeneration23. Hypertrophy is known to trigger apoptosis of cartilage cells. The type of fatty acid clearly plays 
a role since LA did not induce these changes. PA and SA showed decreased proteoglycan content and increased 
release of sGAG, which confirmed their destructive properties on both cartilage explants and re-differentiated 
chondrocyte pellets. We further studied the effects of SFA and inflammatory cytokines such as IL-1β on chon-
drocytes. Co-treatment with IL-1β decreased the proteoglycan content and facilitated the increased release of 
sGAG in both human and bovine cartilage. Increases in gene expression of MMP13, ADAMTS 4 and 5 in PA- and 
SA-treated cartilage explants correlated with the increased release of sGAG. These results collectively suggest that 
catabolic effects of PA and SA together with IL-1β co-treatment in both human and bovine cartilage are likely to 
be mediated by the increased expression of cartilage-degrading enzymes that then trigger the changes similar to 
OA in chondrocytes. Furthermore, the number of empty lacunae is a clear indicator of osteocyte death24. In our 
recent study, the functional properties of osteocytes changed in OA patients, signifying the potential role of these 
cells in subchondral bone sclerosis25. Our results confirmed the increased presence of empty lacunae in H, HPA 
and HSA diet rats suggesting increased bone remodelling and unregulated mineral metabolism.
The correlation between obesity and OA is well-established, indicating that metabolic-induced inflamma-
tion in obesity26 plays an important role in OA27. The initiators of the inflammatory processes in rats fed this 
obesogenic diet are most likely to be SFA, since SFA such as PA activate macrophages10, and therefore increase 
infiltration of inflammatory cells throughout the body. Thus, obesity by itself does not cause OA, nor the reverse, 
but increased circulating SFA may induce infiltration of inflammatory cells throughout the body to produce 
parallel development of both disease states. While SFA may initiate the inflammation, there is good evidence 
that adipokines produced by inflammatory cells within fat pads also produce major physiological responses and 
Figure 3. Proteoglycan content and sulphated glycosaminoglycan (sGAG) release of chondrocyte pellets 
stimulated with different SFA. All pictures were obtained under 20X magnification (n = 5 per group). 
(A) Safranin O/Fast Green staining shows the extent of proteoglycan loss among the different diet groups 
both in non-IL-1β treated and IL-1β treated pellets. (B) Quantification of sGAG release in the supernatant 
was performed by DMB assay, which showed that PA and SA-treated pellets exhibited a trend of decreased 
chondrogenesis irrespective of IL-1β treatment. (C,D) Graph showing the increase in sGAG release in response 
to increasing concentration of PA and SA. All values are represented as mean ± SD. Scale bar is 100 μ m 
(P < 0.05).
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Figure 4. Extracellular matrix-related gene expression of chondrocyte pellets stimulated with different 
SFA (n = 5 per group). (A) ACAN, (B) COL10A, (C) MMP13, (D) ADAMTS4, (E) ADAMTS5 and (F) RUNX2 
mRNA levels were assessed by RT-PCR both in non-IL-1β treated and IL-1β treated pellets. All experimental 
samples were performed in triplicate. All values are represented as mean ± SD (P < 0.05).
Figure 5. Proteoglycan content, sGAG release and sGAG depletion of bovine cartilage explants (n = 3) 
stimulated with different SFA. (A) Safranin O/Fast Green staining of bovine cartilage explants shows the loss 
of proteoglycans in the different diet groups both in non-IL-1β treated and IL-1β treated explants.  
(B) Quantification of sGAG release in the supernatant was performed by DMB assay, which showed that PA 
and SA-treated explants increased release of sGAG into the media on both day 3 and day 7 when compared to 
the other diet groups. In addition, zone of sGAG depletion (C) in the cartilage explants was the highest in SA-
treated explants irrespective of IL-1β treatment (P < 0.05).
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may therefore increase the inflammatory responses in OA28. Key cytokines are likely to include leptin and adi-
ponectin, with possible roles of more recently discovered adipokines such as resistin and visfatin, in both obesity 
and OA4,28,29. The involvement of these cytokines in the development of obesity-induced OA could underlie the 
improvements following loss of abdominal obesity30, and so decreased cytokine production, such as improved 
lean mass/fat mass ratio leading to increased mobility and physical activity with decreased OA-induced pain, for 
example in the knees. The local inflammatory reactions in obesity-associated OA may then be increased by the 
development of insulin resistance in type 2 diabetes31. Type 2 diabetes is strongly predictive of the severity of OA, 
independent of BMI and age32,33, suggesting the involvement of insulin as type 2 diabetes is an insulin-resistant 
state. Insulin decreased autophagy in immortalised human chondrocytes and human cartilage explants, provid-
ing a mechanism by which cartilage could be damaged in an insulin-resistant state34. The correlation of decreased 
plasma insulin concentrations and decreased OA-like changes in rats fed LA, and the increased OA-like changes 
in rats fed PA and SA in our study strongly supports the role of insulin in OA associated with glucose intolerance 
and obesity. Oxidative stress as an increased biological activity of oxygen free radicals is also a key initiator of 
damage in both obesity35 and OA36. Ageing is associated with an increased oxidative stress, and also increased 
prevalence of both obesity and OA, suggesting oxidative stress as a possible causative link. Further, functional 
foods such as omega-3 polyunsaturated fatty acids may improve oxidative status as an important therapeutic 
mechanism37.
The limitations of this study include that we have not measured the morphological changes of the synovium 
or changes in synovial fluid cytokine concentrations. These two additional parameters may contribute additional 
insights to understanding local changes due to inflammation in SFA diets and so improve understanding of 
obesity-induced OA.
In conclusion, this study provides evidence that SFA can produce similar changes in both metabolic syndrome 
and OA. These changes correlate with the plasma concentrations of leptin and insulin, both involved in obesity, 
type 2 diabetes and OA. Our data suggest that replacement of traditional diets containing coconut-derived LA 
with palm oil-derived PA or animal fat-derived SA has the potential to worsen the development of both metabolic 
syndrome and OA. Further, human clinical trials are necessary to determine whether replacement of PA and SA 
in the diet with LA will attenuate or reverse the development of both OA and metabolic syndrome, especially 
obesity and hypertension.
Methods
Study design and diets. All animal experiments for this study were approved by the Animal Ethics 
Committees of the University of Southern Queensland and Queensland University of Technology while the 
human sample collection was approved by the Price Charles Hospital Human Ethics Committee. The proce-
dures for using animal and human samples were performed in accordance with the guidelines of the National 
Health and Medical Research Council of Australia. The experimental groups consisted of 72 male Wistar rats 
(9–10 weeks old) weighing 330–350 g purchased from Animal Resource Centre, Perth, WA, Australia (www.
arc.wa.gov.au). Rats were individually housed in a temperature-controlled, 12-hour light/dark cycle environ-
ment with free access to water and food at the University of Southern Queensland Animal House. The rats were 
randomly divided into 6 groups of 12 rats. Corn starch (C) diet contained 57% corn starch, 15.5% powdered rat 
food (Specialty Feeds, Glen Forest, WA, Australia), 2.5% HMW salt mixture and 25% water. High-carbohydrate, 
high-fat diet consisted of 17.5% fructose, 39.5% sweetened condensed milk, 20% beef tallow (H) or SFA (20% LA 
(HLA), 20% MA (HMA), 20% PA (HPA) or 20% SA (HSA)), 15.5% powdered rat food, 2.5% HMW salt mixture 
and 5% water. C diet included drinking water without any additives while H-based diet-fed rats were given drink-
ing water supplemented with 25% fructose14. The carbohydrate intake in both C and H groups was approximately 
68%. Rats had ad libitum access to food and water during the protocol.
Measurements of metabolic variables. Daily measurements of body weight and intakes of food and 
water were performed to monitor the day-to-day health of rats. Feed conversion efficiency (%) was calculated 
as previously described14. Percent body weight increase over 16 weeks was calculated as body weight difference 
between day 0 and day 112. Abdominal circumference was measured every 4 weeks using a standard measuring 
tape under light anaesthesia with Zoletil (tiletamine 10 mg/kg, zolazepam 10 mg/kg i.p; Virbac, Peakhurst, NSW, 
Australia).
Oral glucose tolerance tests were performed on rats as previously described14. Briefly, rats were deprived of 
food for 12 hours before basal blood glucose concentration measurements followed by oral gavage of 40% aque-
ous glucose solution and measuring glucose concentrations again at 30, 60, 90 and 120 minutes, with calculation 
of AUC (area under the curve) from these measurements. Systolic blood pressure was measured every 4 weeks 
under light sedation with Zoletil (10 mg/kg tiletamine, 10 mg/kg zolazepam, i.p.)14. Echocardiography was per-
formed to measure the cardiovascular structure and function14. Indirect calorimetry was used to measure oxy-
gen consumption and carbon dioxide production using a 4-chamber Oxymax system (Columbus Instruments, 
Columbus, OH) with one rat per chamber. Rats had ad libitum access to food and water during the measurement. 
Oxygen consumption (VO2) and carbon dioxide production (VCO2) were measured individually from each cham-
ber. The respiratory exchange ratio (RER = VCO2/VO2) was calculated by Oxymax software (v. 4.86). The oxidation 
of carbohydrates produces an RER of 1.00, whereas fatty acid oxidation results in an RER of about 0.7038. Energy 
expenditure was calculated by assessment of the exchange of oxygen for carbon dioxide that occurs during the 
metabolic processing of food.
Rats were euthanised after 16 weeks using Lethabarb® (100 mg/kg pentobarbitone sodium, i.p.). After eutha-
nasia, blood was collected to isolate plasma and the plasma was stored at −20 °C before further analysis. Hearts 
were isolated to perform Langendorff heart preparation to measure diastolic stiffness constant14. Following this, 
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tissues such as liver, left ventricle (with septum), right ventricle and abdominal fat pads (including retroperito-
neal, epididymal and omental) were removed for weighing and expressed as mg/mm of tibial length. Plasma con-
centrations of leptin, insulin, total cholesterol, triglycerides and non-esterified fatty acids (NEFA) were measured 
as described previously14.
Assessment of articular cartilage. After 16 weeks of dietary interventions, rats were euthanised and the 
knee joints harvested and then processed for histology. Briefly, the intact joints were fixed in 4% paraformalde-
hyde for 48 hours, decalcified in 10% EDTA for 8 weeks, bisected laterally and embedded in paraffin. Paraffin 
blocks were then trimmed to expose tissue using a rotary microtome (Leica, Wetzlar, Germany). Two 5-μ m 
sections within every consecutive six sections were cut and mounted on glass slides. Each knee yielded about 12 
sections for standard haematoxylin and eosin (H&E) staining or proteoglycan staining with safranin O as pre-
viously described39. The severity of cartilage damage was assessed using the standard Mankin grading system40. 
The mean damage score from 5–6 samples from each animal was used to determine the mean ± standard devi-
ation for each group. Two independent observers assessed cartilage damage in a blinded manner. Furthermore, 
immunostaining was performed with antibodies against matrix metalloproteinase-13 (MMP13) (1:50 Labvison, 
RB1681-P0, Fremont, CA, USA), aggrecan (AGAN) (1:200 Millipore, AB1031, New South Wales, Australia) and 
type 10 collagen (COL10) (1:200 Abcam, ab58632, New South Wales, Australia)39. For controls, the same proce-
dures were carried out either without primary antibody or with isotype-matched IgG instead of primary antibody. 
For semi-quantitative data analysis, the positive cells from different fields of observation in the tibial medial 
compartment of the knee were counted and normalised to the cell number per 100 total cells in each group, using 
ImageJ (NIH, Bethesda, MD)39.
TUNEL apoptosis assay. Terminal deoxynucleotidyl transferase (TdT) dUTP Nick-End Labelling 
(TUNEL) was used to identify cells that show degradation of their DNA during apoptosis. The tissue slices were 
first permeabilised with proteinase K for 30 minutes at 37 °C. The slides were then washed with PBS and the assay 
was performed using the manufacturer’s protocol (Roche, Germany). The sections were incubated with DNase1 
for 10 minutes at room temperature as a positive control. For semi-quantitative data analysis, the positive cells 
from different fields of observation were counted and normalised to the cell number per 100 total cells in each 
group, using ImageJ (NIH, Bethesda, MD)39.
Assessment of subchondral bone changes. Micro-CT was performed to analyse the subchondral bone 
changes. Femur and tibia were scanned using a micro-CT (Scanco μ CT 40, Scanco Medical, Switzerland) with 
isotropic voxel size of 18 μ m with voltage of 55 kV and current of 145 μ A with a 0.5 mm aluminium filter. The 
exposure time was 1180ms and Scanco’s inbuilt software was used to segment the data set39. Manual regions of 
interest (ROI) were drawn around the anatomical contour in the subchondral bone region in the medial and lat-
eral tibial plateau. The volume of interest (VOI) consisted of a stack of ROIs (25 cross-sections). The VOI started 
below the subchondral plate which extended distally towards the growth plate. Ratio of bone volume to the total 
volume (BV/TV) and bone mineral density (BMD) of the VOI were calculated.
Analysis of osteocytes. Average osteocyte empty lacunae (Avg OS.L) and average osteocyte nucleus (Avg 
OS.N) were counted per unit area (mm2) in the subchondral bone region in the medial tibial plateau using ImageJ 
(NIH, Bethesda, MD).
Treatment of chondrocytes and cartilage explants with SFA. Preparation of SFA. LA, MA, PA and 
SA were purchased commercially at the highest purity available (Sigma-Aldrich, GC-purified, chemically syn-
thesised). Bovine serum albumin (BSA) (fatty-acid free, Sigma Aldrich) was chosen as the carrier. The SFA-BSA 
complex solutions were made using a protocol described earlier6. Individual SFA were dissolved in 100% ethanol 
at 70 °C to yield a 200 mM stock solution. The stock solution was then diluted 1:10 in 10% (w/v) BSA made with 
Dulbecco’s Modified Eagle Medium (DMEM) for 10 minutes at 55 °C. The resultant SFA solution (20 mM) was 
sterile-filtered (0.45 μ M filter) prior to application to the cell cultures using a protocol described earlier6. The 
vehicle control (negative control) was the fatty acid free-BSA with the same concentration of ethanol.
Chondrocyte pellet and bovine explant culture. Chondrocytes were harvested using enzymatic digestion and 
cultured using our published protocols39. Briefly, biopsies of articular cartilage were obtained from primary OA 
patients undergoing knee replacement surgery at The Prince Charles Hospital (Brisbane, QLD, Australia). All car-
tilage biopsies were taken from a part of the surface of the femoral condyle considered by the surgeon to resemble 
intact and healthy cartilage. The five donors were all males aged 60–65 years and all provided written informed 
consent. The study was approved by The Prince Charles Hospital and Queensland University of Technology 
Human Ethics Committees. Each cartilage specimen was further characterised and scored according to Mankin 
score with only samples with scores of 0–1 (healthy cartilage) being used for further experiments.
The cartilage was dissected from the bone and digested with collagenase 2 solution (Invitrogen, Lakewood, 
NJ) overnight in the DMEM culture medium for the isolation of the articular cartilage chondrocytes (ACC). 
After digestion, ACCs (2.5 × 105 cells) were pelleted by centrifugation in 15 mL Falcon tubes and cultured in 
three-dimensional (3D) pellet culture system39, for 14 days in chondrogenic medium in the presence or absence 
of different SFA.
For bovine explant studies, fresh adult bovine knee joints (n = 3) were obtained on the day of slaughter. Full 
thickness articular cartilage explants without the subchondral bone were then harvested from the knee joints. 
Cartilage discs were then aseptically dissected using a 4-mm dermal punch. The discs were cultured in DMEM, 
and supplemented with 10% Foetal Bovine Serum (FBS) and antibiotics at 37 °C with 5% CO2 for 48 hours.
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The pellets and discs were then stimulated with each SFA (final concentration: 30 μ g/ml, derived from MTT 
assay – data not shown). The negative control, in which no SFA were added, was treated with BSA vehicle only. 
To study the effects of SFA and inflammatory cytokines, some ACC pellets and bovine cartilage discs were treated 
with IL-1β (10 ng/mL) in the presence or absence of different SFA. After day 3 and day 7, media were collected 
and stored in − 80 °C for quantification of sulphated glycosaminoglycans. The cartilage discs and ACC pellets 
were later processed for histological analysis and quantitative real time PCR analysis (qPCR). To further assess 
the responses to certain SFA, different concentrations (10 μ M, 30 μ M, 60 μ M and 90 μ M) of PA and SA were added 
to chondrocyte pellets both in the absence and in the presence of IL-1β (10 ng/mL). After day 3 and day 7, media 
were collected and stored at − 80 °C for quantification of sulphated glycosaminoglycans (sGAG). In addition, to 
assess the effects of IL-1β used in this study, chondrocyte pellets were treated with various concentrations of IL-1β 
(1–10 ng/ml). The day 3 and day 7 media were collected and stored at − 80 °C for quantification of sGAG.
Sulfated glycosaminoglycans (sGAG) assay. To measure sGAG release, supernatants were collected from the wells 
containing the bovine cartilage discs or chondrocyte pellets treated with or without SFA at day 3 and day 7. The 
sGAG was measured using the dimethylmethylene blue method (DMB) with the kit (Blyscan™ , Biocolor Ltd) 
following the manufacturer’s instructions. Zone of sGAG depletion in cartilage explants were determined using 
images of Safranin O staining and were measured using ImageJ (NIH, Bethesda, MD).
RNA extraction and real-time PCR. Total RNA was extracted using TRIzol reagent (Invitrogen), treated with 
DNase and purified according to manufacturer’s protocol using an RNeasy Mini Kit (Qiagen). cDNA was synthe-
sised from 1 μ g of the total RNA according to manufacturer’s protocol using an SensiFAST cDNA Synthesis Kit. 
Real-time quantitative PCR41, using SYBR Green detection chemistry, was performed on the ABI 7500 Fast Real 
Time PCR system (Applied Biosystems, Foster City, CA, USA). Melt curve analyses of all real-time PCR products 
were performed and shown to produce a single DNA duplex. All samples were measured in triplicate and the 
mean value of all experimental samples was considered for comparative analysis. Quantitative measurements of 
all primers used in this study were determined using the (2−ΔΔCt) method, and 18 s and β -actin expression were 
used as the internal controls, as described previously by our group39,41–43.
Statistics. Statistical analyses were performed using Graphpad Prism. The data are presented as mean ± stand-
ard deviation (SD) for all variables and analysed with ANOVA method. Repeated-measures analysis of variance 
with post hoc tests (Dunnett’s/Bonferroni) was used to assess statistical significance. The level of significance was 
set at P < 0.05.
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Chapter 4 Linseed components on metabolic 
parameters in rats. 
4.1 Introduction 
Metabolic syndrome refers to a group of linked abnormalities including 
abdominal obesity, glucose homeostasis disorders including type 2 diabetes, impaired 
fasting glucose, glucose intolerance and insulin resistance, and dyslipidaemia with 
increased cardiovascular disease risk including hypertension and coagulation disorders 
(Kassi et al., 2011, Kaur, 2014). The prevalence of metabolic syndrome has increased, 
now affecting one quarter of the world’s population (Thaman and Arora, 2013). The 
increase in prevalence reflects the transition from a traditional hunter-gatherer diet to 
a diet high in fats and carbohydrates with a sedentary lifestyle, changing body 
composition and metabolism leading to central obesity and other metabolic disorders 
(O'Neill and O'Driscoll, 2015).  
The clinical management of metabolic syndrome is based on targeting obesity, 
insulin resistance and hypertension as these are fundamental risk factors of the 
syndrome. Modest changes in dietary intake can delay, if not prevent, the onset of 
metabolic disorders, for example including grains in the diet (Everitt et al., 2006). The 
consumption of linseed (Linum usitatissimum L.) has been reported to protect against 
metabolic syndrome and cardiovascular disease by lowering blood pressure, reducing 
blood glucose concentrations, delaying postprandial glucose absorption and 
decreasing oxidative stress and inflammation (Rodriguez-Leyva et al., 2013, Hutchins 
et al., 2013). These changes may be due to linseed being a rich source of bioactive 
compounds (Bozan and Temelli, 2008, Oomah, 2001), in particular providing an oil 
rich in α-linolenic acid (ALA, 18:3n-3) together with lignans, digestible proteins and 
mucilage from soluble fibre (Singh et al., 2011a). There is growing support for the 
ALA component of linseed being the active component in reducing blood 
triglycerides, blood pressure, platelet reactivity, neutrophil activity and increasing 
high-density lipoprotein (HDL) cholesterol thereby helping in lowering cardiovascular 
risk (Gorder et al., 1986, Cunnane et al., 1993, Li et al., 1999). Further, the 
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administration of 3% of linseed oil to high-carbohydrate, high-fat fed rats normalised 
systolic blood pressure, and improved heart function and glucose tolerance (Poudyal 
et al., 2013a). 
Linseed is one of the richest dietary sources of plant lignans with 
secoisolariciresinol diglucoside (SDG) being the major component of lignans and 
found at a concentration 75–800 times higher than in other foods (Poluzzi et al., 2014). 
SDG is converted by enterolignan-producing bacteria in the mammalian colon to 
enterodiol and enterolactone (Muir, 2006). Animal and human studies have shown 
benefits of linseed lignans in chronic diseases such as the slowing of progression and 
regression of atherosclerosis and the amelioration of cardiovascular disease, diabetes, 
cancer and metabolic syndrome (Adolphe et al., 2010, Prasad and Jadhav, 2016). 
Visceral fat, liver triacylglyceride content, serum triacylglycerides, total cholesterol, 
and insulin and leptin concentrations were reduced compared with the high-fat diet 
without SDG in C57BL/6 mice (Fukumitsu et al., 2008).  
 However, the physiological responses of SDG, raw linseed and defatted linseed 
as separate interventions have not been evaluated in the same disease model and 
linseed as a much cheaper source of alpha-linolenic acid grown locally has not been 
tested. This is also necessary to extend the measured physiological responses of ALA 
from the linseed oil fraction in diet-induced obesity in rats (Poudyal et al., 2013a), 
while the metabolic effects of other linseed components are yet to be elucidated. The 
rats were fed either corn starch diet, high-carbohydrate, high-fat diet or either diet 
containing either 0.03% of 40% SDG to give an SDG dose approximating 6mg/kg/day, 
5% raw linseed or 3% defatted linseed supplement. These rates were chosen to be 
similar to previous studies of SDG supplementation (Fukumitsu et al., 2008, Felmlee 
et al., 2009), whole seed supplementation (Poudyal et al., 2012a) and non-oil content 
of seeds as flour (Dugani et al., 2008). The aim of this study therefore was to determine 
the effects of lignans, raw linseed and defatted linseed on cardio-metabolic health 
parameters on high-carbohydrate, high-fat induced obesity in rats.  
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4.2 Materials and methods 
4.2.1 SDG and raw linseed composition analysis 
SDG (40% purity) was a kind gift from Archer Daniels Midland Company 
(Chicago, Illinois, USA). Raw linseed and defatted linseed were kind gifts from 
AustGrains (Moree, NSW, Australia). The analysis of SDG content was conducted by 
St. Boniface Hospital Research, Winnipeg, Canada and the nutritional analysis of raw 
linseed was provided by Agrifood Technology, Victoria, Australia. 
 
4.2.2 Bomb calorimetry 
Total gross energy content of SDG, raw linseed and defatted linseed samples 
were measured by bomb calorimetry (XRY-1A Oxygen Bomb calorimeter, Shanghai 
Changji Geological Instrument Co. Ltd) in triplicate. About 1 g of SDG, raw linseed 
and defatted linseed were burnt in compressed oxygen (25 kg/cm2) in the calorimetric 
bomb immersed in water.  
4.2.3 Rats and diet 
Male Wistar rats (6 – 8 weeks old, weighing 250 - 300 g, n = 96) were 
purchased from Animal Resource Centre from Perth, Australia. All the rats were 
housed individually in temperature-controlled, 12-hour-light/-dark conditions in the 
animal house facility of the University of Southern Queensland. The rats were 
acclimatised and given free access to water and standard rat powdered food prior to 
diet intervention. All experimental protocols were approved by the University of 
Southern Queensland Animal Ethics Committee under the guidelines of the National 
Health and Medical Research Council of Australia.  
After an acclimatisation period, rats (average weight 336±0.2 g) were 
randomly divided into 8 experimental groups: corn starch-rich diet-fed rats (CS; n = 
12), corn starch + 40% SDG (CSLF; n = 12), corn starch + 5% raw linseed (CSRL; n 
= 12), corn starch + 3% defatted linseed (CSDL; n = 12), high-carbohydrate, high-fat 
diet-fed rats (HCHF; n = 12), high-carbohydrate, high-fat + 40% SDG (HLF; n = 12), 
90 
high-carbohydrate, high-fat + 5% raw linseed (HRL; n = 12) and high-carbohydrate, 
high-fat + 3% defatted linseed (HDL; n = 12). The SDG-supplemented diets were 
prepared by adding sufficient SDG-enriched product (0.03% of 40% SDG) to give an 
average daily intake of 6 mg/kg body weight SDG from the CS and HCHF diets; raw 
linseed supplemented diets were prepared by replacing 5% water with 5% of raw 
linseed in the CS and HCHF diets and defatted linseed supplemented diets were 
prepared by replacing 3% water with 3% defatted linseed in the CS and HCHF diets.  
The dosages were chosen based on previous study using 6mg SDG/kg body 
weight/day with the purity of SDG at 99% (Felmlee et al., 2009). We were provided 
with SDG at 40% purity, so we aimed for a dose to the rats of 15 mg/kg/day to give 
the same SDG dose. Next, the raw linseed was the same dose as in a study which used 
5% chia seeds in food (Poudyal et al., 2012a), as the oil composition of chia seed and 
linseed are same. Since the oil content of linseed is about 40% (Dugani et al., 2008), 
the non-oil component, defined here as defatted linseed, is therefore 60%. Hence, the 
defatted linseed flour was dosed at 3% in the food or 60% of the dose of the whole 
linseed. 
The SDG, raw linseed and defatted linseed supplemented diets were 
administered for 8 weeks starting 8 weeks after the initiation of the corn starch or high 
carbohydrate, high-fat diet. HCHF, HLF, HRL and HDL groups were given 25% 
fructose in drinking water along with the diets for the 16 week duration of the study. 
Normal drinking water without any supplementation was given to CS, CSLF, CSRL 
and CSDL rats. The preparation and macronutrient and micronutrient compositions of 
CS and HCHF diets were previously described (Poudyal et al., 2012a, Panchal et al., 
2011). Rats were monitored daily for body weight and food and water intake. Energy 
intake and food conversion efficiency were calculated (Poudyal et al., 2012a, Panchal 
et al., 2011).
4.2.4 Other methods 
All other methods were performed as described in Chapter 2 which included 
oral glucose tolerance test, systolic blood pressure, body composition, isolated 
Langendorff heart preparation, aortic contractility, ileum and colon contractility, tissue 
collection, histology and biochemical analysis. 
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4.2.5 Statistical analysis 
All data are presented as mean ± SEM. A total of 8 groups were analysed using 
two-way analysis of variance (ANOVA) with each group consisting of 12 rats. All 
group data were tested for variance using Bartlett’s test. Variables that were not 
normally distributed were transformed (using log 10 function) prior to statistical 
analysis. The effects of diet, treatment and their interactions were tested by two-way 
analysis of variance. When interaction and/or the main effects were significant, means 
were compared using Newman-Keuls multiple-comparison post hoc test. Where 
transformations did not result in normality or constant variance, a Kruskal-Wallis 
nonparametric test was performed. All statistical analyses were performed using 
GraphPad Prism version 6 for Windows (San Diego, CA). A p value of < 0.05 was 
considered as statistically significant. 
 
4.3 Results 
4.3.1 Nutritional analysis of raw linseed 
The proximate composition of raw linseed is presented in Table 4.1.  
Table 4.1: Proximate composition of raw linseed. 
Test Result 
Dry matter (%) 93.3 
Moisture (%) 6.7 
Ash (% of dry matter) 2.8 
Crude fibre (% of dry matter) 17.9 
Crude protein (% of dry matter) 25.4 
Fat by acid hydrolysis (% of dry matter) 32.6 
Nitrogen free extract (%) 19.9 
 
4.3.2 Total gross energy 
The total gross energy as measured by bomb calorimetry was found to be 
lowest in defatted linseed (16.87±0.12 kJ/g), followed by SDG with 17.48±0.07 kJ/g 
and the highest total gross energy was found in raw linseed (23.76±0.06 kJ/g). 
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4.3.3 Dietary intake 
The results on food intake, water intake and energy intake that were determined 
after 8 weeks of lignans, raw linseed or defatted linseed supplementation are presented 
in Figure 4.1 and Table 4.2. Food and water intakes were higher in CS-fed rats than in 
HCHF-fed rats. However, energy intake was higher in HCHF rats than in CS rats. 
There were no differences in the food intake of CSLF, CSRL and CSDL with corn 
starch control group (CS). HLF, HRL and HDL also showed no differences in the food 
intake with high-carbohydrate, high-fat fed group (HCHF). Water intake was 
unchanged in CS, CSLF, CSRL and CSDL groups and there was also no difference in 
water intake between HCHF, HLF, HRL and HDL rats. The same results were found 
in energy intake, hence no change in feed conversion efficiency among high-
carbohydrate, high-fat groups, whereas CSRL-fed rats showed the highest feed 
conversion efficiency among all corn starch fed rats. 
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Figure 4.1: Food intake, water intake, energy intake and feed conversion efficiency in 
rats supplemented with lignan, raw linseed or defatted linseed at week 16.  
Data are presented as mean ± SEM of. Means with unlike superscript differ; p< 0.05. 
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4.3.4 Body composition 
 Body weight throughout the protocol of 16 weeks are presented in Figure 4.2. 
All groups showed weight gains. H-fed rats had higher body weight gain than C-fed 
rats. Raw linseed group showed the highest weight gained as compared to control 
groups, while HRL showed no difference in weight gain compared to HCHF group. 
The contribution of bone mineral content to body composition can be seen in Table 
4.2, where HRL group had higher bone mineral content compared to CS, CSRL, CSDL 
and HDL groups (Figure 4.3) and no difference was found with HLF and HCHF 
groups. CSRL supplemented rats had the highest total lean mass and this group showed 
no differences in total fat mass and bone mineral content with CS and CSLF groups 
(Figure 4.3).  
Abdominal circumference and visceral adiposity index were not changed in 
CSLF and CSRL rats, respectively, compared to CS rats (Table 4.2). HRL showed 
higher abdominal circumference and higher visceral adiposity index as compared to 
HCHF control group and this might be the consequence of higher total fat mass in 
HRL rats. HLF showed no difference in total fat mass and total abdominal fat with 
HCHF control group. HDL supplemented rats were shown to have higher total lean 
mass as compared to HCHF and HLF group. 
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Figure 4.2: Body weight in rats from 0 to 16 week. Rats were supplemented with either 
lignans, raw linseed or defatted linseed starting at week 8.  
Data are presented as mean ± SEM, n = 10-12. Values marked with different letters 
are significantly different at the level of p < 0.05. 
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Figure 4.3: Bone mineral content, total lean mass, total fat mass (gram) in rats fed CS, 
CSLF, CSRL, CSDL, HCHF, HLF, HRL and HDL.  
Data are presented as mean ± SEM, n = 10-12. Values marked with different letters 
are significantly different at 16 weeks at the level of p<0.05.
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Table 4.2: Dietary intakes, body compositions and organ wet weights in groups fed the CS, CSLF, CSRL, CSDL, HCHF, HLF, HRL and HDL in 
the diet. 
 Variable CS CSLF CSRL CSDL HCHF HLF HRL HDL P Value 
Diet Treatment Interaction 
Food intake (g/d) 35.0±0.6a 35.5±0.8a 34.6±1.2a 33.9±1.2a 25.2±0.6b 26.3±0.4b 23.4±0.6b 24.4±0.4b <0.0001 0.0452 0.3957 
Water intake 
(mL/d) 
28.7±1.8a 30.4±2.7a 30.7±2.1a 32.7±0.9a 25.6±1b 25.2±1.0b 26.9±0.4ab 25.7±1.1b 0.0047 0.6175 0.8185 
Body weight 
gained (%) (week 8 
- 16) 
7.4±1.0d 9.1±1.7d 18.2±0.8b 13.2±1.6c 23.3±0.9a 18.9±1.3b 23.4±0.6a 22.7±1.4a <0.0001 <0.0001 <0.0001 
Energy intake 
(kJ/d) 
392±7b 420±13b 433±14b 397±14b 552±13a 555±8a 561±14a 542±9a <0.0001 0.1323 0.3855 
Feed conversion 
efficiency (%) 
1.8±0.2c 2.6±0.5c 4.9±0.3b 3.2±0.4c 9.6±0.6a 8.1±0.7a 9.2±0.6a 9.0±0.6a <0.0001 0.0043 0.0048 
Bone mineral 
content (g) 
12.0±0.4c 13.2±0.6c 12.1±0.2c 11.9±0.2c 16.5±0.4a 16.8±0.4a 17.3±0.7a 15.3±0.6b <0.0001 0.3256 0.2829 
Each value is presented as mean±S.E.M, n = 8-12. Means within a row with unlike superscript differ; p< 0.05. 
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Table 4.2: Continued. 
 Variable CS CSLF CSRL CSDL HCHF HLF HRL HDL P Value 
Diet Treatment Interaction 
Total fat mass (g) 98.3±16c 122±16c 103±7c 76.9±6c 256±21a 227±7ab 253±21a 189±22b <0.0001 0.9756 0.23 
Total lean mass (g) 276±14ab 267±9b 317±7a 309±5a 268±14b 246±7b 277±11ab 312±15a 0.0094 0.0013 0.3115 
Visceral adiposity 
index (%) 
4.9±0.4d 4.8±0.6d 4.7±0.3d 4.2±0.1d 9.6±0.7ab 8.5±0.4bc 10.4±0.9a 7.3±0.5c <0.0001 0.2846 0.2256 
Tissue wet weight (mg/mm) 
Retroperitoneal fat  189±18c 194±31c 179±18c 151±20c 531±41a 469±31ab 554±59a 407±31b <0.0001 0.5539 0.3445 
Epididymal fat 89±10d 112±20cd 98±8d 74±5d 259±17a 211±11b 278±28a 154±16c <0.0001 0.2903 0.0374 
Omental fat 114±15c 102±13c 124±9c 102±7c 240±25ab 207±8b 280±18a 198±14b <0.0001 0.013 0.2607 
Total abdominal fat  392±39d 408.±63d 401±35d 308±36d 1031±79ab 887±45b 1113±105a 683±92c <0.0001 0.2336 0.1831 
Liver 201±5b 213±8b 213±12b 216±7b 327±12a 306±9a 337±15a 310±8a <0.0001 0.3163 0.215 
Heart 22.0±1.0c 21.5±0.4c 25.4±0.7bc 25.3±0.9bc 26.8±1.1b 23.6±0.9bc 31.5±2.1a 26.9±0.9b <0.0001 <0.0001 0.183 
Kidney 45.2±1.7b 44.9±0.6b 46.5±1.0b 49.9±1.0b 57.1±2.4a 55.1±1.6a 56.6±2.1a 56.7±0.9a <0.0001 0.6216 0.8278 
Spleen 12.2±0.5b 14.7±0.9ab 15.9±1.1ab 14.5±0.9ab 17.9±1.0a 16.2±0.7a 17.7±1.1a 17.3±1.5a 0.0002 0.1364 0.0419 
Each value is presented as mean±S.E.M, n = 8-12. Means within a row with unlike superscript differ; p< 0.05.
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Fat depots (retroperitoneal, epididymal and omental fat) and organ wet weights 
(liver, heart, kidney and spleen) were measured and data are presented in Table 4.2. 
Retroperitoneal fat in HCHF rats was increased compared to CS rats, with the greatest 
weight found in HCHF and HRL fed groups. Average wet weight of epididymal and 
omental fats for HRL group was higher than HCHF, HLF and HDL groups. For HLF 
and HDL groups, the total abdominal fats were lower than HCHF group by 14% and 
34%, respectively. Organ wet weight of liver, kidney and spleen showed no change 
among groups of high-carbohydrate, high-fat groups. However, the wet weight of heart 
for HRL group was higher as compared to HCHF, HLF and HDL groups. These data 
suggest that rats fed HRL diet gained weight particularly in the heart and abdominal 
fats, but rats fed HLF and HDL had lower average abdominal fats, heart, liver, kidney 
and spleen. 
4.3.5 Plasma biochemistry analysis 
Plasma total cholesterol concentrations of lignans, raw linseed and defatted 
linseed supplemented groups showed no difference with control groups (Table 4.3). 
HLF and HDL groups showed a lower concentration of plasma NEFA and TAG as 
compared to HCHF and HRL groups (Table 4.3). In CSLF, CSRL and CSDL rats, both 
plasma NEFA and TAG were unchanged as compared to CS group. Plasma insulin 
concentrations were lower in CSLF and CSDL groups when compared to CS and 
CSRL groups (Table 4.3). Compared to HCHF rats, HLF, HRL and HDL rats had 
lower plasma insulin concentrations. Plasma leptin concentrations were lower in HLF 
group as compared to HCHF, HRL and HDL groups (Table 4.3). Plasma leptin 
concentrations were unaffected among C-fed rats.  
High-carbohydrate, high-fat rats control and supplemented groups showed 
higher basal glucose concentrations than corn starch control and corn starch 
supplemented groups (Figure 4.4). Results showed that there was no difference in total 
area under curve among H-fed rats and similar findings were also found in CS-fed rats. 
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Figure 4.4: Oral Glucose Tolerance Test (OGTT) at 16 weeks in rats fed CS, CSLF, 
CSRL, CSDL, HCHF, HLF, HRL and HDL.  
Data are presented as mean ± SEM, n = 10. End-point means without a common 
alphabet in each data set significantly differ at p < 0.05.  
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Table 4.3: Plasma biochemistry analyses in groups fed the CS, CSLF, CSRL, CSDL, HCHF, HLF, HRL and HDL in the diet. 
Variable 
CS 
 
CSLF 
 
CSRL 
 
CSDL HCHF 
 
HLF 
 
HRL 
 
HDL P Value 
  
  
  
  
  Diet Treatment Interaction 
Lipid profile   
 
  
  
  
  
  
Plasma total 
cholesterol 
(mmol/L) 1.5±0.05a 1.6±0.06a 1.3±0.10a 
 
 
1.4±0.10a 1.6±0.04a 1.6±0.06a 1.5±0.10a 
 
 
1.6±0.10a 0.0973 0.0226 0.3917  
Plasma NEFA 
(mmol/L) 0.9±0.20b 1.4±0.19b 1.5±0.20b 
 
1.5±0.20b 4.3±0.60a 3.7±0.51a 4.0±0.30a 
 
3.7±0.40a <0.0001 0.8585 0.3055  
Plasma TAG 
(mmol/L) 0.4±0.06b 0.4±0.06b 0.4±0.10b 
 
0.5±0.01b 1.6±0.30a 1.3±0.20a 1.5±0.20a 
 
1.3±0.20a <0.0001 0.6784  0.6784  
OGTT-AUC      
(mmol/l x min) 636±19bc 687±20b 625±14c 
 
680±14b 794±13a 765±25a 735±17ab 
 
770±17a <0.0001 0.0365 0.0940 
Plasma insulin 
(µmol/L) 1.3±0.01e 1.7±0.01d 2.9±0.05c 
 
1.7±0.05d 7.7±0.09a 6.0±0.11b 5.9±0.12b 
 
5.8±0.04b <0.0001 <0.0001 <0.0001 
Plasma leptin 
(µmol/L) 3.2±0.40d 2.1±0.62d 4.2±0.06d 
 
3.9±0.03d 12.3±1.54a 6.3±0.97c 13.1±0.03a 
 
10.2±0.08b <0.0001 <0.0001 0.0052 
Each value is a mean ± S.E.M, n = 10. Means within a row with unlike superscript differ; p< 0.05. NEFA: Non-esterified fatty acids, TAG: 
Triglycerides, OGTT-AUC: Oral glucose tolerance test- area under curve.
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4.3.6 Cardiovascular function 
HLF, HRL and HDL groups showed lower systolic blood pressures as 
compared to HCHF group (Table 4.4). There was no difference in systolic blood 
pressure between CSDL and CS groups. These results with H-fed rats were reflected 
in Langendorff isolated heart measurement as the diastolic stiffness constant was 
improved in HLF and HDL groups. The heart wet weight in HLF group was same as 
corn-starch fed rats (Table 4.2).   
HCHF rats showed diminished α1-adrenoceptor-mediated vascular contraction 
to noradrenaline in isolated thoracic aortic rings compared to CS rats (Figure 4.5A). 
Additionally, HCHF rats showed decreased smooth muscle-dependent relaxant 
responses to sodium nitroprusside (Figure 4.5B) and endothelium-dependent relaxant 
responses to acetylcholine (Figure 4.5C). Lignan-supplemented groups showed 
improved α1-adrenoceptor-mediated vascular contraction to noradrenaline and smooth 
muscle-dependent and endothelium-dependent relaxant responses to sodium 
nitroprusside and acetylcholine, respectively (Figures 4.5A, B and C). However, raw 
linseed groups did not show any improvement in vascular contraction and relaxation 
(Figures 4.5A, B and C).    
HLF rats had improved histological profile of the left ventricle after 16 weeks 
(Figures 4.6 and 4.7). HCHF showed greater interstitial collagen deposition (marked 
“cd”; Figure 4.6E) as compared to other groups (Figure 4.6) and increased infiltration 
of inflammatory cells (Figure 4.7E). HLF, HRL and HDL rats showed reduced 
ventricular collagen deposition (Figures 4.6 F, G and H). No change was observed in 
CSLF rats (Figures 4.6B and 4.7B) and the tissue morphology of the heart appeared 
normal.
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Table 4.4: Systolic blood pressure and diastolic stiffness constant of CS, CSLF, CSRL, CSDL, HCHF, HLF, HRL and HDL at 16 weeks. 
Variable 
CS CSLF CSRL CSDL HCHF HLF HRL HDL P Value 
Diet Treatment Interaction 
Systolic blood 
pressure, mmHg 128±3bc 133±2b 129±2bc 120±3c 148±2a 133±3b 134±2b 129±5bc <0.0001 0.0256 0.0004 
Diastolic 
stiffness 
constant, κ 23.0±0.4bc 23.0±0.8bc 24.2±0.7abc 21.9±0.3c 26.6±0.9a 22.0±0.5c 25.1±0.5ab 23.7±1.3bc 0.0344 0.0012 0.0039 
Data are presented as mean ± SEM, n = 10-12. Values marked with different letters are significantly different at the level of p < 0.05. 
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Figure 4.5: Cumulative concentration–response curves for noradrenaline (A), sodium nitroprusside (B) and acetylcholine (C) in thoracic aortic 
rings from rats fed the CS, CSLF, CSRL, HCHF, HLF and HRL diet.  
Data are shown as means ± S.E.M.; n=9–10/group.  
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Figure 4.6: Picrosirius red staining of left ventricular interstitial collagen deposition (×20) in rats fed the CS (A), CSLF (B), CSRL (C), CSDL (D), 
HCHF (E), HLF (F), HRL (G) and HDL (H) diet.  
Collagen deposition is marked as “cd,” and hypertrophied cardiomyocytes are marked as “hy.” 
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Figure 4.7: Haematoxylin and eosin staining of heart (x20) in rats fed the CS (A), CSLF (B), CSRL (C), CSDL (D), HCHF (E), HLF (F), HRL (G) 
and HDL (H) diet. 
Inflammatory cell is marked as “in”. 
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4.3.7 Liver structure and function 
HCHF rats had elevated plasma markers of liver function in comparison to CS 
rats (Table 4.5). Plasma liver function (ALT and AST) was unchanged in CSLF and 
HRL rats. ALT activity remained unchanged in HLF, HRL and HDL groups with 
HCHF rats. Plasma AST showed no difference among all H-fed groups. Figure 4.8 
showed increased hepatic lipid deposition and inflammatory cell infiltration in H 
groups compared to C groups. HLF and HDL groups showed decreased lipid vacuoles 
(Figures 4.8F and 4.8H) compared to HCHF and HRL groups. CSLF and CSDL groups 
showed minimal hepatic steatosis and portal inflammation and tissue morphology 
appeared normal.
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Table 4.5: Plasma liver enzymes of CS, CSLF, CSRL, CSDL, HCHF, HLF, HRL and HDL rats at week 16. 
Variable 
CS CSLF CSRL CSDL HCHF HLF HRL HDL P Value 
Diet Treatment Interaction 
Hepatic function 
Plasma ALT 
(U/L) 26.8±2.5b 23.2±1.6b 30.9±3.8b 28.3±2b 33.7±1.5a 33.6±1.7a 27.8±2.5ab 33.8±1.5a 0.0173 0.7369 0.0169 
Plasma AST 
(U/L) 64.6±4.6a 61.6±1.8a 66.4±5.9a 66.3±2.8a 68.8±2.6a 69.6±6.8a 61.6±3.7a 67.5±2.9a 0.5189 0.8439 0.3753 
Data are presented as mean ± SEM, n = 10-12. Values marked with different letters are significantly different at the level of p < 0.05. 
ALT; Alanine aminotransferase, AST: Aspartate transaminase.
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Figure 4.8: Haematoxylin and eosin staining of liver (x20) in rats fed the CS (A), CSLF (B), CSRL (C), CSDL (D), HCHF (D), HLF (E), HRL (F) 
and HDL (H) diet. 
Figures with “fv” marked the fat vacuoles and “in” marked inflammatory cells. 
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4.3.8 Gut structure and function 
Acetylcholine-induced contraction on ileum and colon is shown in Figure 4.9. 
There were no difference in ileal contractions between high fat, high carbohydrate 
dietary treatments at the maximum dose of acetylcholine. Similarly, there were no 
differences between corn starch control group and treated groups. Increased colon 
contractility was evident in HDL rats compared to CSRL and HRL rats, with no 
difference found in other groups. In histological sections, fewer goblet cells were 
observed in small intestines of treatment rats as compared to control rats (Figure 4.10). 
In the colon, fewer goblet cells were observed in HLF and HRL rats as compared to 
control rats, whereas the density of goblet cells was increased in the colon of HDL rats 
compared to control rats (Figure 4.11).  
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Figure 4.9: Concentration-response curves for acetylcholine in ileum and colon from 
rats fed the CS, CSLF, CSRL, CSDL, HCHF, HLF, HRL and HDL diet.  
Data are shown as means ± S.E.M.   
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Figure 4.10: Periodic acid Schiff’s staining of small intestine (x20) in rats fed the CS (A), CSLF (B), CSRL (C), CSDL (D), HCHF (E), HLF (F), 
HRL (G) and HDL (H) diet. 
Figures with “gc” marked the goblet cells. 
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Figure 4.11: Periodic acid Schiff’s staining of colon (x20) in rats fed the CS (A), CSLF (B), CSRL (C), CSDL (D), HCHF (E), HLF (F), HRL (G) 
and HDL (H) diet. 
Figures with “gc” marked the goblet cells. 
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4.4 Discussion 
The established metabolic syndrome rat model (Panchal et al., 2011) was used 
to investigate the comparative effects of 6 mg/kg/day SDG, raw linseed (5% in the 
diet) or defatted linseed (3% in the diet) in high-carbohydrate, high-fat rat model. The 
model shows progressive increases in body weight, energy intake, abdominal fat 
deposition, and abdominal circumference along with impaired glucose tolerance, 
dyslipidaemia, hyperinsulinaemia and increased plasma leptin concentrations. 
Moreover, after 16 weeks feeding with high-carbohydrate, high-fat diet, rats showed 
diminished cardiovascular function (Panchal et al., 2011). In addition, the same model 
was used in a previous study to determine the effect of α-linolenic acid (ALA) from 
linseed oil in adiposity, cardiovascular and liver structure in rats fed either a diet high 
in simple sugars and mainly saturated fats or a diet high in polysaccharides (corn 
starch) and low in fat (Poudyal et al., 2013a). This study only used linseed oil, therefore 
the current study explored other components of linseed for comparison with raw 
linseed. No studies have examined the effects of SDG, raw linseed and defatted linseed 
supplementation using the same model as it is crucial to see their biological actions 
towards reversing the metabolic syndrome. Thus, we examined the effects of 
6mg/kg/day SDG, 5% of raw linseed or 3% defatted linseed diet supplementation for 
8 weeks on biomarkers associated with metabolic syndrome which include glucose, 
leptin, insulin, blood pressure, diastolic stiffness and lipid profiles. 
Rats fed with HCHF diet developed abdominal obesity, hypertension, impaired 
glucose, leptin and insulin tolerance, dyslipidaemia and diminished cardiac function 
which supports the findings of the previous study (Panchal et al., 2011). However, the 
addition of low dose lignans as 6 mg/kg/day SDG to the diet for only 8 weeks lowered 
body weight gain as compared to HCHF control group together with lower total fat 
mass and total abdominal fat weight. Moreover, lower plasma concentrations of leptin 
reflected a low visceral adiposity index in SDG-fed rats. HLF also showed improved 
insulin concentrations and lower blood glucose concentrations compared to HCHF. 
These changes were also reported with lignan-enriched linseed (35% SDG) powder 
fed to high-fructose, high-fat rats for 12 weeks [12]. With lower doses of SDG (0.5 
and 1.0% SDG), weight changes were not as pronounced as in our study. However, 
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the same study found a reduction in visceral and liver fat accumulation, and improved 
plasma lipids, cholesterol, insulin and leptin concentrations in high-fat diet induced 
mice (Fukumitsu et al., 2008). These results are consistent with our study findings. An 
underlying mechanism of changes in adiponectin and leptin has been demonstrated to 
increase rates of fatty acid oxidation that mediates the insulin-sensitising effects (Dyck 
et al., 2006). Further, GLUT4 expression was increased in the insulin target tissue 
adipose, where it increased glucose uptake and enhanced insulin sensitivity (Armoni 
et al., 2003). Increased glucose elimination was suggested via increased translocation 
of GLUT4 to the cell membrane and increased basal glucose uptake by redistribution 
of GLUT1 (Pilar et al., 2014).  
Physiological responses of CSRL and HRL supplementation showed increased 
body weight gain of the rats after 8 weeks. It is noted that the total lean mass of CSRL 
was higher than CS control group. Meanwhile, HRL had a higher total fat mass and 
total abdominal fat that may contribute to higher body weight gained. Raw linseed had 
no effect on body weight as a study using 10%, 20% and 30% raw flaxseed (linseed) 
by adding into mouse pellet commercial diet for 30 days showed no difference in body 
weight between all groups (Saman et al., 2011). Similarly, a short-term trial using a 
40g aliquot of golden linseed daily for 28 days showed no differences in body weight, 
BMI and waist circumference in metabolic syndrome patients in both men and women 
(Pilar et al., 2014). In Zucker fatty rats, 10% (w/w) linseed supplementation for 9 
weeks also showed no effect on obesity in this genetic model with hyperphagia (Gillam 
et al., 2009). These results suggest that 5 to 30% raw linseed supplemented in the diet 
for at least 4 to 8 weeks does not change body weight. 
Removal of fat from linseed (CSDL and HDL) did result in weight changes 
with lower total fat mass, higher lean mass and lower abdominal circumference as seen 
in the CSDL and HDL groups. A clinical trial using 30g brown defatted flaxseed 
(linseed) flour given to obese subjects as a complement for breakfast showed that it 
promoted greater satiety and reduced their appetite (Monteiro et al., 2016). It appears 
that the higher protein and dietary fibre content from other linseed flours contain an 
important factor that reduced appetite and prolonged the sensation of satiety (Monteiro 
et al., 2016). Many possible mechanisms include homeostasis in weight maintenance 
that involved neuroendocrine signals that influence appetite and energy expenditure 
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(MacLean et al., 2015). Glucagon-like peptide-1 (GLP-1), an insulinotropic hormone 
released from the intestinal L cells in response to nutrient ingestion, inhibited gastric 
emptying and gastric acid secretion (Abu-Hamdah et al., 2009) and also association 
between ghrelin, satiety and cravings where a study on high protein and carbohydrate 
breakfast showed reduced cravings that will result in long term weight-loss 
(Jakubowicz et al., 2012). The present study also demonstrated that CSDL and HDL 
rats have lower glucose tolerance, plasma insulin and leptin concentrations. This is 
consistent with previous study on consumption of defatted flaxseed by obese women 
postoperative Roux-en-Y gastric bypass that resulted in reduced postprandial glucose 
and higher postprandial leptin concentrations (Cohen et al., 2013).   
Raw linseed is a rich source of ALA, lignan and fibre (mucilage). In a previous 
study by our group, we demonstrated that linseed oil supplementation for 8 weeks 
containing about 59% ALA did not reduce total body fat in this high-carbohydrate, 
high-fat diet-induced model of metabolic syndrome in rats which is consistent with 
present study (Poudyal et al., 2013b). However, the previous study showed that ALA 
from linseed oil induced lipid redistribution away from the abdominal area and 
improved glucose tolerance, insulin sensitivity, dyslipidaemia, hypertension and left 
ventricular dimensions, contractility, volumes and stiffness (Poudyal et al., 2013b). 
Linseed oil supplementation also reversed inflammation in the heart and the liver, 
cardiac fibrosis and hepatic steatosis (Poudyal et al., 2013a, Poudyal et al., 2013b). 
Additionally, ALA-rich linseed oil supplemented diet for 8 weeks decreased adipocyte 
size and adipose tissue concentrations of MCP-1, IL-10 and TNF-α (Baranowski et al., 
2012). Linseed oil supplementation reduced T-cell infiltration into the adipose tissue 
but did not alter macrophage infiltration (Baranowski et al., 2012). This suggests that 
concentrated ALA-rich linseed oil in the diet attenuated pro-inflammatory state and 
improved other obesity metabolic markers. 
SDG, raw linseed and defatted linseed supplementation for 8 weeks decreased 
systolic blood pressure in HLF (~10%), HRL (~10%) and HDL (~13%) compared to 
HCHF rats, and these findings also showed that all treated rats had similar blood 
pressure to CS rats. HLF and HDL groups also showed lower left ventricular diastolic 
stiffness as compared to HCHF control group. The use of 20% whole flaxseed (linseed) 
in spontaneously hypertensive rats and normotensive Wistar-Kyoto male rats for 10 to 
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11 weeks showed no changes in systolic blood pressure (Talom et al., 1999). A study 
using 35% SDG supplementation in Sprague-Dawley male rats fed high-fat and high-
fructose diet for 12 weeks reported a 45% lower blood pressure (Park and Velasquez, 
2012). It is noted that there may be a difference between the rats’ types and it may be 
their mutations that are influencing the result. However, the study findings indicate 
that a higher dosage of linseed and a longer duration of study may promote more 
reduction in systolic blood pressure.  
The mechanisms of action of reduced blood pressure may be explained by the 
subsequent increase in ALA, EPA, DHA, and the antioxidant pool of blood (Touré and 
Xueming, 2010) or the gradual increase in intestinal gut flora, which may improve 
lignan absorption (Setchell et al., 2014) and consequently reduce blood pressure. ALA 
may lower blood pressure by acting as a precursor for eicosanoids, which can generate 
the production of prostaglandins and leukotrienes that may reduce vascular tone 
(Salonen et al., 1988). The other possible mechanism was ALA reduced the activity of 
soluble epoxide hydrolase (an enzyme that causes a loss of vasodilation and promotes 
inflammation) which results in decreased soluble epoxide hydrolase-derived oxylipins 
that subsequently reduce the systolic blood pressure (Caligiuri et al., 2014). The 
antioxidant effects of lignans were found to be mediated by its metabolites enterodiol 
and enterolactone, where enterolactone can induce phase 2 protein activation which 
leads to decreased oxidative stress (Caligiuri et al., 2014).  
Few previous studies have measured the effects of lignans and linseed on the 
vascular endothelium. In the present study, HCHF rats showed impaired vascular 
contraction and endothelial-dependent relaxation, however with the addition of lignans 
to the diet the vascular contractility was identical to the CS group. This suggests that 
lignans improved α1-adrenoceptor-mediated vascular contraction to noradrenaline. 
One previous study using 20% flaxseed diet on spontaneously hypertensive rats (SHR) 
for 10-11 weeks showed that flaxseed diet enhanced vascular responsiveness to 
acetylcholine but not sodium nitroprusside (Talom et al., 1999). This is in contrast to 
our findings where HRL showed a better response to sodium nitroprusside but not 
acetylcholine. The mechanism that was explained by the previous study was diet 
supplemented with flaxseed alters the release of endothelium-derived relaxing factors 
(EDRFs) which maybe either  change the receptor affinity or the coupling of the 
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receptor to the effector system (Talom et al., 1999). SDG is known to possess 
antioxidant activity, thus another potential mechanism contributing to the beneficial 
effect of endothelial function could involve a protective effect of lignans on the 
breakdown of nitric oxide (NO). 
The present study indicates that lignans, raw linseed and defatted linseed 
supplementation for 8 weeks did not change plasma lipid profiles and liver function. 
There are variations of results obtained in previous studies, such as 7.5 g/kg daily 
flaxseed (linseed) diet given for 2 months did not change the serum lipid 
concentrations in rabbits (Prasad, 1997). However, SDG isolated from flaxseed 
(linseed) meal lowered serum concentrations of total cholesterol by 33% in 
hypercholesterolaemic rabbits but had no effect in normocholesterolaemic rabbits 
(Prasad, 1999). This study suggested that the hypolipidaemic effect of flaxseed 
(linseed) resides in the SDG component of flaxseed meal that could be due to variation 
in the total amount of SDG in the given dose of flaxseed (linseed). The mechanism of 
reduced total cholesterol was suggested to be due to the 3-hydroxy-3-methyl glutaric 
acid and SDG content of the lignans complex (Prasad, 1999). Male Sprague-Dawley 
rats fed 10% fructose in drinking water supplemented with 0, 3 and 6 mg SDG/kg body 
weight/day for 2 weeks showed no changes in serum triglycerides (TG) and non-
esterified fatty acid (NEFA) concentrations (Felmlee et al., 2009). SDG administration 
showed no effect on hepatic expression of PPAR-α or SREBP-1c following 10% 
fructose in water supplementation (Felmlee et al., 2009). Consistent with the present 
study, flaxseed (linseed) consumption for 4 weeks did not have deleterious effects on 
the liver function (Felmlee et al., 2009). Linseed also contained an important source 
of dietary fibre (35-45%) of which the ratio of soluble to insoluble fibre in linseed 
varies between 1:4 and 2:3 (Singh et al., 2011b). A study demonstrated that 3 flaxseed 
(linseed) fibre drink and bread per day with each drink and bread providing 5.2 g 
dietary fibres/10MJ when given to 17 subjects (men and women) for 7 days resulted 
in decreased plasma total cholesterol. This contrasts with present study findings, where 
no differences were found in total cholesterol of HRL and HDL groups compared to 
HCHF group. This differences in study findings could be attributed by higher content 
of dietary fibre in flax drink and bread given to the subjects. 
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Insoluble fibre inhibits intestinal digestive processes to result in decreased 
transit times within stomach and small intestine (Brownlee, 2011). The viscosity of 
insoluble fibre can cause chyme to have a larger bulk in the intestines (Brownlee, 
2011). Partially defatted flaxseed meal (PDFM) decreased small intestinal transit time 
in normal mice (Xu et al., 2012). Further, PDFM increased colonic motility and 
stimulated colonic transit via fermentation of soluble and insoluble fibre by colonic 
microflora that resulted in increase of bacterial mass and short-chain fatty acids such 
as acetate, propionate and butyrate [44]. In addition, laxative effects after PDFM 
consumption may have resulted from residual oil that acts as a lubricant (Xu et al., 
2012). This is consistent with the present study, where higher contractility in the colon 
was found in defatted linseed rats. Diet-induced obese rats demonstrated a faster 
gastric emptying, a weaker contraction of duodenal movement, a stronger contraction 
and relaxation of ileal movement but no differences in gastric emptying with control 
(non-obese) group (Fu et al., 2014). To support this, accelerated gastric emptying and 
reduced gastric distension could affect satiety and predispose healthy subjects to 
overeating (Cohen et al., 2013).  
Previously, it has been reported that diabetes could impair the contraction and 
relaxation capacities of gastrointestinal smooth muscles that include adrenergic, 
cholinergic and serotonergic stimulation (Ozturk et al., 1996, Lincoln et al., 1984). 
However, conflicting results were reported with either increased, decreased or 
unchanged contractions of smooth muscle (Bektaş and Öztürk, 2012). In the present 
study, both CSDL and HDL rats showed lower contractility in small intestines and 
higher contractility in the large intestine, whereas HLF rats showed high contractility 
in ileum and colon compared to controls. Further exploration is required to explain the 
differences in the gut contractility especially in obese animal models. 
In animal studies, a high-fat diet increased the number of goblet cells in the 
intestines (Benoit et al., 2015b, Hazarika et al., 2016). Increased numbers of goblet 
cells and mucins are indicators of intestinal disorders such as inflammatory bowel 
disease and cystic fibrosis (Kim and Ho, 2010). Lignans and raw linseed supplemented 
rats showed fewer goblet cells in both small intestine and colon. However, increased 
density of goblet cells were shown in the colon of HDL rats. A study done using 10% 
whole ground flaxseed (linseed) for 3 weeks in mice displayed goblet cell hyperplasia 
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(increase in goblet cells density), as well as increased colonic MUC2 expression 
(Power et al., 2016). This study suggests that increased colonic mucus secretion is 
attributed by enhanced microbial activity through increased production of caecal 
SCFA in flaxseed-fed mice, also increased viscosity of the luminal content, as well as 
faecal bulk (Power et al., 2016). In addition, a study using highly viscous soluble fibre 
(mucilage) produced faecal bulking effects (Dahl et al., 2005). Furthermore, dietary 
fibre induced higher production of goblet cells (Hedemann et al., 2006, Tanabe et al., 
2006) along the small intestinal epithelium. In regards to the results of this study, 
particularly consumption of defatted linseed might lead to changes in the colonic 
microenvironment and this may be beneficial to health. However, this study is only a 
preliminary study and further studies comparing linseed components relating to 
production of goblet cells, mucin secretion or goblet cell-associated genes should be 
performed to decipher the mechanisms involved in the changes within the gut and 
assessing how these changes impact in attenuating metabolic syndrome. 
4.5 Conclusion 
In this study, I highlight the metabolic effects of each component from linseed 
using the same diet-induced rat model. Lignans and dietary fibre from the non-oil 
components in linseed improved physiological response especially in cardioprotection 
and other metabolic changes some of which can be regarded as beneficial to health. In 
addition, these positive effects of lignans and defatted linseed could be promoted as 
functional foods, however further research on the use of these components of linseed 
in treating some signs of metabolic syndrome, especially in relation to gut health, is 
warranted. A longer study duration with an increase dosage of linseed components 
should be considered as this may also possibly enhance the effects in attenuating 
metabolic syndrome.  
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Chapter 5 High amylose wheat on metabolic 
parameters. 
5.1 Introduction 
Wheat was the third most produced grain in 2014 after maize and rice 
(FAOSTAT., 2014). In 2015, an estimated 733 million tonnes of wheat were produced 
(FAO (UN), 2016) and this is expected to rise to 746.7 million tonnes in 2016 (FAO, 
2016). Since the Green Revolution, food crop productivity had tripled with only a 30% 
increase in land area cultivated despite increasing land scarcity and rising land values 
(Pingali, 2012). The most widely cultivated wheat today is Triticum aestivum (bread 
wheat) (Fasahat et al., 2014). The varieties of wheat can be distinguished on the basis 
of seed coat colour, endosperm texture, dough strength and sowing season (Gooding, 
2009).  
Wheat grains contain approximately 60-70% starch while white flour contains 
65-75% starch (Shewry, 2009). Starch content is important as it provides the main
energy supply in the human diet and it has two main components: linear amylose (20-
30%) and highly branched amylopectin (70-80%) (Huang et al., 2015a, Tester et al.,
2004). Amylose is an essentially linear polymer of α-1,4 linked glucose units, while
amylopectin is a polymer of linear α-1,4 linked D-glucose units with branching points
consisting of α-1,6 linkages of D-glucose units every 20-25 D-glucose residues
(Regina et al., 2015). These branch linkages are organised in clustered structures
(Figure 5.1) in terms of linear A, B and C chains, where A chains do not carry any
other chains, are linked to B chains which in turn are linked to a C chain containing
the single reducing group (Fasahat et al., 2014).
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Figure 5.1: Amylopectin clustered structure.  
Adapted from (Fasahat et al., 2014). 
 
Although amylose constitutes only 20-30% of the starch component of common 
wheats, this polymer greatly influences the physicochemical properties, which can 
influence both the palatability of the grain and its health impact (Regina et al., 2015). 
Three genetic approaches to increasing amylose content in wheat include the alteration 
of the increased expression of genes involved in determining the trait via transgenic 
approaches, or through conventional crosses involving lines exhibiting various values 
of the trait or through the isolation of mutants (Fasahat et al., 2014). A variety of 
hexaploid wheat with unusually high levels of amylose in the starch has been 
developed through a normal selective breeding (non-GM) process (Collin Jenner), 
targeting induced local lesions in genomes (TILLING) process (Slade et al., 2012) and 
RNA interference by down-regulating the two different isoforms of starch-branching 
enzyme (SBE) II (SBEIIa and SBEIIb) in wheat endosperm to decrease amylopectin 
and increase amylose content (Regina et al., 2006).  
The amylose content is associated with the rate at which starch is broken down 
in the small intestine, leading to the release of glucose in the bloodstream, but this may 
not explain all the factors involved as other components of the meal will also have an 
effect (Fasahat et al., 2014). Australian high amylose wheat contains 15.3% protein, 
50.2% amylose and 3.2% fat content (Štěrbová et al., 2016). In addition, wholemeal 
wheat flour from this variety contains 34.4% rapidly digestible starch (RDS), 3.4% 
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slowly digestible starch (SDS), 16.9% resistant starch (RS) and 24.8% fibre as opposed 
to common white flour containing 38.4% RDS, 9.2% SDS, 6.6% RS and 12.2% fibre 
(Štěrbová et al., 2016). 
 High amylose content in food is associated with increased resistant starch. 
Resistant starch is one class of fibre that is inadequate in common modern diets. It is 
noteworthy that this type of fibre is associated with mitigating the risk of chronic 
diseases which include type 2 diabetes and bowel-related diseases (Jenkins and 
Kendall, 2000). Resistant starch is a starch that is non-digestible by enzymes in small 
intestine, but is then fermented in large intestine where bacteria that form the gut 
microbiota metabolise starch into sugars and then into short chain fatty acids and other 
metabolites (Nugent, 2005). Gastrointestinal microbiota play a major part in shaping 
host health, including immune system development, nutritional acquisition and 
protection against infections (Sekirov et al., 2010). Modulation of diet affects the gut 
microbiome (dysbiosis) which has been associated with human diseases such as 
obesity, diabetes, inflammatory bowel diseases and colorectal cancer (Sekirov et al., 
2010). Resistant starch metabolised by human gut microflora provides a source of 
carbon and energy for the 400–500 species of bacteria present in this anaerobic 
environment (Englyst and Macfarlane, 1986). Consumption of resistant starch results 
in increases of Actinobacteria and Bacteroidetes and decreases of Firmicutes 
(Martínez et al., 2010). This modulation of gastrointestinal bacteria by resistant starch 
may lead to interactions with the host which can reduce postprandial glucose 
concentrations and concomitant insulin responses compared with the consumption of 
foods containing ordinary starch (Hasjim et al., 2010). Resistant starches also have 
been proposed to aid weight management, although it has yet to be adequately 
demonstrated (Belobrajdic et al., 2012, Aziz et al., 2009). 
Replacement of common wheat with high amylose wheat to provide more 
resistant starch in the diet may improve gastrointestinal function and therefore general 
health. Therefore, the development of improved food products with increased resistant 
starch is important especially when wheat supplies approximately 20% of the food 
calories for the world population and is preferred for most cereal-based processed 
products, such as bread, pasta and noodles. The high resistant starch content of high 
amylose wheat flour could be useful as one of the best approaches to deliver functional 
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foods for people with high risk of diabetes and obesity. The aim of this study therefore 
was to determine the effects of low-dose (5%) and high-dose (20%) high amylose 
wheat flour on cardio-metabolic health parameters on high-carbohydrate, high-fat 
induced obese rats. A 5% dose of high amylose wheat was based on the same dose as 
a previous study from our research group using inulin which is a known prebiotic 
(Kumar et al., 2016). Inulin is likely to improve gut health by modulating the gut 
microbiota that will modulate signalling pathways to reduce metabolic diseases such 
as obesity and diabetes. It was hypothesised that consumption of high amylose wheat 
flour would reduce food intake, appetite, blood glucose and fat mass and that these 
effects would be dose-dependent. It is important to establish minimal levels of RS 
intake that elicit favourable metabolic effects in diet-induced obese rats to assist in 
identifying appropriate intakes for future human intervention trials. 
5.2 Low-dose high amylose wheat (5%) 
5.2.1 Materials and methods 
High amylose wheat flour was supplied by Austgrains Pty Ltd, Moree, NSW, 
Australia. All animal experimentation was approved by the Animal Experimentation 
Ethics Committee of the University of Southern Queensland under the guidelines of 
the National Health and Medical Research Council of Australia. 
5.2.1.1 Bomb calorimetry 
Total gross energy content of high amylose wheat flour was measured by bomb 
calorimetry (XRY-1A Oxygen bomb calorimeter, Shanghai Changji Geological 
Instrument Co. Ltd) in triplicate. About 1 g of high amylose wheat flour was burnt in 
compressed oxygen (25 kg/cm2) in the calorimetric bomb immersed in water. 
5.2.1.2 Rats and diets 
A total of 48 male Wistar rats aged 8-9 weeks old were randomly divided into 
4 groups (12 rats per group). Group I was fed with corn starch diet (CS), group II was 
fed with corn starch diet + 5% high amylose wheat (CHAW), group III was fed with 
the high-carbohydrate, high-fat (HCHF) diet and group IV was fed with HCHF diet + 
5% high amylose wheat (HAW). CS and HCHF rats received their diets for 16 weeks 
and CHAW and HAW received CS or HCHF diets for the first 8 weeks while both 
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diets were supplemented with 5% high amylose wheat by replacing equivalent 
amounts of water for a further 8 weeks. The drinking water in HCHF and HAW diet-
fed groups was augmented with 25% fructose for the duration of the study. Daily 
measurements of food and water intake, and body weight changes were recorded. The 
rats had unrestricted access to food and water. 
5.2.1.3 Other methods 
All other methods were conducted as detailed in Chapter 2, specifically oral 
glucose tolerance test, systolic blood pressure, body composition, isolated 
Langendorff heart preparation, ileum and colon contractility, tissue collection, 
histology and biochemical analysis. 
5.2.2 Results 
5.2.2.1 Total gross energy 
The total gross energy of high amylose wheat flour as measured by bomb 
calorimetry was 15.53±0.08 KJ/g.  
5.2.2.2 Dietary intake and body composition 
The food intake in CS rats was higher than HCHF rats. However, the mean 
energy intake, feed efficiency and body weight gains were higher in HCHF rats than 
in CS rats (Table 5.1). HAW and HCHF rats had similar daily food intakes. There were 
also no differences in the food intakes of CS and CHAW rats. Water intake for all rats 
was similar. Hence, there were no differences in energy intake between CS and CHAW 
and HCHF and HAW rats. CHAW rats gained more weight than CS rats and there was 
no difference between HCHF and HAW rats at 16 weeks (Figure 5.2). Table 5.1 
showed more than doubled feed conversion efficiency in CHAW rats compared to CS 
rats and no difference in HCHF and HAW rats. This reflects the body weight gains in 
CHAW rats. Bone mineral content of H-fed rats was higher than C-fed rats. HAW rats 
revealed a higher bone mineral content as compared to other groups. There were no 
differences found in the bone mineral content of CS and CHAW rats. 
Chronic HCHF feeding for 16 weeks resulted in increased total fat mass, 
abdominal circumference, visceral adiposity index, retroperitoneal fat, epididymal fat, 
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omental fat and liver, heart, kidney and spleen wet weights compared to CS rats. Total 
body lean mass was unchanged in HCHF and CS rats (Table 5.1). Treatment with 
either CHAW and HAW for 8 weeks showed no difference in body fat mass with CS 
and HCHF, respectively (Table 5.1) or in retroperitoneal, epididymal or omental fat 
weights (Table 5.2). Thus, no changes were found in visceral adiposity index and 
abdominal circumference on CHAW rats compared to CS rats and HAW rats 
compared to HCHF rats. Liver wet weight of HAW rats was found to be lower as 
compared to HCHF rats (Table 5.2). No differences were found in the liver wet weight 
for CS and CHAW rats. No differences were evident in heart weight of CS with 
CHAW rats and HCHF with HAW rats  (Table 5.2). Kidney and spleen wet weight for 
CHAW and CS showed no differences and similar results were shown in HAW and 
HCHF rats (Table 5.2). 
Figure 5.2: Body weight in control rats (CS and HCHF) and rats supplemented with 
5% high amylose wheat flour (5% CHAW and 5% HAW) throughout 16 weeks.  
Data are presented as mean ± SEM, n= 10-12. Values marked with different letters are 
significantly different at 16 weeks at the level of p<0.05.
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Table 5.1: Dietary intakes and body composition at 16 weeks in groups fed CS, CHAW, HCHF and HAW diets. 
Variable CS CHAW HCHF HAW p-Value 
     Diet Treatment Interaction 
Food intake (g/d) 35.5±0.8a 36.0±0.8a 25.7±0.6b 23.8±0.9b < 0.0001 0.3760 0.1324 
Water intake (mL/d) 27.9±1.6 27.2±1.4 27.5±1.2 27.2±1.2 0.8838 0.7149 0.8838 
Body weight gained (%) 8.2±1.9c 17.4±1.1b 23.2±1.1a 23.2±1.4a < 0.0001 0.0028 0.0028 
Energy intake (kJ/d) 399±9b 431±10b 561±13a 553±17a <0.0001 0.3612 0.1250 
Feed conversion efficiency (%) 2.2±0.5c 4.8±0.4b 10.1±0.7a 10.4±1.1a <0.0001 0.0521 0.1250 
Bone mineral content (g) 11.6±0.3c 12.6±0.3c 15.8±0.6b 17.3±0.7a < 0.0001 0.0213 0.6309 
Total fat mass (g) 62.7±12.5b 111.2±10.4b 238.2±24.6a 252.8±26.9a < 0.0001 0.1238 0.4021 
Total lean mass (g) 315±7 307±5 269±20 266±17 0.0042 0.7308 0.8495 
Abdominal circumference (cm) 18.8±0.3b 19.2±0.1b 23.4±0.4a 23.2±0.2a < 0.0001 0.7576 0.3571 
Visceral adiposity index (%) 4.1±0.4b 5.5±0.4b 8.3±0.7a 8.6±1.0a < 0.0001 0.2011 0.4049 
Data are presented as mean ± SEM. Values marked with different superscripts are significantly different at 16 week at the level of p<0.05. 
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Table 5.2: Organ wet weight and cardiovascular functions in groups fed CS, CHAW, HCHF and HAW in the diet at 16 weeks. 
Variables CS CHAW HCHF HAW p-Value 
     Diet Treatment Interaction 
Organ wet weight 
Retroperitoneal fat (mg/mm) 188.8±17.8b 209.1±22.7b 431.7±44.6a 465.8±56.5a < 0.0001 0.4833 0.8584 
Epididymal fat (mg/mm) 89.1±10.3b 125.3±10.3b 226.9±20.8a 210.7±19.9a < 0.0001 0.5414 0.1153 
Omental fat (mg/mm) 113.9±14.8b 125.5±11.1b 226.9±23.4a 219.3±24.6a < 0.0001 0.9186 0.6242 
Total abdominal fat(mg/mm) 329.2±31.7b 459.8±41.1b 885.6±84.1a 895.8±97.6a <0.0001 0.3149 0.3892 
Liver (mg/mm) 210.3±5.6c 204.2±7.0c 330.1±11.5a 300.0±6.3b < 0.0001 0.0320 0.1475 
Heart (mg/mm) 23.0±0.4b 25.0±1.1ab 25.6±1.0ab 28.3±1.3a 0.0051 0.0229 0.7248 
Kidney (mg/mm) 46.5±1.4b 45.7±1.7b 57.6±2.4a 55.4±1.7a <0.0001 0.4249 0.7086 
Spleen (mg/mm) 12.9±0.6b 13.5±1.0b 17.2±1.1a 18.1±0.9a <0.0001 0.4198 0.8712 
Cardiovascular function 
Systolic blood pressure (mmHg) 126±1c 129±4c 150±3a 137±4b <0.0001 0.1019 0.0151 
Diastolic stiffness constant, κ 22.7±0.3b 24.1±0.9b 26.4±0.8a 23.3±0.9b 0.0740 0.2869 0.0072 
Data are presented as mean ± SEM. Values marked with different superscripts are significantly different at 16 week at the level of p<0.05.
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5.2.2.3 Cardiovascular function and structure 
Values for systolic blood pressure and diastolic stiffness of control groups and 
high amylose wheat flour supplemented rats are given in Table 5.2. HCHF rats showed 
impaired cardiovascular function with elevated systolic blood pressure and diastolic 
stiffness compared to CS rats (Table 5.2). HAW rats showed lower systolic blood 
pressure compared to HCHF rats but there was no difference between CHAW and CS 
groups. Reduced diastolic stiffness constant is also found in HAW rats compared to 
HCHF rats, whereas no difference is found in CHAW and CS rats.  
Histological examinations supported the preceding results. CS-fed rats showed 
minimal collagen deposition, whereas HCHF-fed rats showed greater collagen 
deposition as well as infiltration of inflammatory cells in the left ventricle (Figures 
5.3A and 5.3C). CHAW supplemented rats showed normal collagen deposition when 
compared to CS rats (Figures 5.3B and 5.3A). Reduced collagen deposition in HAW 
rats was seen (Figures 5.3C and 5.3D). The haematoxylin and eosin staining of the left 
ventricle of HAW rats (Figure 5.4D) also showed normalised infiltration of 
inflammatory cells as compared to HCHF rats. This can be seen from the infiltration 
of inflammatory cells in HCHF rats marked as “in” (Figure 5.4C). There were no 
changes observed in CS and CHAW rats as the tissue morphology appeared normal 
(Figures 5.4A and 5.4B). 
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Figure 5.3: Picrosirius red staining of left ventricular interstitial collagen deposition 
(20x magnification) in CS (A), CHAW (B), HCHF (C) and HAW (D) rats.  
Collagen deposition marked as “cd” and hypertrophied marked as “hy”. 
  
Figure 5.4: Haematoxylin and eosin staining of left ventricle (20x magnification) in 
CS (A), CHAW (B), HCHF (C) and HAW (D).  
Inflammatory cells marked as “in”.
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5.2.2.4 Liver function and structure 
Elevated plasma alanine transferase (ALT) activity was found in HCHF rats, 
but there were no differences between CS and HAW rats (Table 5.3). CHAW rats 
showed a lower plasma ALT activity compared to CS rats. No changes were observed 
in plasma AST in all groups (Table 5.3). Histological sections of hepatic tissue were 
evaluated using haematoxylin and eosin staining examining the hepatic lipid 
deposition marked as “fv” (Figure 5.5). HCHF rats showed more fat vacuoles 
compared to CS rats. Liver tissues from CHAW and HAW rats showed decreased 
macrovesicular steatosis than HCHF rats (Figure 5.5). This is consistent with the 
finding of liver wet weight of HAW rats, which is lower compared to the liver weight 
of HCHF rats.  
Figure 5.5: Hepatocytes stained with haematoxylin and eosin are shown in CS (A), 
CHAW (B), HCHF (C) and HAW (D). 
Fat vacuoles marked as “fv”.  
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5.2.2.5 Plasma metabolic parameters 
 Plasma lipid profiles are presented in Table 5.3. Plasma total cholesterol was 
found to be unaffected in CS and HCHF rats. However, plasma concentrations of 
triglycerides and non-esterified fatty acids (NEFA) were increased in HCHF rats 
compared to CS rats. No changes in total cholesterol were found after 8 weeks 
supplementation of high amylose wheat flour in the diet. HAW rats had higher plasma 
NEFA and triglycerides compared to CS and CHAW rats and there was no difference 
found with HCHF rats.  
The blood glucose response to oral glucose loading was greater in HCHF rats 
than CS rats (Table 5.3). Rats supplemented with 5% high amylose wheat flour showed 
no difference in glucose area under the curve (AUC) with their respective controls. 
Plasma insulin concentrations were lower in CS rats than HCHF rats. Decreased 
plasma insulin concentrations were also found in HAW rats compared to HCHF rats 
(Table 5.3), whereas CHAW rats showed greater plasma insulin concentration than CS 
rats, but lower than HCHF and HAW rats. Plasma leptin concentrations were higher 
in HCHF and HAW rats compared to CS and CHAW (Table 5.3). No differences in 
plasma leptin were found in either high amylose group compared to their respective 
controls and this is consistent with the findings in total fat mass and total abdominal 
fat pads. 
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Table 5.3: Plasma biochemistry analyses in groups at 16 weeks fed CS, CHAW, HCHF and HAW diets. 
Variable 
CS 
 
CHAW 
 
HCHF 
 
HAW 
 
P Value 
  
  
 
 
Diet Treatment Interaction 
Hepatic function 
Plasma ALT (U/L) 31.6±4.2ab 23.5±1.4b 38.7±5.4a 27.4±1.7ab 0.1346 0.0105 0.6588 
Plasma AST (U/L) 71.1±7.3 63.1±2.6 78.4±6.6 62.0±3.0 0.5627 0.0274 0.4338 
 
       
Lipid profile        
Plasma total cholesterol (mmol/L) 1.4±0.1 1.5±0.1 1.5±0.05 1.7±0.1 0.1048 0.1048 0.5825 
Plasma NEFA (mmol/L) 1.7±0.2b 1.4±0.1b 4.5±0.5a 3.6±0.4a <0.0001 0.0853 0.3822 
Plasma TAG (mmol/L) 0.5±0.1b 0.4±0.05b 1.7±0.3a 1.2±0.2a <0.0001 0.1175 0.2922 
        
OGTT-AUC (mmol/l x min) 669.1±20.3b 618.0±16.4b 752.1±21.1a 730.1±16.8a <0.0001 0.0556 0.4237 
Plasma insulin (µmol/L) 1.3±0.01d 3.1±0.03c 8.1±0.1a 6.2±0.1b <0.0001 0.2969 <0.0001 
Plasma leptin (µmol/L) 3.5±0.2b 5.1±0.6b 12.9±1.6a 13.1±1.5a <0.0001 0.4609 0.5578 
Each value is a mean±S.E.M. Means within a row with unlike superscript differ; P≤ 0.05. ALT:  Alanine transaminase, AST: Aspartate 
transaminase, NEFA: Non-esterified fatty acids, TAG: Triglycerides, OGTT-AUC: Oral glucose tolerance test – Area under curve.
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5.2.2.6 Gut contractility and structure 
 Contractility measurements for both ileum and colon are presented in Figure 
5.6. There were no significant differences between dietary groups for acetylcholine-
induced contraction of the ileum or colon at maximal contraction (Figures 5.6A and 
5.6B). Figure 5.7 and 5.8 showed periodic acid and Schiff reagent’s staining that 
showcases the number of goblet cells in small intestine and large intestine. The density 
of goblet cells was unaffected in small intestines; however, there was an increased 
density of goblet cells observed in CHAW and HAW as compared to CS and HCHF, 
respectively.  
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  P-Value 
Figure Diet Treatment Interaction 
A 0.1045 0.8009 0.5212 
B 0.8099 0.9573 0.6502 
 
Figure 5.6: Ileum contractility (Figure A) and colon contractility (Figure B) at week 
16 in rats fed CS, CHAW, HCHF and HAW.
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Figure 5.7: Periodic acid and Schiff reagent (PAS) staining (magnification 20x) in the small intestine and in the colon of rats fed CS, 
CHAW, HCHF and HAW. 
Top row: Periodic acid and Schiff reagent (PAS) staining (magnification 20x) in the small intestine of CS (A), CHAW (B), HCHF (C) 
and HAW (D). Bottom row: Periodic acid and Schiff reagent (PAS) staining (magnification 20x) in the colon of CS (E), CHAW (F), 
HCHF (G) and HAW (H).   
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Figure 5.8: Periodic acid and Schiff reagent (PAS) staining (magnification 10x) in the colon of CS (A), CHAW (B), HCHF (C) and HAW 
(D). 
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5.3 Intervention with increased dose of high amylose wheat  
5.3.1 Materials and methods 
5.3.1.1 Rats and diets 
A total of 48 male Wistar rats aged 8-9 weeks old were randomly divided into 
4 groups (12 rats per group). For this study, we were using a reformulation of CS and 
HCHF diet to allow an increased dose of 20% high amylose wheat. A 20% dose of 
wheat translates to around 5g wheat intake/rat/day as average rat food intake is around 
25g food/day for rats weighing 450g. This corresponds to about 11.11 g/kg/day for 
rats and this equates to around 220g/day for an adult human (~70Kg) using the 
accepted scaling equation (Bachmann et al., 1996b). Modified corn starch (MCS) diet 
contained 57% corn starch, 2.5% Hubble, Mendel and Wakeman salt mixture, 0.5% 
canola oil, 4.5% skim milk powder, 0.5% vitamin mixture and 35% water (Figure 5.9). 
Modified high fat-high, carbohydrate (MHCHF) - based diets consisted of 17.5% 
fructose, 39.5% sweetened condensed milk, 15% beef tallow, 2.5% Hubble, Mendel 
and Wakeman salt mixture, 0.5% canola oil, 4.5% skim milk powder, 0.5% vitamin 
mixture and 20% water (Figure 5.9). Group I was fed with modified corn starch diet 
(MCS) for 16 weeks. Group II was fed with MCS + 20% high amylose wheat for 8 
weeks (20%CHAW). Group III was fed with the modified high-carbohydrate, high-fat 
(MHCHF) diet for 16 weeks. In group IV, rats were fed with MHCHF diet + 20% high 
amylose wheat for 8 weeks (20%HAW). MCS and MHCHF rats received their diets 
for 16 weeks and 20%CHAW and 20%HAW received MCS or MHCHF diets for the 
first 8 weeks while both diets were supplemented with 20% high amylose wheat by 
replacing equivalent amounts of water for a further 8 weeks. The drinking water in 
MHCHF and 20%HAW diet-fed groups was augmented with 25% fructose for the 
duration of the study. Daily measurements of food and water intake, and body weight 
changes were recorded. The rats had unrestricted access to food and water.  
 
5.3.1.2 Other methods 
All other methods were conducted as detailed in Chapter 2, specifically oral 
glucose tolerance test, systolic blood pressure, body composition, isolated 
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Langendorff heart preparation, ileum and colon contractility, tissue collections, 
histology and biochemical analysis. 
Figure 5.9: Ingredients used to make modified diet supplemented with 20% high 
amylose wheat flour. 
5.3.2 Results 
5.3.2.1 Dietary intake and body composition 
The average food intake was the same for both modified high-carbohydrate, 
high-fat (MHCHF) rats and modified corn starch (MCS) rats (Table 5.4). 20%HAW 
rats had lower average food intake as compared to MHCHF rats. There was no 
difference in food intake between MCS rats and 20%CHAW rats (Table 5.4). A lower 
water intake was found in MHCHF rats compared to MCS, 20%CHAW and 20%HAW 
rats (Table 5.4). Despite the lower water intake in MHCHF rats, the mean energy 
intake and feed efficiency were higher in MHCHF rats than in MCS rats (Table 5.4).  
The body weight gains were found to be in this sequence; 20%CHAW > 
20%HAW > MHCHF > MCS (Table 5.4). Figure 5.10 showed that 20%HAW had a 
consistent body weight gain from week 8 until week 14 when the rats started to reduce 
body weight. 20%CHAW rats showed a consistent body weight gain until week 16. 
 
 
136 
 
Similar trend was found in MHCHF but it was only a gradual increase throughout the 
study. In contrast with MCS rats, their body weight had a slight decrease but not 
significant starting at week 8 until week 16. This reflects in the feed conversion 
efficiency where MCS showed negative feed conversion efficiency and the highest is 
from 20% HAW rats.  
 Body composition of rats is presented in Table 5.4. Compared to MCS rats, 
MHCHF rats had higher bone mineral content, total lean mass and total fat mass. 
Supplementation with 20%CHAW for 8 weeks showed a higher bone mineral content 
compared to MCS rats. However, it is lower compared to MHCHF and 20%HAW rats. 
There is no difference in total fat mass between 20%CHAW, MCS and 20%HAW. 
MHCHF had the highest total fat mass and it is higher from MCS and 20%CHAW, 
but not with 20%HAW. Total lean mass increased in the 20% high amylose wheat 
flour supplemented rats compared to MHCHF and MCS rats.  
The abdominal circumference was found to be higher in MHCHF rats than 
MCS rats. Similarly, 20%HAW rats also had higher abdominal circumference 
compared to 20%CHAW and MCS rats and no difference with MHCHF rats. MHCHF 
rats had highest visceral adiposity index than 20%CHAW and MCS rats. There was 
no difference in visceral adiposity index between MHCHF and 20%HAW rats (Table 
5.4). The retroperitoneal, epididymal and omental fat tissues were found to be higher 
in MHCHF than MCS rats (Table 5.5). 20% CHAW rats had higher wet weight of 
retroperitoneal, epididymal and omental fat tissues compared to MCS rats, but lower 
than MHCHF and 20%HAW rats. Lower omental fat was found in 20%HAW rats 
compared to MHCHF rats. These results are then consistent with total abdominal fat 
results.  
 MHCHF rats had higher liver wet weight than MCS rats (Table 5.5). There is 
no change observed in liver wet weight of 20%HAW with 20%CHAW rats. However, 
the liver wet weight of 20%CHAW and 20%HAW were found to be lower than 
MHCHF rats and higher than MCS rats. Treatment with 20% high amylose wheat in 
either diet for 8 weeks did not change heart wet weights (Table 5.5). Kidney wet weight 
and spleen weight were reduced in MCS rats compared to 20%CHAW, 20%HAW and 
MHCHF (Table 5.5).  
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Figure 5.10: Body weights in control rats (MCS and MHCHF) and rats supplemented with 20% high amylose wheat flour (20% CHAW and 20% 
HAW) throughout 16 weeks.  
Data are presented as mean ± SEM, n= 10-12. Values marked with different letters are significantly different at 16 weeks at the level of p<0.05. 
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Table 5.4: Dietary intakes, body composition and organ wet weights in groups fed MCS, 20%CHAW, MHCHF or 20%HAW diets. 
Variable MCS 20%CHAW MHCHF 20%HAW p-Value
Diet Treatment Interaction 
Food intake (g/d) 32.6±1.3ab 34.5±1.1a 29.8±1.3b 22.0±1.0c <0.0001 0.0162 0.0002 
Water intake (mL/d) 33.0±3.2a 35.3±1.9a 21.5±1.4b 29.0±1.1a <0.0001 0.0189 0.2029 
Body weight gains (%) -2.4±1.4d 49.2±3.4a 18.1±1.5c 38.8±3.6b 0.0890 <0.0001 <0.0001 
Energy intake (kJ/d) 321±13c 446±14b 517±24a 503±19a <0.0001 0.0046 0.0006 
Feed conversion efficiency (%) -0.3±0.2c 11.2±0.9b 6.5±0.8b 19.6±2.5a <0.0001 <0.0001 0.6177 
Bone mineral content (g) 9.1±0.3c 11.1±0.2b 12.9±0.5a 12.8±0.3a <0.0001 0.0086 0.0041 
Total fat mass (g) 34.2±7.4b 32.7±6.8b 110.1±18.9a 75.8±13.8ab <0.0001 0.1583 0.1950 
Total lean mass (g) 256±9c 385±8a 328±11b 399±7a <0.0001 <0.0001 0.0023 
Abdominal circumference (cm) 16.5±0.2c 19.4±0.2b 20.7±0.4a 20.9±0.2a <0.0001 <0.0001 <0.0001 
Visceral adiposity index (%) 4.0±0.3b 4.6±0.4b 6.7±0.4a 6.1±0.5a <0.0001 >0.9999 0.1483 
Data are presented as mean ± SEM. Values marked with different superscripts are significantly different at 16 weeks at the level of p<0.05. 
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Table 5.5: Organ wet weight and cardiovascular functions in groups fed CS, CHAW, HCHF and HAW in the diet at 16 weeks. 
Variables MCS 20%CHAW MHCHF 20%HAW p-Value 
     Diet Treatment Interaction 
Organ wet weight 
Retroperitoneal fat (mg/mm) 128.3±15.8b 197.9±25.5b 378.1±43.2a 295.2±21.9a <0.0001 0.8213 0.0139 
Epididymal fat (mg/mm) 47.2±5.9c 89.2±12.0b 134.3±15.6a 129.7±16.3a <0.0001 0.1487 0.0747 
Omental fat (mg/mm) 81.8±8.4d 121.9±11.3c 217.5±17.7a 172.9±17.3b <0.0001 0.8728 0.0049 
Total abdominal fat (mg/mm) 257.4±3.0d 408.9±4.6c 730.0±8.9a 597.7±1.7b <0.0001 0.0960 <0.0001 
Liver (mg/mm) 180.2±9.6c 254.5±6.0b 347.6±25.7a 300.6±12.3ab <0.0001 0.4006 0.0007 
Heart (mg/mm) 19.2±2.6 25.7±1.0 28.4±4.3 26.0±1.1 0.1069 0.4788 0.1300 
Kidney (mg/mm) 38.5±1.1c 48.8±0.7b 66.6±5.3a 54.0±1.1b <0.0001 0.7013 0.0006 
Spleen  11.0±1.0b 16.0±1.0a 18.3±1.4a 18.9±1.9a 0.0006 0.0428 0.1068 
Cardiovascular functions 
Systolic blood pressure (mmHg) 137±2a 130±2a 141±3a 120±3b 0.2644 <0.0001 0.0114 
Diastolic stiffness constant, κ 25.1±0.5a 20.4±0.9b 25.2±0.7a 23.7±0.8a 0.0245 0.0002 0.0334 
Data are presented as mean ± SEM. Values marked with different superscripts are significantly different at 16 week at the level of p<0.05.
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5.3.2.2 Cardiovascular structure and function 
Systolic blood pressure and diastolic stiffness are given in Table 5.5. Rats 
supplemented with 20%HAW showed lower systolic blood pressure compared to 
MHCHF, 20%CHAW and MCS rats. There is no difference in diastolic stiffness 
constant in 20%HAW rats with MHCHF rats. 20%CHAW rats showed lower diastolic 
stiffness constant as compared to all other groups.  
The results above were supported by histological evaluation. Normal collagen 
deposition was found in both MCS and 20%CHAW rats (Figures 5.11A and 5.11B). 
MHCHF rats showed striking collagen deposition in the left ventricle, meanwhile 
20%HAW rats showed reduced collagen deposition (Figures 5.11C and 5.11D). The 
haematoxylin and eosin staining of the left ventricle sections of 20%CHAW was 
observed to be normal (Figure 5.12B). Infiltration of inflammatory cells in MHCHF 
rats were seen in Figure 5.12C. 20%HAW fed rats (Figure 5.12D) showed an 
improvement in the left ventricle as compared to MHCHF rats.  
Figure 5.11: Picrosirius red staining of left ventricular interstitial collagen deposition 
(20x magnification) in MCS (A), 20%CHAW (B), MHCHF (C) and 20%HAW (D) 
rats.  
Collagen deposition marked as “cd”. 
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Figure 5.12: Haematoxylin and eosin staining of left ventricle (20x magnification) in 
MCS (A), 20%CHAW (B), MHCHF (C) and 20%HAW (D). 
Figures with “in” showing inflammatory cells. 
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5.3.2.3 Liver structure and function 
 Plasma alanine transferase (ALT) activity was similar in all groups (Table 5.6). 
20%HAW rats had decreased plasma AST activity compared to MCS rats, but no 
difference was observed with 20%CHAW and MHCHF groups. Liver histological 
sections were evaluated using haematoxylin and eosin staining looking at the fat 
vacuoles deposition marked as “fv” (Figure 5.13). MHCHF rats showed more fat 
vacuoles compared to other groups. 20%CHAW and 20%HAW rats had smaller fat 
vacuoles in liver tissues and appeared to be normal as can be seen in MCS rats (Figure 
5.13). This is consistent with the finding of liver wet weight of 20%HAW rats, where 
it had lower liver wet weight compared to MHCHF rats.  
 
Figure 5.13: Hepatocytes stained with haematoxylin and eosin were shown in MCS 
(E), 20%CHAW (F), MHCHF (G) and 20%HAW (H). 
Figures with “fv” marked the fat vacuoles and “in” marked the infiltration cells.
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5.3.2.4 Plasma biochemistry analysis 
 Plasma concentrations of total cholesterol, non-esterified fatty acids (NEFA) 
and triglycerides (TAG) are presented in Table 5.6. Plasma total cholesterol remained 
unchanged in MCS and MHCHF rats, and in rats supplemented with 20% high 
amylose wheat flour. In contrast, MHCHF group had increased plasma NEFA and 
TAG concentrations at week 16. It was also found that 20%HAW rats had higher 
NEFA and TAG concentrations than 20%CHAW and MCS rats. There was no 
difference found between 20%HAW and MHCHF rats in plasma NEFA and TAG. 
Compared to MCS rats, MHCHF rats showed higher glucose area under the 
curve (AUC). Rats supplemented with 20%HAW had lower glucose AUC compared 
to MHCHF and it was no difference from 20%CHAW and MCS rats (Table 5.6). 
Consistent results were found in plasma insulin concentrations (Table 5.6). 20%HAW 
rats had lower plasma insulin concentration than MHCHF rats. 20%CHAW rats 
showed greater plasma insulin concentration than MCS rats, but lower than HCHF and 
HAW rats. Both MHCHF and 20%HAW rats had higher plasma leptin concentrations 
compared to 20%CHAW and MCS rats (Table 5.6). No difference was observed in 
plasma leptin concentrations between MCS and 20%CHAW rats, but it was found that 
MHCHF rats had higher plasma leptin concentrations than 20%HAW rats.  
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Table 5.6: Plasma biochemistry analyses in groups fed the MCS, 20%CHAW, MHCHF and 20%HAW in rats at week 16. 
Variable 
MCS 
 
20%CHAW 
 
MHCHF 
 
20%HAW 
 
P Value 
  
  
 
 
Diet Treatment Interaction 
Hepatic function 
Plasma ALT (U/L) 26.9±1.0 32.1±2.8 30.8±2.8 30.6±2.2 0.6213 0.3063 0.2699 
Plasma AST (U/L) 
 86.0±6.1a 70.7±4.2ab 69.1±5.8ab 65.1±2.9b 0.0213 0.0459 0.2332 
Lipid profile        
Plasma total cholesterol (mmol/L) 1.6±0.1 1.7±0.1 1.6±0.1 1.6±0.1 0.6270 0.6270 0.6270 
Plasma NEFA (mmol/L) 1.6±0.3b 2.0±0.2b 4.4±0.3a 3.4±0.5a <0.0001 0.3888 0.0500 
Plasma TAG (mmol/L) 
 0.7±0.1b 0.5±0.1b 1.6±0.2a 1.3±0.2a <0.0001 0.1201 0.7514 
OGTT-AUC (mmol/l x min) 703.8±16.8c 735.3±15.6c 844.3±28.8a 732.3±11.1bc 0.0010 0.0434 0.0007 
Plasma insulin (µmol/L) 1.1±0.1d 3.8±0.1c 6.7±0.2a 5.1±0.1b <0.0001 0.0005 <0.0001 
Plasma leptin (µmol/L) 2.6±0.4c 3.1±0.7c 13.2±2.1a 9.1±1.0b <0.0001 0.1137 0.0473 
Data are presented as mean ± SEM. Values marked with different supercripts are significantly different at 16 weeks at the level of p<0.05. 
ALT: alanine transaminase, AST: aspartate transaminase, NEFA: non-esterified fatty acids, TAG: triglycerides, OGTT-AUC: oral glucose 
tolerance test – area under curve.
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5.3.2.5 Gut function and structure 
 Contractility measurements for both ileum and colon are presented in Figure 
5.14. There were no significant differences between dietary groups for acetylcholine-
induced contraction of the ileum at maximal contraction (Figure 5.14A). For the colon, 
maximal contractility induced by acetylcholine showed a higher contractility between 
20%HAW supplemented rats and other groups of rats (Figure 5.14B). Figure 5.15 
showed periodic acid and Schiff reagent’s staining that showcase the density of goblet 
cells in small intestine and large intestine. There were increases in the density of goblet 
cells in small intestine from both 20%CHAW and 20%HAW compared to their 
respective control groups (Figure 5.15B and 5.15D). However, the density of goblet 
cells in 20%CHAW and 20%HAW appeared to be similar to MCS and 
MHCHF,respectively. 
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  P-Value 
Figure Diet Treatment Interaction 
A 0.4090 0.0791 0.9891 
B 0.2827 0.0126 0.0196 
 
Figure 5.14: Ileum contractility (Figure A) and colon contractility (Figure B) at week 
16 in rats fed MCS, 20%CHAW, MHCHF and 20%HAW.
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Figure 5.15: Periodic acid and Schiff reagent (PAS) staining (magnification 20x) in small intestine and colon of rats fed MCS, 20%CHAW, 
MHCHF and 20%HAW. 
Periodic acid and Schiff reagent (PAS) staining (magnification 20x) in small intestine of MCS (A), 20%CHAW (B), MHCHF (C) and 
20%HAW (D). Similar staining in colon of MCS (E), 20%CHAW (F), MHCHF (G) and 20%HAW (H).  Goblet cells marked as “gc”. 
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Figure 5.16: Periodic acid and Schiff reagent (PAS) staining (magnification 10x) in colon of MCS (A), 20%CHAW (B), MHCHF (C) and 
20%HAW (D). 
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5.4 Discussion 
 
One of the most consistent factors in development of metabolic syndrome is a 
high intake of fats and simple sugars. However, the multi-faceted nature of metabolic 
syndrome is complex and more diverse studies should be conducted to better define 
causation and amelioration of this issue. This present study evaluated the effect of high 
amylose wheat flour (5% and 20%) when supplemented in a high-carbohydrate and 
high-fat diet using a rat model which mimics metabolic syndrome in humans. High 
amylose wheat flour contains increased resistant starch that is characterised as an 
increased ratio of amylose to amylopectin content. Unlike regular starch, resistant 
starch acts as functional fibre that is beneficial to health. However, there is insufficient 
evidence for the beneficial effects of high amylose wheat in metabolic syndrome to 
date. Most studies used healthy animals or humans rather than models of metabolic 
syndrome. Therefore, the current study was warranted as it examined the physiological 
effects of high amylose wheat flour supplementation using a diet-induced metabolic 
syndrome rat model. 
In this study, the corn starch and high-carbohydrate, high-fat diet were 
supplemented with 5% or 20% of high amylose wheat flour. These amounts translate 
to approximately 55g/day and 220g/day in the average 70kg adult human using a 
relevant scaling equation (Bachmann et al., 1996a). There is approximately 17% 
resistant starch in high amylose wheat (Štěrbová et al., 2016) so this would equal to 
9.35g and 37g of resistant starch from 5% and 20% high amylose wheat when 
incorporated in the human diet. An adequate intake (AI) for dietary fibre was set by 
National Health and Medical Research Council (Council, 2006) at 30g/day for men 
and 25g/day for women. A suggested dietary intake for dietary fibre set by Food 
Standards Australia New Zealand (FSANZ) is 38g/day for men and 28g/day for 
women (Zealand., 2012). To date, there is still no Nutrient Reference Value (NRV) 
specifically set for resistant starch. Previously, 20g/day resistant starch was suggested 
as necessary to obtain bowel-related health benefits (Baghurst P.A et al., 1996).  
 In this study, high-carbohydrate and high-fat model was used to induce 
metabolic syndrome in rats because it showed the associated complications including 
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central obesity, dyslipidaemia, hypertension and impaired glucose tolerance. In 
addition, there are also deficits in cardiovascular function that include cardiac 
hyperthrophy, fibrosis and increased diastolic stiffness. The hepatic changes included 
steatosis, infiltration of inflammatory cells and portal fibrosis along with increased 
plasma activities of liver functions. These are consistent with previous study findings 
using the established HCHF diet (Panchal et al., 2011, Panchal et al., 2013).  
 The addition of the high amylose wheat flour to the HCHF and MHCHF diets 
resulted in a decrease in food intake by 7% and 26%, respectively. Previous studies in 
humans indicate resistant starch may play a role in enhancing both short-term (Willis 
et al., 2009, Anderson et al., 2010) and long-term satiety (Nilsson et al., 2008, 
Bodinham et al., 2010). This is also supported by a study in young men using 66% 
RS2 high amylose maize starch (HAMS) that found a reduction in cumulative food 
intake by 15% (Anderson et al., 2010). Animal models also suggested a reduction in 
food intake is associated with increased gene expression and circulating concentrations 
of PYY and GLP-1 after consumption of dietary resistant starch and these satiety 
hormones remained elevated for 24 hours (Keenan et al., 2006, Zhou et al., 2006, Zhou 
et al., 2008). The authors postulated that fermentation of resistant starch and the 
production of short chain fatty acids in the colon was responsible in regulating the 
hormones and the gene expression of GLP-1, PYY and proglucagon (Zhou et al., 
2008).  
Rats supplemented with high amylose wheat flour both in corn starch and high-
carbohydrate and high-fat (5% and 20%) for 8 weeks showed an increased body 
weight. In 5% high amylose wheat flour fed rats, no changes in body compositions 
were seen compared to HCHF rats. However, 20% high amylose wheat flour 
supplemented rats showed that the body weight gains are mainly increases in body 
lean mass rather than body fat mass. This is consistent with previous findings that 
found no change in body weight, but also found lower fat mass and/or higher lean body 
mass with resistant starch ingestion (Shen et al., 2009, So et al., 2007, Shimotoyodome 
et al., 2010). These data suggest that resistant starch causes a change in metabolic flux 
that increased fat oxidation with a concomitant decrease in carbohydrate and protein 
oxidation (Higgins, 2014). This leads to increased protein accretion (lean body mass) 
and reduced fat deposition without changing total energy expenditure (Higgins, 2014). 
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The mechanisms suggested that there is a link between the consumption of fermentable 
resistant starch and PYY. PYY was effective in reducing food intake in obese humans 
(Batterham  et al., 2003) and adiposity in obese mice (Adams et al., 2006). Studies also 
demonstrated that obesity is “a peptide YY-deficient, but not peptide YY-resistant, 
state” (le Roux et al., 2006, Young, 2006). The metabolic effects were also postulated 
to be through pro-opiomelanocortin gene expression in the arcuate nucleus of the 
hypothalamus (Shen et al., 2009) and oxidation of fat as demonstrated by reduced 
respiratory quotient (Zhou et al., 2009).  
 Interesting observations from this study are the lower glucose area under the 
curve (AUC) and plasma insulin concentrations in both 5% and 20% high amylose 
wheat flour supplemented rats in high-carbohydrate, high-fat diet compared to HCHF 
and MHCHF rats. Food starch is normally rapidly digested and absorbed as glucose, 
resulting in a hyperglycaemic response (Birt et al., 2013). It also triggers insulin 
secretion and tissue-specific intracellular uptake of glucose that can then result in 
hypoglycaemia. Repetition of this cycle results in insulin resistance and type 2 
diabetes, thereby contributing to obesity (Birt et al., 2013). In contrast, enzyme-
resistant starches improve glycaemic control. A few human studies reported that the 
ingestion of whole grain high amylose maize flour produced low blood glucose areas 
under the curve (Anderson et al., 2010, Luhovyy et al., 2014) and improved insulin 
sensitivity (Maki et al., 2012a, Robertson et al., 2003). One of the potential 
mechanisms for the insulin-sensitising effects of fermentable fibre is the absorption of 
short chain fatty acids generated in the large intestine due to fermentation by gut 
microbes. Increased butyrate production was associated with higher insulin sensitivity 
and improved glycaemic control (Gao et al., 2009).  
The fermentation and production of short chain fatty acids may also trigger a 
reduction in release of free fatty acids (FFA) and glycerol from adipose depots, 
presumably through direct or indirect inhibition of hormone-sensitive lipase (Higgins, 
2004). Many reports in the literature indicate that the consumption of RS markedly 
reduces NEFA and triglycerides concentrations (Metzler-Zebeli et al., 2015, Brites et 
al., 2011). However, the present study showed no difference between rats fed with 5% 
and 20% high amylose wheat with respective control groups, but decreased fat 
vacuoles in liver tissues were found in the high amylose wheat group. The present 
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study also did not find any changes in total cholesterol and a study fed high amylose 
rice to diabetic Zucker fatty rats also showed similar findings, where an increased 
resistant starch does not exert positive effects on the rats’ lipid metabolism (Zhu et al., 
2012). In contrast, Himalaya 292 a high amylose barley cultivar given to pigs in the 
diet for 3 weeks resulted in reduction of plasma total and non-HDL cholesterol (Bird 
et al., 2004). However, this study proposed that this effect is largely through β-glucan 
or low non-starch polysaccharide content in the barley (Bird et al., 2004). 
 Rats from 20% high amylose wheat flour in high-carbohydrate, high-fat diet 
reduced plasma leptin concentrations compared to MHCHF rats despite higher body 
weight. This highlights the observation that changes in circulating leptin 
concentrations are driven by the lipid content rather than the overall body weight 
(Skurk et al., 2007).  Readily digestible starch increased leptin concentrations, with 
larger adipocytes and generally higher insulin:glucose ratio as compared to high 
resistant starch (So et al., 2007). Mechanisms behind lowering of leptin after ingestion 
of 20% high amylose wheat flour could possibly include the binding of short chain 
fatty acids to the G protein–coupled receptors GPR41 and GPR43. This G protein–
coupled receptors trigger leptin release from adipocytes (Robertson et al., 2005). To 
support this, high-fat diet induced rats fed with sorghum resistant starch also showed 
low leptin concentrations compared to control group and it was proportional to body 
fat loss (Shen et al., 2015). This low leptin concentration was suggested to be related 
to increased activity of the hypothalamic orexigenic signals, which stimulated appetite 
and suppressed energy expenditure (Valassi et al., 2008). 
 Cardiovascular risk factors are among the cluster of metabolic dysfunction. 
This includes the associations of the systolic and diastolic blood pressure parameters. 
This study has demonstrated that 5% and 20% high amylose wheat supplementation 
for 8 weeks to rats had no effect on systolic blood pressure and diastolic stiffness 
compared to their controls. Although values in the supplemented rats were lower, this 
was not statistically different. An increased feeding time in this trial may have shown 
significance. This can be visualised from the histological sections, where improved 
left ventricular structures were found in high amylose wheat-treated rats. There is lack 
of information available regarding the effect of resistant starch on blood pressure or 
heart functions. Significant difference in response of resistant starch Type 4 (RS4) was 
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reported in diastolic blood pressure but there was no difference in systolic blood 
pressure (Upadhyaya et al., 2016). The authors reported that this was correlated with 
changes in fasting glucose and IL-6 concentrations (Upadhyaya et al., 2016). In 
contrast, there were no differences in blood pressure, carotid–femoral pulse wave 
velocity or any of the clinical markers of vascular function following type 2 resistant 
starch (HAM-RS2) in type 2 diabetic patients (Bodinham et al., 2014).   
 Resistant starch undergoes fermentation and produces short chain fatty acids; 
acetate, propionate and butyrate which substantially contribute to gastrointestinal 
function and health (Patten et al., 2015). To our knowledge, there are limited data 
reported on ileal and colonic muscular contractility using metabolic syndrome induced 
rats, particularly testing high amylose wheat. The current data show that there were no 
changes in the contractility of the ileum and colon in 5% CHAW and 5% HAW 
compared to control groups. Similarly, 20% CHAW showed no change in contractility. 
However, we found an increased colonic contractility in 20% HAW compared to other 
rats. Previous reports on butyrylated low-amylose maize starch demonstrated that 
elevation of butyrate concentrations in the large bowel of the rat reduced the contractile 
activity of colonic musculature (Bajka et al., 2010). They suggested that butyrate 
stimulated Na+ and fluid absorption, thus reduced colonic contractility and colonic 
motility. This is in contrast with our findings and this is probably due to the differences 
in nature of experiment being done which include the agonists used, cumulative or 
non-cumulative addition of agonist, the composition of experimental diet, the duration 
of the experiment and strain of rats used. Another study testing high amylose wheat in 
rats fed a western diet found no changes to the genes or colonic contractility relative 
to the effect of low-amylose maize starch (Patten et al., 2015). Inconsistent results 
were also shown in the findings for dietary supplementation of fish oil rich in the long-
chain n-3 polyunsaturated fatty acids, which increased muscarinic-induced ileal 
contractility in healthy rats (Patten et al., 2002) and both ileal and colonic contractility 
in hypertensive rats (Patten et al., 2005).  
In addition to the physiological effects on the gut, changes on the intestinal 
sections can be assessed and more details can be provided in term of the capacity for 
the mucosa to produce mucins. Dietary fibre increased the number of goblet cells 
found in the mucosa in comparison to low fibre or fibre-free controls (Hino et al., 2013, 
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Hino et al., 2012). There was no change in the density of goblet cells in the 5% high 
amylose wheat, however supplementation with 20% high amylose wheat showed 
increased density of goblet cells compared to non-supplemented rats. Certain types of 
fibre, such as isolated cellulose, appear to have minor or no effects on goblet cell 
numbers, while other fibre types such as arabinoxylans doubled goblet cell coverage 
in the villus with modest impacts of around 25% increase in the intestinal crypts (Chen 
et al., 2015). Furthermore, diet high in fibre or resistant starch altered gastrointestinal 
health through the production of short chain fatty acids, which in turn will affect the 
intestinal morphology (Bird et al., 2004). Intravenous infusion of short chain fatty 
acids in rats reverses colonic atrophy linked to butyrate production (Topçu et al., 
2002). Hence, inclusion of the increased fibre or resistant starch in the diet may 
contribute to positive changes in gut and this could probably affect systemic responses. 
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5.5 Conclusion 
The present study shows that a daily consumption for a period of 8 weeks of 
20% high amylose wheat flour supplemented in the diet elicited more favourable 
effects on cardio-metabolic health than a daily consumption of 5% high amylose wheat 
flour. Addition of 20% high amylose wheat in the diet reduced food intake, increased 
lean mass and lowered total fat pads in obese rats, although there was no effect on 
body weight. Supplementation of 20% high amylose wheat flour is also associated 
with a better glycaemic control, improved insulin and leptin metabolism with 
cardioprotective and hepatoprotective effects. These effects are probably due to the 
increased resistant starch in high amylose wheat. Therefore, high amylose wheat flour 
can be used as a value-added ingredient to replace flour containing higher amounts of 
rapidly digestible starch and thereby aimed to attenuate the risk of having metabolic 
syndrome. However, further investigation comparing high amylose wheat with a low 
amylose wheat as a baseline of normal wheat will give a better understanding on the 
evaluation of the effects. Translation of these animal studies to human is also 
warranted to show reproducibility of findings, however caution is warranted before 
extrapolating these results to dosage in humans. 
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Chapter 6 General conclusion and future 
directions. 
6.1 Conclusions 
It is well established that obesity, particularly an excessive visceral adiposity, is 
associated with insulin resistance, hyperglycaemia, dyslipidaemia and hypertension, 
which together are termed “metabolic syndrome” (as discussed in Chapter 1). These 
clusters of metabolic abnormalities increase the risk of cardiovascular disease and type 
2 diabetes which contribute to increased morbidity and mortality (Alberti et al., 2009). 
Environmental factors especially physical inactivity and unhealthy dietary lifestyle 
play strong roles in driving the increase in obesity prevalence. Thus, the promotion of 
healthy diets, nutrition and lifestyles to reduce the global burden of these diseases is 
continually being advocated. One possible solution is an increased consumption of 
functional foods and value-added food products with disease-preventing 
characteristics (as discussed in Chapter 1). Therefore, research is warranted in 
evaluating these functional foods using appropriate animal model as a foundation 
before translation to human clinical trials.  
Research in metabolic syndrome testing possible interventions requires a well-
established and well-designed animal model mimicking human pathogenesis to 
provide better understanding of physiology, biochemistry and pathophysiology. Thus, 
my study utilised the most relevant model that mimics the diet responsible for human 
metabolic syndrome and cardiovascular complications. Young male Wistar rats fed 
with a combination of simple sugars and saturated/trans fats in the diet for sixteen 
weeks developed central obesity, hypertension, impaired glucose tolerance, 
dyslipidaemia, hyperinsulinemia, hyperleptinemia, cardiovascular complications and 
hepatic steatosis (Panchal et al., 2011). The physiological effects of saturated fatty 
acids (Chapter 3), linseed components (Chapter 4) and high amylose wheat (Chapter 
5) were determined in this diet-induced rat model of metabolic syndrome.  
Saturated fatty acid has long been generalised as the main culprit in developing 
obesity and the associated morbidities. Previous research also highlighted the effects 
of saturated fatty acids as a whole rather than of individual fatty acids. Since effects of 
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individual saturated fatty acids remain to be fully elucidated, Chapter 3 investigated 
the physiological effects of lauric, myristic, palmitic and stearic acids in response to 
the metabolic syndrome biomarkers. It shows that not all saturated fatty acids gave 
undesirable effects. The longer-chain saturated fatty acids (myristic, palmitic and 
stearic) and the mixture of stearic and trans fats in beef tallow produced obesity, in 
contrast to rats treated with lauric acid with low total fat mass, abdominal 
circumference and visceral adiposity index. This study found that increased chain 
length is associated with worsening of disease state and the most obvious changes in 
rats fed the individual saturated fatty acids were found with stearic acid. However, 
stearic acid exhibited less abnormalities compared to the combination diet of high-
carbohydrate and high-fat diet which contained 20% beef tallow with similar amounts 
of stearic acid and trans fats, suggesting that the trans fats worsen the responses to 
stearic acid. From this chapter, it is clear that individual saturated fatty acids produce 
distinctly different responses. This study suggests that replacing beef tallow with 
palmitic and stearic acids would show small improvements but replacement with lauric 
and possibly myristic acids in human diets would markedly decrease the development 
of metabolic syndrome. Reductions in the prevalence and incidence of metabolic 
syndrome would lead to significant improvements in the health and wellbeing of 
individuals and families, and this indirectly leads to substantial savings to the 
healthcare system and to overall workplace productivity. 
In Chapter 4, supplementation of lignan or defatted linseed in the high-
carbohydrate, high-fat diet improved cardiovascular function, reduced hepatic 
steatosis and altered metabolic profiles, some of which can be regarded as beneficial 
to health, whereas raw linseed exacerbated adiposity with no changes in other 
metabolic biomarkers except for reduced systolic blood pressure. This study suggests 
that lignan (SDG) and dietary fibre in defatted linseed could reduce the symptoms of 
metabolic syndrome. However, raw linseed diminishes the nutritional or positive 
physiological effects of the seeds and induced an increased intake of fat and energy. 
There could be a possibility that ground linseed is easier to digest compared to whole 
raw linseed. Whole linseed may pass through the intestine undigested, which means 
the nutritional benefits are unable to be realised. Thus, to unlock the benefits of linseed, 
lignan powder and defatted linseed powder would be better choices to be included in 
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the diet. Lignan powder and defatted linseed powder could be used in many ways such 
as adding these components into our breakfast cereals, yoghurt or salad, or including 
lignan and defatted linseed powder in baked goods such as muffins, cookies, bagels 
and bread. It would not only taste good, but also provide health benefits when 
consumed daily at an appropriate dosage. This could be one dietary approach for 
subjects with metabolic syndrome, hence reducing the health-care costs in the 
community. 
 Another functional food described in this thesis is high amylose wheat flour 
(Chapter 5). Two dosages (5% and 20%) high amylose wheat were given to diet-
induced obese rats for 8 weeks. The addition of 20% high amylose wheat in the diet 
reduced food intake, increased lean mass and lowered total fat pads in obese rats, with 
no changes in body weight. Supplementation of 20% high amylose wheat flour was 
also associated with a better glycaemic control, improved insulin and leptin 
metabolism with cardioprotective and hepatoprotective effects. These effects are 
probably due to the increased resistant starch content in high amylose wheat. Resistant 
starch is broken down by resident colonic bacteria thus generating a range of beneficial 
changes that include increased stool bulk which give a mild laxative effect (Phillips et 
al., 1995), encouraging the growth of healthy bacteria in the bowel (Topping et al., 
2003) and producing short chain fatty acids which promote intestinal health (Weaver 
et al., 1992) and overall health. These findings will need further research to be 
translated to humans and one possible study would be to determine the effects of high 
amylose wheat in food products such as bread, pasta and noodles. As wheat supplies 
approximately 20% of the food calories for the world population, it could possibly 
attract policy-makers to replace normal wheat with high amylose wheat flour. This 
will benefit farmers, food industry and economy as well as the health of everyone 
especially in ameliorating metabolic syndrome and risk of colon cancer.  
This thesis emphasises that generalisation of saturated fatty acids based on the 
chemical class rather than on their biological actions may give misleading information 
to consumers. A classification of fatty acids based on their pharmacological or 
therapeutic effects may be more relevant for clinicians and nutritionists when 
formulating therapeutic and dietary guidelines (Poudyal and Brown, 2015). Lauric 
acid could be classified with other bioactive fatty acids that elicit physiological 
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responses that may reduce one or more cardiometabolic risk factors (Poudyal and 
Brown, 2015). This thesis also highlights that inclusion of lignans, defatted linseed and 
high amylose wheat in the diet may be value-added ingredients to a range of 
convenience foods to consumers. These foods will be the most practical source for 
everyday consumption as these foods are natural and staples for most societies. It is 
also advisable for diabetics or obese patients to consume at least the amount of fibre 
and whole grains recommended for the general public. Inclusion of defatted linseed 
and high amylose wheat in the diet could indirectly increase the daily intake of lignans, 
dietary fibre and resistant starch since the present study have shown that these linseed 
components and high amylose wheat give better glycaemic controls and have potential 
in reversing most of the risk factors associated with metabolic syndrome. This could 
be achieved without making a major change to the dietary intake of linseed or cereal 
grains.  
In overview, the study findings highlight that saturated fatty acids are not equal 
and linseed components and high amylose wheat have potential as functional foods 
ingredients that could ameliorate metabolic syndrome. Further, the study findings 
suggest that improving the nutrient profile of foods through incorporation of these 
functional foods ingredients will then increase the availability of healthy food choices 
and indirectly improve the health and well-being of individuals and families. Emphasis 
on functional foods and bioactive components could also attract policy makers to 
strategise new action plans especially in making decisions regarding methods to 
encourage the development and consumption of healthier foods. Innovations in the 
agriculture and food sector could also lead to the development and increased 
production of foods that provide additional health benefits to consumers. Food 
products that confer health benefits can result in wider social benefits through reducing 
health-care costs and the associated cost of illness, such as losses in productivity and 
long-term disability. 
Overall, this study had achieved the aims set in Chapter 1, where effects of 
different saturated fats, lignans, raw linseed, defatted linseed and high amylose wheat 
on cardio-metabolic health and on gut structure and function were hypothesised. The 
first hypothesis is proven that saturated fats together with a high intake of fructose 
induced metabolic changes in the host and these changes depended on the saturated 
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fatty acid that was administered. The second hypothesis is proven for lignans, defatted 
linseed and high amylose wheat except for raw linseed, as raw linseed exacerbated 
most of the cardio-metabolic parameters.  
6.2 Observed limitations and future directions 
There are clear indications that lauric acid as a saturated fatty acid, linseed 
components and high amylose wheat improved the markers of metabolic syndrome in 
these obese rat model. However, the mechanisms of action of these foods and their 
bioactive components remain unclear, as does their ability to be translated to humans. 
It is acknowledged that there is generally not a direct numerical equivalence between 
animal and human experiments but responses to treatments are, on the whole, 
qualitatively similar allowing responses of animals to more extreme treatments to be 
used to predict the anticipated response in humans (Litten-Brown et al., 2010). 
Although the dosages used in these studies corresponds to human dose given accepted 
translation equations, the translation of results from rodent studies to human trials 
remains a problem.  
Relevant human doses have been estimated from rodent doses, but these doses 
assume high oral bioavailability given in the food while the metabolism may vary 
between rats and humans. Bioavailability is an important factor to be consider in 
determining the biological effects of any functional foods or bioactive compounds. In 
addition, animal studies conditions are usually optimized to demonstrate the 
hypothesized effects, and the doses used are usually higher than the levels of human 
consumption. Effects of confounding factors related to lifestyle, such as smoking, 
physical activity, and dietary intake of calories, fat, and fiber, make it difficult to 
interpret human data (Yang and Hong, 2013). Further, the food matrix is a well-known 
variable affecting absorption of food components. The oral absorption of small 
molecules can be extremely variable between rodents and humans due to interspecies 
differences in organ structure and drug-metabolizing enzymes in the small intestines 
(Cao et al., 2006). Moreover, the length of dosing is a factor to consider too, with the 
average life-span of laboratory rats of about 2 years being much less than the average 
human life-span of 75-80 years in many countries. Thus, 8 weeks interventions in rats 
are approximately 6 years interventions in humans, based on life-span. Longer 
interventional studies in humans, at higher doses, may be necessary to show 
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therapeutic benefits. However, caution should be applied in using high doses as it may 
impose the risk of hepatotoxicity and other safety issues in the use of new interventions 
in humans. 
The investigations in this thesis also raised several valid topics for further 
research. These topics include:  
• Determining the molecular mechanism for lauric acid improving glucose
metabolism and reducing inflammation.
• Quantifying the effects of lauric acid on the diversity of gut microbiota.
• Extending the fatty acid trials to include the effects of trans fatty acids in
the obese rat model used in the studies described in this thesis.
• Elucidating the effects of linseed and linseed components on mucin
production at the genetic and the protein level.
• Ascertaining the impact of low amylose wheat in the current obese rat
model.
• Compiling data to determine the most appropriate avenue for translation
of these results to humans to ameliorate the obesity epidemic.
These studies will provide novel insights to the knowledge gap and a better 
understanding of molecular mechanisms will then strengthen the results from this 
current study. These further studies could also improve individual health and thus 
impact on the whole community by providing functional foods to reduce the financial 
costs of the metabolic syndrome. 
 “Nutrition has often been the subject of conjectures and ingenious hypotheses—but 
our actual knowledge is so insufficient that their only use is to try to satisfy our 
imagination. If we could arrive at some more exact facts they could well have 
applications in medicine” Francois Magendie (1783–1855). 
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Appendix IBackground/Aims: Insulin is one of the most potent anabolic agents
involved in themacronutrients synthesis and storage. It plays a pivotal role
in the development of obesity while within the central nervous system
acts as a growth factor in synaptogenesis and nerve growth. Therefore the
lack of insulin or presence of insulin resistance (IR) could potentially lead
to cognitive decline and impaired learning. This review focuses on animal
and human studies that assess the relationship between the IR and
regulation of cognitive function and mood.
Methods: Literature searches were conducted on electronic databases
examining the association between insulin resistance, glucose regulation,
obesity, cognitive function and mood.
Results: In animal models, the central focus is on effects to the hypotha-
lamic-pituitary-adrenal axis (HPA-axis), an area identified as the most
likely area to influencemood and stress. Damage to the insulin receptors in
this regionwas found to be associated with the increase in food intake and
occurrence of adiposity. In humans, these areas play a central role in
motivation and decision making. Furthermore, IR and major depressive
illness share several pathologies, including disorders of the HPA-axis, the
autonomic nervous system, platelets and endothelial function.
Conclusions: There is increasing evidence suggesting a close association
between the obesity and mood disorders such as depression, anxiety,
panic and bipolar disorders. However, there is no clear evidence of indi-
vidual aspects that can be ascribed as pathological drivers of the problem.
Funding source(s): N/A.
IMPAIRED CEREBROVASCULAR RESPONSIVENESS TO A WORKING
MEMORY TASK IN OLDER ADULTS WITH TYPE 2 DIABETES MELLITUS
(T2DM)
R.S. Nealon, P.R.C. Howe, L. Jansen, M.L. Garg, R.H.X. Wong. Clinical
Nutrition Research Centre, School of Biomedical Sciences and Pharmacy,
University of Newcastle, NSW, Australia
E-mail address: rhenan.nealon@uon.edu.au (R.S. Nealon)
Background/Aims: Impairments in specific cognitive domains in T2DM
may be partly attributable to stiffness in cerebral arteries, resulting in poor
cerebral perfusion. This cross-sectional study investigated whether im-
pairments in the ability of the cerebrovasculature to supply blood in
response to a battery of cognitive tests could predict poorer cognition in
T2DM.
Methods: Forty nine T2DM and 28 non-T2DM adults underwent trans-
cranial Doppler ultrasound measurements of basal mean cerebral blood
flow velocity (MBFV) and pulsatility index, a measure of arterial stiffness,
in the left and right middle cerebral arteries (MCA). A battery of cognitive
tasks assessing domains of working memory, executive function and in-
formation processing speed was then administered whilst MBFV was
recorded. Cerebrovascular responsiveness (CVR) to cognitive tasks was
calculated as a percentage increase in MBFV from the basal level.
Results: Using t-tests, we found no differences in basal MBFV; however,
cerebral vessels were 14 percent stiffer in T2DM (p < 0.05). As expected,
T2DM performed poorer in tasks relating to working memory (i.e. N-back,
Digit-Symbol Coding, Symbol-Digit Coding), executive function (Concept
Shifting Task) and information processing speed. Importantly, CVR to the
N-back task was reduced by 53 percent in T2DM (p < 0.05) but was in-
dependent of task performance.
Conclusions: We have shown for the first time that impaired cerebral
perfusion during a working memory task is accompanied by poor task
performance. We plan to evaluate the ability of selected vasoactive nutri-
ents to enhance cerebrovascular function and see whether this improves
cognition in at-risk populations.
Funding source(s): N/A.
INCIDENCE AND RISK FACTORS OF TYPE 2 DIABETES: RESULTS FROM
THE THAI COHORT STUDY
K. Papier 1, S. Jordan 2, C. D'est 1, C. Banwell 1, C. Bain 2, V.
Yiengprugsawan 1, S. Seubsman 3, A. Sleigh 1. 1National Centre for
Epidemiology and Population Health, Australian National Uni., ACT,
Australia; 2 Population Health, Queensland Institute of Medical Research
QLD, Australia; 3 School of Human Ecology, Sukhothai Thammathirat OpenUni., Nonthaburi, Thailand
E-mail address: keren.papier@anu.edu.au (K. Papier)
Background/Aims: The global prevalence of type 2 diabetes mellitus
(T2DM) is high and increasing rapidly in countries undergoing a nutrition
transition like Thailand. This study aimed to assess the relationship be-
tween T2DM and factors associated with the nutrition transition among
Thai adults.
Methods: Data were from Thai Cohort Study participants surveyed in
2005, 2009 and 2013 (n ¼ 39,519). Cumulative incidence of diabetes was
calculated and multivariable analyses were conducted using logistic
regression.
Results: T2DM incidence (per 1000) was higher inmales (24.9 vs. 11.9). The
factors most strongly associated with T2DM in both sexes were increasing
age and BMI but, amongst males, smoking [Odds Ratio (OR) ¼1.70, 95%CI:
1.29-2.24] and alcohol intake (OR ¼ 1.67, 95%CI: 1.00-2.82) were also
associated with increased risk. Infrequent gardening, low vegetable intake,
and urban childhood residence were also related to T2DM risk however
these associations attenuated after adjusting for BMI. Among females, high
income was associated with T2DM (OR ¼ 1.72, 95%CI: 1.03-2.89). Urban
childhood residence and education were also associated with T2DM
however these associations were attenuated after adjusting for BMI.
Conclusions: The factors associated with T2DM risk in our study are
consistent with findings from previous studies conducted in countries
undergoing a nutrition transition. With the prevalence of these factors
projected to increase it is likely that the incidence of T2DMwill keep rising.
This may be of particular concern for Thai men who appear to be in the
earlier stages of the nutrition transition. Our study suggests that females
are at a more advanced stage of the nutrition transition.
Funding source(s): NHMRC.
LAURIC ACID DIFFERS FROM OTHER SATURATED FATTY ACIDS IN
METABOLIC SYNDROME IN RATS
S. Shafie 1,2, L. Brown 1. 1 School of Health & Wellbeing, Faculty of Health,
Engineering & Science, Uni. of Southern Queensland, QLD, Australia; 2Dept.
of Nutrition & Dietetics, Faculty of Medicine & Health Sciences, Universiti
Putra Malaysia, Malaysia
E-mail address: sitiraihanah.shafie@usq.edu.au (S. Shafie)
Background/Aims: The aim of this study is to evaluate different saturated
fatty acids on cardio-vascular, liver and metabolic responses in rats.
Methods: Rats were fed 20% lauric (HLA), myristic (HMA), palmitic (HPA)
or stearic (HSA) acids or beef tallow (HCHF) for 16 weeks with increased
fructose and condensed milk. Control rats were fed a corn starch (C) diet.
Food and water consumption, body weight, body composition, heart
stiffness, blood pressure, blood glucose, lipid profiles and liver function of
rats were measured.
Results: Final body weight ranked HLA < C < HMA ¼ HPA ¼ HSA < HCHF
rats with HLA rats showing 11.1% decrease. Total fat mass reflected changes
in body weight with HLA (54.4 ± 3.2 g) < C (79.5 ± 11.0 g) < HPA (122.7 ±
12.9 g) ¼ HSA (122.9 ± 9.5 g) ¼ HMA (132.4 ± 9.9 g) < HCHF rats (207.7 ±
27.2 g). Left ventricular diastolic stiffness (k) was similar in control (22.0 ±
0.5) and HLA rats (21.8 ± 1.0) but less than HMA (25.3 ± 0.7), HPA (26.6 ±
0.7), HSA (27.0 ± 0.4) and HCHF rats (28.2 ± 0.5). Systolic blood pressure
increased with C (127.7 ± 1.1 mmHg) < HLA (136.2 ± 5.3 mmHg) ¼ HMA
(141.7 ± 1.2 mmHg) < HPA (150.4 ± 2.5 mmHg)¼ HSA (152.9 ± 3.5 mmHg)
¼ HCHF rats (157.8 ± 2.8 mmHg). HLA rats showed improved glucose
tolerance, insulin sensitivity and attenuated dyslipidaemia compared to
HMA, HPA, HSA and HCHF rats. Plasma liver enzymes increased in HLA,
HMA, HPA, HSA and HCHF rats compared to C rats.
Conclusions: For most parameters, lauric acid produced less pathophysi-
ological changes than other saturated fatty acids in this model of diet-
induced metabolic syndrome.
Funding source(s): University of Southern Queensland.
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Abstract 27 
Objective: Increased consumption of fruits and vegetables as functional foods leads to the 28 
reduction of signs of metabolic syndrome. In this study, we have compared and measured 29 
cardiovascular, liver and metabolic parameters following chronic administration of the same 30 
dose of anthocyanins either from chokeberry (CB) or purple maize (PM) in rats with diet-31 
induced metabolic syndrome. Research methods and procedures: Male Wistar rats were fed 32 
with cornstarch diet (C) or high-carbohydrate, high-fat diet (H) diet and divided into six 33 
groups for 16 week feeding with C, C with CB or PM for last 8 weeks (CCB or CPM), H, H 34 
with CB or PM for last 8 weeks (HCB or HPM); CB and PM rats received ~8 mg 35 
anthocyanins/kg/day. The rats were monitored for changes in blood pressure, cardiovascular 36 
and hepatic structure and function, glucose tolerance and adipose tissue mass. Results: HCB 37 
and HPM rats showed reduced visceral adiposity index, total body fat mass and systolic 38 
blood pressure, improved glucose tolerance, liver and cardiovascular structure and function, 39 
decreased plasma triglycerides and total cholesterol compared to H rats. Inflammatory cell 40 
infiltration was reduced in heart and liver. Conclusion: CB and PM interventions gave similar 41 
responses, suggesting that anthocyanins are the bioactive molecules in the attenuation or 42 
reversal of metabolic syndrome by prevention of inflammation-induced damage.  43 
 44 
Keywords: anthocyanins; chokeberry; Aronia melanocarpa; purple maize; Zea mays; 45 
metabolic syndrome   46 
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Introduction 47 
Fruits and vegetables rich in antioxidant phytochemicals such as flavonoids and 48 
polyphenols are effective in attenuating the signs of metabolic syndrome [1, 2]. An increased 49 
intake of fruits and vegetables has been associated with a decrease in cardiovascular diseases 50 
[3], and better control of type 2 diabetes [4] and non-alcoholic fatty liver disease [5]. 51 
Anthocyanins are bioactive flavonoids that give red to purple colours to a wide range of fruits 52 
and vegetables including rhubarb, cabbage, berries, cherries and red grapes [6]. Regular 53 
consumption of anthocyanins has been credited with reducing risk of chronic diseases such as 54 
obesity, non-alcoholic fatty liver, diabetes and cardiovascular diseases [7-9]. It is estimated 55 
that ~1000 mg of polyphenols, including up to 215 mg of anthocyanins, are consumed daily 56 
by an average adult in the USA [9, 10].  57 
This study focuses on black chokeberry and purple maize as two rich dietary sources 58 
of anthocyanins similar to purple carrots and Queen Garnet plums [11, 12]. Black chokeberry 59 
(Aronia melanocarpa) is described as an attractive garden plant, native to eastern North 60 
America but now grown widely in northern Europe, primarily Poland, where the sour fruit is 61 
eaten raw or processed for incorporation into foods. Black chokeberries are rich in cyanidin 62 
anthocyanins, chlorogenic acids and proanthocyanidins, and also contain quercetin flavonols 63 
[13]. While these components indicate that black chokeberries may be an effective functional 64 
food, more rigorous studies are needed to support popular indications for heart disease, 65 
hypertension, hyperlipidaemia and urinary tract infections, as well as actions against bacteria 66 
and viruses, and to strengthen memory and digestion [14, 15]. In metabolic syndrome 67 
subjects, chokeberry extract decreased blood pressure and plasma lipid concentrations with 68 
no change in body weight [16]. Chokeberry attenuated body weight gain and insulin 69 
resistance in rats fed with fructose-rich diet [17].  70 
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Purple maize has been cultivated in the Andean region, especially Peru and Bolivia, 71 
for centuries where it is used as a food and a colourant in a drink believed to improve health 72 
[18, 19]. Treatment with purple maize (Zea mays) decreased abdominal adiposity [20], 73 
improved glucose metabolism [21] and decreased blood pressure in healthy humans [22].  74 
However, there is no clear evidence that intervention with these anthocyanin-containing 75 
traditional functional foods will improve the widespread organ dysfunction observed in 76 
patients with metabolic syndrome, despite improvements in individual signs.  77 
This study has compared the cardiovascular, liver and metabolic responses of two 78 
dietary sources of anthocyanins, chokeberry and purple maize, at the same daily anthocyanin 79 
dose as in rats fed cyanidin 3-glucoside or Queen Garnet plums [12] using the same high-80 
carbohydrate, high-fat diet as a model of human metabolic syndrome [23]. These 81 
measurements included systolic blood pressure, echocardiography, vascular reactivity, 82 
collagen deposition and stiffness of heart, plasma biochemistry and histology for structural 83 
changes on heart and liver. Our results suggest that an adequate intake of foods containing 84 
cyanidin-type anthocyanins can normalise the metabolic, cardiovascular and liver changes 85 
induced by a high-carbohydrate, high-fat diet by decreasing infiltration of inflammatory cells 86 
in the organs.  87 
Materials and methods 88 
Analysis of chokeberry juice and purple maize flour 89 
Chokeberry juice (CB) was supplied by Fasbay Pty Ltd, Sydney, Australia and purple 90 
maize flour (PM) was supplied by Spectrum Ingredients Pte Ltd, Singapore. The anthocyanin 91 
contents were determined by HPLC based on the method outlined in the British 92 
Pharmacopoeia 2014 (Eur. Pharm 2394) using an Agilent 100 series HPLC system. Briefly, 93 
samples were prepared by extraction by 2% v/v HCl in methanol, using sonication for 15 94 
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minutes in volumetric flasks, then made up to volume and diluted as required to be within the 95 
standard calibration. Analysis was performed using a gradient of mobile phases A (water and 96 
formic acid, 91.5:8.5) and B (acetonitrile, methanol, water and formic acid, 97 
22.5:22.5:41.5:8.5) over 56 minutes. The gradient ran from 7 to 25% B in 35 minutes, to 65% 98 
at 45 minutes followed by 100% B to 50 minutes and return to 7%. The column used was a 99 
Phenomenex 250mm C18 5µm column with a flow rate of 1 mL per minute and temperature 100 
30°C. Detection and quantification were performed using a diode array detector (DAD) at 101 
535nm with cyanidin chloride (PhytoLab, CAS No. 528-58-5, B# 80022 5368) as the 102 
calibrating standard. Total anthocyanins were calculated as cyanidin chloride and cyanidin 3-103 
glucoside by mass correction.  104 
Rats and diets 105 
The experimental groups consisted of 72 male Wistar rats (8-9 weeks old; weighing 106 
335 ± 3 g) purchased from Animal Resource Centre, Murdoch, WA, Australia and 107 
individually housed in a temperature-controlled (20±2°C), 12-hour light/dark cycle 108 
environment with ad libitum access to water and rat diet at the University of Southern 109 
Queensland Animal House. All experimentation was pre-approved by the Animal Ethics 110 
Committee of the University of Southern Queensland under the guidelines of the National 111 
Health and Medical Research Council of Australia. The rats were randomly divided into six 112 
separate groups (n = 12 each) and fed with maize starch (C), maize starch + chokeberry juice 113 
(CCB), maize starch + purple maize flour (CPM), high-carbohydrate, high-fat (H), high-114 
carbohydrate, high-fat + chokeberry juice (HCB) and high-carbohydrate, high-fat + purple 115 
maize flour (HPM).  116 
 The preparation and macronutrient composition of basal diets, including the dietary 117 
fatty acid profiles, have been described [23-25]. C and H rats received their diets for 16 118 
weeks and CCB, CPM, HCB and HPM rats received C or H diets for the first 8 weeks while 119 
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both diets were supplemented with chokeberry juice 50 ml/kg or purple maize flour 50 g/kg 120 
by replacing equivalent amounts of water for a further 8 weeks. The drinking water in all H 121 
diet-fed groups was augmented with 25% fructose for the duration of the study. Body weight 122 
and food and water intakes were measured daily and feed efficiency (%) was calculated [24] 123 
using the following equation: 124 
feed conversion efficiency %= 
increase in body weight	%
daily energy intake	kJ  x 100  
Increase in body weight (%): body weight difference between day 56 (week 8) and day 112 125 
(week 16); daily energy intake: average of daily energy intake from week 8 to week 16.  126 
Oral glucose tolerance test 127 
For the oral glucose tolerance testing, the glucose concentrations in blood collected by 128 
tail prick on tail vein of overnight food-deprived rats were measured using Medisense 129 
Precision Q.I.D glucose meter (Abbott Laboratories, Bedford, USA). Fructose-supplemented 130 
drinking water in H, HCB and HPM rats was replaced with normal water for the overnight 131 
food-deprivation period. The rats were given 2 g/kg body weight of glucose as a 40% 132 
aqueous solution via oral gavage. Tail vein blood samples were taken at 30, 60, 90 and 120 133 
minutes following glucose administration. 134 
Body composition measurements  135 
Dual energy X-ray absorptiometric (DXA) measurements were performed on rats 136 
after 16 weeks of feeding, 2 days before rats were euthanased for pathophysiological 137 
assessments, using a Norland XR36 DXA instrument (Norland Corp., Fort Atkinson, USA). 138 
DXA scans were analysed using the manufacturer’s recommended software for use in 139 
laboratory animals (Small Subject Analysis Software, version 2.5.3/1.3.1, Norland Corp., 140 
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Fort Atkinson, USA) [24]. The precision error of lean mass for replicate measurements, with 141 
repositioning, was 3.2%. Visceral adiposity index (%) was calculated [23].  142 
Cardiovascular measurements 143 
Systolic blood pressure was measured under light sedation following intraperitoneal 144 
(i.p.) injection of Zoletil (tiletamine 10 mg/kg, zolazepam 10 mg/kg; Virbac, Peakhurst, 145 
NSW, Australia) using a MLT1010 Piezo-Electric Pulse Transducer and inflatable tail-cuff 146 
connected to a MLT844 Physiological Pressure Transducer using PowerLab data acquisition 147 
unit (ADInstruments, Sydney, Australia) [24]. 148 
Anaesthesia using Zoletil (tiletamine 10 mg/kg and zolazepam 10 mg/kg i.p.) and 149 
Ileum xylazil (xylazine 6 mg/kg; Troy Laboratories, Smithfield, NSW, Australia) was used 150 
for echocardiographic examination (Hewlett Packard Sonos 5500, 12 MHz transducer) 151 
performed at 16 week [23-25], in accordance with the guidelines of the American Society of 152 
Echocardiography using the leading-edge method [26].  153 
The left ventricular (LV) function of the rats in all groups was assessed using the 154 
Langendorff heart preparation [23-25]. Terminal anaesthesia was induced via i.p. injection of 155 
pentobarbitone sodium (Lethabarb®, 100 mg/kg). After heparin (200 IU; Sigma-Aldrich 156 
Australia, Sydney, Australia) administration through the right femoral vein, blood (~5 mL) 157 
was taken from the abdominal aorta. Isovolumetric ventricular function was measured by 158 
inserting a latex balloon catheter into the left ventricle of the isolated heart connected to a 159 
Capto SP844 MLT844 physiological pressure transducer and Chart software on a MacLab 160 
system (ADInstruments Australia and Pacific Islands, Bella Vista, NSW, Australia). All left 161 
ventricular end-diastolic pressure values were measured during pacing of the heart at 250 162 
beats per minute using an electrical stimulator. End-diastolic pressures were obtained starting 163 
from 0 mmHg up to 30 mmHg. 164 
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Thoracic aortic rings (~4 mm in length) were suspended in an organ bath chamber 165 
with a resting tension of approximately 10 mN. Cumulative concentration-response 166 
(contraction) curves were measured for noradrenaline (Sigma-Aldrich Australia, Sydney, 167 
Australia); concentration-response (relaxation) curves were measured for acetylcholine 168 
(Sigma-Aldrich Australia, Sydney, Australia) and sodium nitroprusside (Sigma-Aldrich 169 
Australia, Sydney, Australia) in the presence of a submaximal (70%) contraction to 170 
noradrenaline [25]. 171 
Organ weights 172 
The right and left ventricles were separated after perfusion experiments and weighed. 173 
Liver, and retroperitoneal, epididymal and omental fat pads were collected following heart 174 
removal and blotted dry for weighing. Organ weights were normalised relative to the tibial 175 
length at the time of their removal (in mg/mm).  176 
Histology 177 
Two rats per group were taken exclusively for histological analysis. Two slides were 178 
prepared per tissue specimen and two random, non-overlapping fields per slide were taken to 179 
avoid biased analysis. Organs were also collected from rats used for perfusion studies. 180 
Immediately after removal, heart and liver tissues were fixed in 10% neutral buffered 181 
formalin for 3 days and then dehydrated and embedded in paraffin wax [23-25]. Thin sections 182 
(~5 µm) of left ventricle and the liver were cut and stained with haematoxylin and eosin stain 183 
for determination of inflammatory cell infiltration with a 20× objective using a Olympus 184 
BX51 microscope (Olympus, Melville, NY). Left ventricular sections were stained with 185 
picrosirius red to determine collagen distribution. Laser confocal microscopy (Nikon A1R+ 186 
upright Confocal Microscope) was used to determine collagen distribution in left ventricular 187 
sections.  188 
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Plasma biochemistry 189 
Blood was centrifuged at 5,000g for 15 minutes within 30 minutes of collection into 190 
heparinised tubes. Plasma was separated and transferred to microcentrifuge tubes for storage 191 
at -20°C before analysis. Activities of plasma enzymes and analyte concentrations were 192 
determined using kits and controls supplied by Olympus using an Olympus analyser (AU 193 
400, Tokyo, Japan) [23-25]. Plasma insulin and leptin concentrations (ALPMO, USA) were 194 
estimated using commercial ELISA kits according to manufacturer-provided standards and 195 
protocols. 196 
Statistical analysis 197 
Data are presented as mean ± SEM. Results were tested for variance using Bartlett's 198 
test and variables that were not normally distributed were transformed (using log 10 function) 199 
prior to statistical analyses. Data from C, CCB, CPM, H, HCB and HPM groups were tested 200 
for effects of diet, treatment and their interactions by two-way ANOVA. When interaction 201 
and/or the main effects were significant, means were compared using a Newman-Keuls 202 
multiple comparison post hoc test. Where transformations did not result in normality or 203 
constant variance, a Kruskal-Wallis non-parametric test was performed. A P-value of <0.05 204 
was considered as statistically significant. All statistical analyses were performed using 205 
GraphPad Prism version 6.00 for Windows (San Diego, California, USA). 206 
Results 207 
Diet and body composition 208 
CB and PM contained similar concentrations of total anthocyanins with cyanidin 3-209 
glucoside as the major anthocyanin (Table 1). The average daily intake of anthocyanins was 210 
higher in CCB and CPM rats compared to HCB and HPM rats, as the food intake was higher 211 
in CCB and CPM rats (Table 2). Compared to C rats, H rats consumed less food but a similar 212 
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amount of water (Table 2). Despite the lower food intake, the mean energy intake, feed 213 
efficiency and the increases in body weight were higher in H rats than in C rats (Table 2). 214 
Chronic H diet feeding for 16 weeks increased abdominal circumference, body mass index, 215 
total body fat mass and the individual abdominal fat pads, and increased the visceral 216 
adiposity index (Table 2). No change in total body lean mass was measured (Table 2). The 217 
bone mineral content was higher in H rats compared to C rats (Table 2).  218 
Table 1. Chokeberry juice and purple maize flour analysis 
Variables Chokeberry juice/ 100 ml Purple-maize flour/ 100 g 
Total anthocyanins (mg)#$ 240 220 
Energy (KJ)* 279 1,592 
Protein (g)* 16.1 7.8 
Total fat (g)* 0.5 4.2 
Total carbohydrates (g)* 0.2 76.7 
Values are represented as mean of duplicate assays.  
#
 Analysed by authors.  
$
 Total anthocyanins calculated as cyanidin 3-glucoside. 
*
 Analysed by a commercial laboratory (Symbio Alliance, Brisbane, QLD, Australia). 219 
 220 
Treatment with either CB or PM for 8 weeks, starting at 8 weeks of the feeding 221 
period, did not change food or water intake (Table 2). Compared to controls, CB treatment 222 
groups had similar energy intake while PM treatment groups had an increased energy intake.  223 
Lower feed conversion efficiency and body weight gain were observed in HCB and HPM rats 224 
(Table 2). Both treatments decreased total body fat mass, except CPM rats had higher total 225 
body fat mass compared to C rats (Table 2). Abdominal fat (retroperitoneal, epididymal and 226 
omental fat pads), body mass index and visceral adiposity index decreased in both HCB and 227 
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HPM rats (Table 2). Total lean mass was unchanged in both HCB and HPM rats, and HCB 228 
rats had decreased bone mineral content compared to H rats (Table 2).  229 
Plasma biochemistry and glucose handling 230 
Plasma concentrations of total cholesterol, triglycerides and non-esterified fatty acids 231 
(NEFA) were increased in H rats compared to C rats (Table 2). HCB and HPM rats showed 232 
decreased plasma lipid concentrations, compared to H rats. However, HPM rats had increased 233 
concentrations of triglycerides and NEFA than HCB rats (Table 2). Plasma leptin 234 
concentrations were doubled in H rats compared to C rats. HCB and HPM showed 235 
normalised leptin concentrations, consistent with the changes in total fat mass and abdominal 236 
fat pads (Table 2).  237 
H rats had increased fasting blood glucose concentrations compared to C rats; HCB 238 
and HPM rats showed similar concentrations to C rats (Table 2). The plasma glucose 239 
response to oral glucose loading was greater in H rats than C rats (Figure 1). At 120 min, 240 
HCB and HPM rats along with C rats had lower plasma glucose concentrations compared to 241 
H rats (Figure 1). Plasma insulin concentrations almost doubled in H rats compared to C, 242 
HCB and HPM rats (Table 2). This change is consistent with glucose tolerance area under the 243 
curve (Table 2); similarly, HCB and HPM rats had improved glucose clearance compared to 244 
H rats (Table 2).  245 
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 246 
Figure 1. Effect of CB and PM on oral glucose tolerance in C, CCB, CPM, H, HCB and 247 
HPM rats. Data are shown as mean ± SEM. End-point means without a common letter in 248 
each data set significantly differ, P<0.05 and n=10/group. 249 
 250 
Cardiovascular structure and function  251 
Compared to C rats, H rats showed eccentric hypertrophy measured as increased left 252 
ventricular internal diameter in diastole (LVIDd) without any changes in relative wall 253 
thickness or end systolic dimensions (Table 3). H rats showed impaired systolic function with 254 
decreased fractional shortening and increased wall stress compared to C rats (Table 3). 255 
However, ejection time and ejection fraction were not affected (Table 3). Diastolic and stroke 256 
volumes and consequently the cardiac output were increased in H rats compared to C rats. 257 
These effects were seen with increased heart rate in H rats compared to C rats (Table 3). 258 
These changes in H rats were accompanied by increased LV wet weight and elevated systolic 259 
blood pressure (Table 3).  260 
Both CB and PM treatment improved LV function by decreasing LVIDd and normalising 261 
developed pressure (Table 3). Ejection time, ejection fraction, fractional shortening and 262 
LVIDs were unaffected in both treatment groups (Table 3). Systolic wall stress, cardiac 263 
output, diastolic and stroke volumes and heart rate were normalised with CB and PM 264 
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treatments. However, systolic volumes were elevated in both HCB and HPM rats with no 265 
change in relative wall thickness (Table 3). In the isolated Langendorff heart, LV stiffness 266 
was increased while LV dP/dt was decreased in H rats; these changes were normalised in 267 
HCB and HPM. These effects were accompanied by decreased LV wet weight and systolic 268 
blood pressure in both HCB and HPM rats (Table 3).  269 
Histological evaluation of the left ventricle after 16 weeks showed greater infiltration 270 
of inflammatory cells into the LV with H diet feeding (Figure 2D), as well as increased 271 
interstitial collagen deposition (Figure 2J) compared to C rats (Figure 2A and G). HCB and 272 
HPM rats showed normalised inflammatory cell numbers (Figure 2E and F) and markedly 273 
reduced ventricular collagen deposition (Figure 2K and L). The reduction in LV fibrosis and 274 
inflammation was consistent with the reduced diastolic stiffness in HCB and HPM rats (Table 275 
3), while CCB (Figure 2B and H) and CPM (Figure 2C and I) rats showed minimal changes. 276 
No other changes were observed and tissue morphology appeared normal.  277 
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 278 
Table 2. Dietary intakes, body composition and anthropometrics, organ wet weights, changes in glucose tolerance test, plasma insulin and 279 
plasma biochemistry in C, CCB, CPM, H, HCB and HPM diet-fed rats (n=10 rats/group) 280 
Variable C CCB CPM H HCB HPM 
P values 
Diet Treatment Interaction 
Food intake (g/d) 32.9±1.1a 33.2±0.6a 34.1±0.4a 27.1±0.8b 26.4±0.8b 28.5±0.7b <0.0001 0.11 0.7 
Water intake (ml/d) 27.4±2.1 24.3±1.5 27.2±1.8 26.6±1.4 26.5±1.6 29.7±1.5 0.34 0.2 0.55 
Chokeberry juice intake (ml/d) 0.0±0.0 1.7±0.0a 0.0±0.0 0.0±0.0 1.4±0.0b 0.0±0.0 <0.0001 <0.0001 <0.0001 
Purple maize powder intake (g/d) 0.0±0.0 0.0±0.0 1.8±0.0a 0.0±0.0 0.0±0.0 1.5±0.0b <0.0001 <0.0001 <0.0001 
Anthocyanins intake (mg/kg/d) 0.0±0.0 9.4±0.0a 9.1±0.0a 0.0±0.0 7.8±0.0b 7.4±0.0b <0.0001 <0.0001 <0.0001 
Energy intake (kJ/d) 369±12d 378±7d 409±5c 580±17b 570±19b 640±17a <0.0001 0.0005 0.39 
Feed conversion efficiency (%) 2.4±0.3b 2.1±0.3b 2.9±0.3b 7.1±0.9a 4.4±1.3b 5.5±0.9ab <0.0001 0.16 0.25 
Body weight gained (8-16 weeks) 
(%) 
8.2±1.4b 7.7±1.4b 8.3±1.3b 21.6±2.6a 9.9±2.8b 10.8±1.6b 0.0004 0.0051 0.0075 
Visceral adiposity index (%) 4.9±0.4b 4.4±0.3b 4.8±0.2b 8.9±0.9a 6.1±0.5b 6.0±0.3b <0.0001 0.0021 0.0137 
Abdominal circumference (cm) 19.2±0.1c 18.2±0.2d 19.1±0.1cd 22.3±0.3a 19.7±0.4c 20.7±0.2b <0.0001 <0.0001 0.0022 
Body mass index (kg/m2) 5.0±0.2d 4.8±0.1d 4.7±0.1d 7.3±0.2a 5.7±0.1c 6.4±0.2b <0.0001 <0.0001 0.0002 
Bone mineral content (g) 11.3±0.3c 11.4±0.3c 11.5±0.3c 15.8±0.4a 13.5±0.5b 14.8±0.4a <0.0001 0.0166 0.009 
Total body lean mass (g) 309±12 303±12 307±11 311±14 305±11 304±8 0.98 0.87 0.98 
Total body fat mass (g) 74.3±7.6d 94.4±8.4d 113.7±8.5cd 224.6±12.6a 144.4±17.2c 177.3±10.4b <0.0001 0.0203 <0.0001 
Tissue wet weight (mg/mm)          
Retroperitoneal adipose tissue 179.7±15.3c 141.9±13.7c 173.0±12.6c 521.7±45.6a 279.2±38.2b 311.8±16.7b <0.0001 <0.0001 0.0003 
Epidydimal adipose tissue 93.4±7.9c 83.3±6.9c 95.4±5.2c 278.5±22.5a 155.4±15.2b 156.8±11.7b <0.0001 <0.0001 <0.0001 
Omental adipose tissue 106.6±8.1d 91.8±8.0d 101.1±5.5d 261.1±21.3a 141.0±12.3cd 193.1±9.9b <0.0001 <0.0001 0.0002 
Liver 214.2±6.7c 188.8±6.2c 204.1±5.5c 319.6±8.9a 250.7±11.1b 268.6±7.0b <0.0001 <0.0001 0.0111 
Glucose metabolism and plasma biochemistry         
Fasting blood glucose (mmol/L)  3.8±0.2 3.7±0.2 3.7±0.3 4.8±0.3 3.9±0.3 3.8±0.3 0.0321 0.17 0.08 
OGTT-AUC (mmol/L min) 591±12d 645±9c 613±6d 786±18a 658±7c 694±6b <0.0001 0.001 <0.0001 
Plasma insulin (µmol/L) 1.4±0.3b 1.1±0.2b 1.7±0.3b 4.1±0.5a 2.3±0.4b 2.6±0.6b <0.0001 0.042 0.07 
Plasma leptin (µmol/L) 5.3±0.7b 4.9±0.6b 6.1±0.5b 11.1±0.9a 7.0±1.5b 7.9±1.0b <0.0001 0.06 0.06 
ALP (U/L) 181±12c 214±16c 166±12c 312±18a 252±20bc 265±18bc <0.0001 0.17 0.0224 
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ALT (U/L) 29.6±2.1b 28.1±2.2b 29.7±1.5b 43.2±2.8a 34.6±3.9ab 38.0±3.1ab <0.0001 0.19 0.4 
AST (U/L) 60.4±1.9b 60.9±2.7b 64.0±1.6b 83.5±3.1a 63.1±7.9b 64.6±2.9b 0.0099 0.0383 0.0099 
Total cholesterol (mmol/L) 1.5±0.2b 1.5±0.1b 1.6±0.1b 2.2±0.0a 1.6±0.1b 1.6±0.0b 0.0038 0.0166 0.0039 
Triglycerides (mmol/L) 0.5±0.0c 0.4±0.0c 0.5±0.0c 1.6±0.2a 0.7±0.1c 1.0±0.1b <0.0001 <0.0001 0.0005 
NEFA (mmol/L) 1.3 ±0.2c 1.2 ±0.1c 1.4 ±0.1c 3.4 ±0.2a 1.8 ±0.4c 2.3 ±0.3b <0.0001 0.0036 0.0073 
Each value is a mean ± SEM. Means within a row with unlike superscripts differ, P<0.05. 281 
* In all groups body-weight gained calculated as percentage of body weight increase from 8 weeks to 16 weeks. OGTT-AUC, oral glucose 282 
tolerance test-area under the curve; ALP, alkaline phosphatase; ALT, aspartate transaminase; AST, aspartate transaminase; NEFA, non-esterified 283 
fatty acids. 284 
 285 
 286 
 287 
Insert Figure 2 here. 288 
Figure 2. Haematoxylin and eosin staining of the left ventricle (original magnification ×20) showing inflammatory cells (marked as “in”) as 289 
dark spots outside the myocytes in C (A), CCB (B), CPM (C), H (D), HCB (E) and HPM (F) rats. Picrosirius red staining of left-ventricular 290 
interstitial collagen deposition (original magnification ×20) in rats fed the C (G), CCB (H), CPM (I), H (J), HCB (K) and HPM (L) diet. 291 
Collagen deposition is marked as “cd” and hypertrophied cardiomyocytes are marked as “hy”. 292 
 293 
 294 
Table 3. Changes in cardiovascular structure and function in C, CCB, CPM, H, HCB and HPM diet-fed rats (n=10-8 rats/group) 295 
Variable     C      CCB     CPM H HCB HPM 
P values 
Diet Treatment Interaction 
Heart rate (bpm) 277±18b 246±9b 256±15b 335±16a 243±9b 265±11b 0.06 0.0001 0.06 
IVSd (mm) 1.9±0.1ab 1.8±0.0b 1.9±0.0ab 2.1±0.1a 1.9±0.1ab 1.9±0.0ab 0.09 0.11 0.38 
LVIDd (mm) 6.4±0.2b 6.7±0.3b 7.0±0.1b 7.9±0.3a 7.1±0.2b 7.2±0.2b 0.0005 0.51 0.0139 
LVPWd (mm) 1.8±0.1b 1.7±0.0b 1.8±0.0b 2.1±0.0a 1.9±0.1b 1.9±0.0b 0.0001 0.0393 0.23 
IVSs (mm) 3.2±0.2b 3.0±0.1b 2.9±0.0b 3.8±0.1a 3.2±0.1b 3.3±0.1b <0.0001 0.0022 0.42 
LVIDs (mm) 3.7±0.2 4.0±0.2 3.7±0.2 4.5±0.2 3.7±0.3 4.3±0.3 0.07 0.58 0.06 
LVPWs (mm) 2.9±0.1b 2.6±0.1b 2.7±0.1b 3.4±0.1a 3.2±0.1ab 3.0±0.1ab <0.0001 0.0099 0.32 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Fractional shortening (%) 50.9±2.1a 53.7±0.8a 53.4±0.9a 47.5±2.1ab 58.0±1.2a 55.7±1.4a 0.39 0.0002 0.0392 
Ejection time (ms) 79.6±2.3 93.3±3.4ab 86.0±2.7 92.8±2.9ab 86.4±3.9 95.0±3.0ab 0.0486 0.33 0.0053 
Ejection fraction (%) 87.3±1.4 83.3±1.3 84.6±1.6 89.0±2.2 84.1±4.0 83.6±2.9 0.8 0.14 0.85 
Diastolic volume (µL) 353±34b 365±33b 364±22b 515±39a 386±28b 395±37b 0.01 0.15 0.07 
Systolic volume (µL) 45±10b 57±8a 56±8a 90±10a 65±23a 63±12a 0.0203 0.72 0.11 
Stroke volume (µL) 268±18b 298±20b 307±18b 425±29a 306±26b 322±19b 0.0018 0.13 0.002 
Cardiac output (mL/min) 92.3±11.2b 70.4±13.6b 78.6±6.6b 144.8±21.7a 93.0±7.7b 100.3±10.7b 0.0038 0.0165 0.41 
LV developed pressure (mmHg) 69.6±3.5a 71.4±4.1a 64.8±5.6a 43.7±3.6b 63.7±5.7a 60.2±3.8a 0.001 0.06 0.0444 
(+)dP/dt (mmHg/S) 1147±61a 1285±53a 1195±65a 784±66c 1089±63a 1002±76ab <0.0001 0.0044 0.33 
(-)dP/dt (mmHg/S) -782±51a -804±49a -795±43a -489±57b -700±44a -711±52a 0.0002 0.0316 0.08 
Diastolic stiffness (k) 22.9±0.8b 22.3±0.4b 23.1±0.6b 28.6±0.6a 23.9±0.7b 24.2±0.5b <0.0001 0.0002 0.0006 
Estimated LV mass, Litwin (g) 0.93±0.06b 0.79±0.08b 0.88±0.02b 1.14±0.05a 1.01±0.06ab 1.10±0.04ab <0.0001 0.05 0.99 
LV+septum wet weight (mg/mm 
tibial length) 
16.1±0.5c 15.3±0.5c 15.0±0.5c 19.5±0.8a 16.9±0.8c 18.5±0.5b <0.0001 0.0268 0.23 
Right ventricle wet weight 
(mg/mm tibial length) 
3.8±0.2 3.8±0.2 4.0±0.2 4.4±0.2 4.3±0.3 5.0±0.4a 0.0018 0.18 0.6 
Relative wall thickness 0.50±0.03 0.57±0.09 0.53±0.02 0.56±0.03 0.51±0.01 0.48±0.01 0.63 0.69 0.29 
Systolic blood pressure (mmHg) 130±2b 130±3b 132±2b 152±2a 120±1b 134±3b <0.0001 <0.0001 <0.0001 
Systolic wall stress (mmHg) 83.0±4.0b 79.1±4.3b 75.3±11.8b 119.6±7.6a 76.8±7.5b 89.5±9.7b 0.0171 0.0129 0.06 
Each value is a mean ± SEM. Means within a row with unlike superscripts differ, P<0.05296 
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H diet feeding diminished α1-adrenoceptor-mediated vascular contraction to 297 
noradrenaline (Figure 3A), endothelium-independent relaxation to sodium nitroprusside 298 
(Figure 3B) and endothelium-dependent relaxation to acetylcholine (Figure 3C) in isolated 299 
thoracic aortic rings compared to C rats. Isolated thoracic aortic rings from HCB and HPM 300 
rats showed increased responses to noradrenaline (Figure 3A), sodium nitroprusside (Figure 301 
3B) and acetylcholine (Figure. 3C). 302 
Insert Figure 3 here. 303 
Figure 3. Cumulative concentration-response curves for noradrenaline (A), sodium 304 
nitroprusside (B) and acetylcholine (C) in thoracic aortic rings from C, CCB, CPM, H, HCB 305 
and HPM rats. Data are shown as mean ± SEM. End-point means without a common letter in 306 
each data set significantly differ, P<0.05 and n=10/group. 307 
 308 
Liver structure and function  309 
Plasma alkaline phosphatase (ALP), alanine transaminase (ALT) and aspartate 310 
transaminase (AST) activities were increased in H rats compared to C rats, indicating liver 311 
damage (Table 2). HCB and HPM showed lowered but not normalised ALP, ALT and AST 312 
activities (Table 2). H rats showed increased inflammatory cell infiltration and lipid 313 
deposition as fat vacuoles in the liver (Figure 4D) compared to C rats (Figure 4A). In HCB 314 
and HPM rats, macrovesicular steatosis and portal inflammation were decreased compared to 315 
H rats (Figure 4E and F). Livers from CCB and CPM rats showed normal tissue architecture 316 
(Figure 4B and C). 317 
Insert Figure 4 here 318 
Figure 4. Haematoxylin and eosin staining of hepatocytes (original magnification 319 
×20) showing inflammatory cells (marked as “in”) and hepatocytes with fat vacuoles (marked 320 
as “fv”) in C (A), CCB (B), CPM (C), H (D), HCB (E) and HPM (F) rats. 321 
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Discussion 322 
Rats fed with H diet developed abdominal obesity, hypertension with endothelial 323 
dysfunction, cardiac fibrosis together with increased left-ventricular stiffness, dyslipidaemia, 324 
inflammation in heart and liver, increased plasma liver enzyme concentrations and impaired 325 
glucose tolerance [23]. Excess fat deposition in the abdomen increases chronic low-grade 326 
inflammation, oxidative stress, dyslipidaemia, non-alcoholic fatty liver disease, 327 
cardiovascular diseases, type 2 diabetes and insulin resistance [27-32]. In this study, we 328 
showed that intervention with the same dose of anthocyanins as cyanidins from either 329 
chokeberry or purple maize attenuated the metabolic, cardiovascular and liver changes in rats 330 
fed a H diet. We suggest that these improvements derive from decreased inflammatory cell 331 
infiltration into the tissues.  332 
Recent studies suggest that modification of the gut microbiome by anthocyanins could 333 
be important in mediating the reduced inflammation throughout the body. Anthocyanins are 334 
extensively metabolised by gut microbiota to protocatechuic acid [33, 34], one of a group of 335 
phenolic acids produced by gut bacteria that may act as potential systemic bioactive 336 
compounds to produce the positive responses to anthocyanins [35, 36]. Further, treatment 337 
diet-induced obesity in mice with anthocyanins decreased intestinal inflammation and 338 
increased gut bacteria especially Akkermansia spp. [37]. Increased Bifidobacteria in faeces 339 
together with increased urinary concentrations of anthocyanin metabolites confirm the 340 
important role of anthocyanins as bacterial substrates [38]. Moreover, anthocyanins may act 341 
like prebiotics to increase the growth of beneficial gut bacteria [35]. Thus, anthocyanins may 342 
improve gut health, possibly decreasing the access of bacterial components into the body, and 343 
also by producing metabolites that improve health when absorbed. These gastrointestinal 344 
responses may decrease the systemic inflammatory stimulus that increases lipid uptake by 345 
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adipocytes and so trigger further changes in the body, especially modifying the production 346 
and release of adipokines.  347 
 Abdominal adipose tissue is a dynamic organ producing adipokines that have pro-348 
inflammatory or anti-inflammatory responses. Dysregulated production of these adipokines 349 
leads to obesity and also induces low-grade inflammation and insulin resistance [39]. In the 350 
current study, plasma insulin concentrations were normalised in rats fed chokeberry and 351 
purple maize, consistent with a previous study with the same dose of cyanidin 3-glucoside 352 
[12] and in HFD-fed mice treated with purified mulberry anthocyanins [40]. In our diet-353 
induced obese rats, plasma leptin concentrations were increased; further, treatment with 354 
either chokeberry or purple maize reduced both plasma leptin concentrations and abdominal 355 
fat mass. Similar results were shown with chokeberry extract [17], cyanidin 3-glucoside and 356 
Queen Garnet plums [12]. All these interventions contain cyanidin 3-glucoside as the major 357 
anthocyanin and this compound is the likely bioactive component. Since leptin is pro-358 
inflammatory, reduced leptin concentrations should reduce inflammation throughout the 359 
body, as we have shown in the heart and liver. Thus, we suggest that normalisation of 360 
adipokine production may be the key systemic change as fat pads reduce in response to 361 
changes by the gut microbiota, thus further reducing inflammation throughout the body and 362 
also reducing organ damage. Our results showing fat pad reduction following anthocyanin 363 
intervention are consistent with studies with purple maize extract in C57BL/6J mice [20]. 364 
Further, KK-Ay mice treated with anthocyanins showed similar changes together with 365 
decreases in mean diameter of the visceral and subcutaneous adipocytes, suggesting that 366 
anthocyanin supplementation inhibits lipid accumulation [41]. 367 
Our study suggests that anthocyanin treatment decreased triglycerides and non-368 
esterified free fatty acids which attenuated the liver steatosis. Cyanidin 3-glucoside showed 369 
increased phosphorylated AMP-activated protein kinase (pAMPK) and decreased lipoprotein 370 
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lipase activity in skeletal muscle and adipocytes [41]. In addition, purple sweet potato 371 
treatment in diet-induced obese mice and HepG2 hepatocytes showed similar 372 
phosphorylation of AMPK [42]. AMP-activated protein kinase (AMPK) regulates and 373 
monitors cellular energy balance [43] and pAMPK stimulates free fatty acid oxidation via 374 
activation of acetyl coenzyme–A carboxylase in skeletal muscle [44] and regulates lipolysis 375 
and lipogenesis by converting adipocytes into lipid oxidising cells [45]. Anthocyanins also 376 
down-regulated lipid metabolism proteins, sterol regulatory element-binding protein-1c and 377 
fatty acid synthase via AMPK inhibitor compound C [42, 46]. Additionally, in C57BL/KsJ 378 
db/db mice treated with purple maize extract also increased pAMPK and decreased 379 
phosphoenolpyruvate carboxykinase and glucose 6-phosphatase gene expression in liver and 380 
glucose transporter 4 expression in skeletal muscle [47]. Therefore, these changes may 381 
decrease adipose storage leading to decrease in body weight gain and improved liver function 382 
and glucose metabolism. 383 
Cardiovascular structure and function was improved by anthocyanins in the CB and 384 
PM interventions together with decreased plasma concentrations of non-esterified free fatty 385 
acids (NEFA). Increased plasma NEFA inhibited aortic endothelia nitric oxide synthase via 386 
oxidative mechanism and caused hypertension [48]. In subjects with metabolic syndrome, 387 
supplementation with CB extract and PM extract powder decreased blood pressure and 388 
plasma lipids [16, 22]. Similarly, many epidemiological studies suggest that increased dietary 389 
intake of anthocyanin-containing strawberries, blueberries and moderate intake of red wine is 390 
associated with a reduction in cardiovascular disease [9]. However, there is no direct 391 
evidence that anthocyanins are helpful in decreasing cardiovascular disease in humans. In 392 
cultured bovine artery endothelial cells, cyanidin 3-glucoside increased the expression of 393 
endothelial nitric oxide synthase (eNOS) [49]. Increased expression of eNOS enhanced nitric 394 
oxide release to improve endothelial function [50]. Similarly, chokeberry juice treatment 395 
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showed improved endothelial function in porcine coronary arteries by redox-sensitive 396 
activation [51]. Anthocyanin treatment with CB and PM also showed consistent improvement 397 
in endothelial function and decreased blood pressure.  398 
In this study, we have treated rats either with 3.2 mg/kg BW of CB juice or 3.1 mg/kg 399 
BW of PM powder, corresponding to ~46 ml/day CB or ~50 g/day PM to achieve a dose of 400 
~110 mg of anthocyanins in a 70 kg human, based on body surface area comparisons between 401 
rats and humans [52]. Similar results to the same dose of anthocyanins either from CB and 402 
PM indicate that anthocyanins are the major bioactive compound in CB and PM in reversing 403 
or attenuating the signs of metabolic syndrome. 404 
Conclusion 405 
The effects of CB and PM in a diet-induced rat model of human metabolic syndrome 406 
are consistent with the reported effects of anthocyanins as they are the only polyphenolic 407 
compounds present in sufficient dose in both the treatments. These findings suggest that 408 
anthocyanin interventions using chokeberry or purple maize might be beneficial in 409 
attenuating obesity and metabolic syndrome in humans. However, further investigations on 410 
anthocyanin-containing foods are necessary to understand the mechanism of action, 411 
especially to determine the changes in the gut microbiota. Similar responses in CB- and PM-412 
treated rats suggest a clinical trial corresponding to the same dose as in this study is necessary 413 
to determine if these positive effects can be translated to humans with metabolic syndrome. 414 
 415 
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Highlights 
 
• Chokeberry and purple maize are sources of cyanidin 3-glucoside, an anthocyanin  
 
• Both interventions reverse diet-induced symptoms of metabolic syndrome in rats 
 
• The mechanism is likely to be prevention of infiltration of inflammatory cells 
